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A myriad of scientists have been fascinated from multiple perspectives by the 
complexity of blood. This biological fluid is known for a variety of functions such as 
transportation of oxygen and carbon dioxide through the lungs, transport and removal of 
nutrients, and heat transport and immunity. Blood collects products of the human 
metabolism throughout the entire body. The first studies on the blood circulation system 
can be dated back to 1260 when the Arabic scholar, mathematician and physician Ibn al-
Nafis described the “minor circulation” of the human body [1]. Later, with the invention 
of the microscope, the Dutch naturalist Jan Swammerdam was the first one to observe red 
blood cells (1658) [2]. These cells have remained the only blood constituents observable 
with a microscope until 1842 when Alfred Donné, a French physician discovered platelets 
[3]. One year later, leukocytes were simultaneously described by Gabriel Andral, a French 
professor of medicine, and William Addison, an English country practitioner [4,5]. 
Nowadays we know that blood is a complex mixture of electrolytes and various 
biomolecules, such as lipids, carbohydrates, and proteins. Often, blood cells and 
fibrinogen are removed through centrifugation, yielding serum or plasma. The wealth of 
bioinformatic information, which can be derived from analysis of blood, in combination 
with the minimally invasive way to obtain blood by antecubital venipuncture have led to 
the availability of many (clinical) tests to routinely analyse specific serum or plasma 
components. The levels of biomolecules change according to the physiological condition 
of the body, although to a lesser extent than in the case of urine. One of the best known 
examples is the glucose concentration in blood, but there are many more species that can 
change in concentration or even identity over time. It is often hypothesized that such 




pathological state. To that end human serum or plasma samples have been studied 
extensively in relation to various diseases. 
Like for other serum components, since a few decades abnormal proteins levels 
have been found to be associated with certain pathological conditions [6,7]. The variety of 
human serum proteins is vast, with over 10,500 gene products described 
(http://www.plasmaproteomedatabase.org/ y2013). Protein concentrations in serum range 
over ten orders of magnitude [8]; these proteins all have different structures, amino acid 
compositions, molecular weights, chemical-physical properties and functionalities. 
Albumin is the most abundant serum protein (34-54 mg/ml in humans) and constitutes 
approximately 95% of the total serum protein content together with immunoglobulins, 
transferrin, macroglobulin, and apolipoproteins. This phenomenon severely hampers the 
analysis of the proteins present at much lower concentrations and although several 
analytical approaches can be used to decrease serum complexity, the investigation of these 
so-called low-abundant proteins remains challenging [8,9]. Serum complexity is 
furthermore increased by the fact that proteins can be cleaved by (endogenous) enzymes 
into smaller peptides or proteins. Specific enzymes are activated as a consequence of a 
change of the physiological condition cleaving specific peptide bonds and producing 
functional peptides or proteins. For example, angiotensinogen is cleaved by renin to form 
angiotensin I peptide, a ten amino acid long peptide that is further cleaved by angiotensin-
converting enzyme to form angiotensin II peptide. This peptide is a hormone that 
increases blood pressure. Furthermore, many unspecific cleavages of proteins are 
observed in blood-related samples: peptides derived from such degradation are often 




Methods for the determination of the elemental composition of proteins have 
been developed since the middle 1910s [10]. For this purpose, two-dimensional gel 
electrophoresis has been a widely applied technology to separate proteins [11]. It is 
commonly agreed that the identification of a protein from a gel by mass spectrometry 
(MS) through peptide sequencing was first reported by Matthias Mann [12]. However, 
several other scientists have pioneered in the field of peptide- and protein identifications 
by means of MS, like Sundqvist, Heerma, Roepstorff, Hunt and Yates [13-17]. It was only 
in the middle 1990s, at the same time that the Human Genome Project received great 
attention, that mass spectrometry for protein identification grew to its current size. It was 
clear that the identification and characterization of all human proteins would provide 
biologically relevant information complementary to genomic studies, however it would 
take a few more years before technology was in place. To make an analogy with the term 
genomics, this new discipline was called proteomics [18]. Consequently, new 
technologies were developed to provide innovative methods for the separation, the 
detection and the characterization of proteins, and MS has evolved from an early, 
laborious protein analysis tool [19,20] into a high-throughput highly automated method. 
Nowadays, MS is the method of choice in proteomics for the analysis of complex protein 
samples (e.g. human serum) [21]. However, its application requires proper and 
standardized sample preparation. There is an enormous variety of techniques that can be 
employed to clean up, separate or fractionate peptides and proteins from biological 
sources [22]. Reversed-phase (RP), ion exchange, size exclusion and affinity 
chromatography have been applied using different technologies including ZipTip pipette 
tips, cartridges and magnetic beads for solid-phase extraction (SPE) and columns for 




of these techniques, it is ready for mass spectrometric analysis. MS-analysis requires an 
ionization source, a mass analyzer and a detector, usually integrated in a commercially 
available mass spectrometer or MS-system. 
In a mass spectrometer, ions are generated in an ionization source and then 
transferred to the detector following a decrease of potential energy; during this path, ions 
can be trapped, focused, “cooled”, excited, accelerated, and fragmented. The technology 
behind all these processes is diverse and is used in different configuration to create mass 
spectrometers with different characteristics, resulting in different performance and 
capability. MS is sensitive, allows the detection of as little as a few hundred molecules 
and the identification of protein amino acid sequence including post-translational 
modifications (PTMs) such as glycosylation or phosphorylation. Despite this, the direct 
analysis of complex protein mixtures (e.g. human serum) by MS, with some exceptions 
(e.g. dried blood analysis, identification of bacteria), requires procedures that result in a 
reduced complexity of the sample (see Figure 1). The combination of these procedures 
with different ionization techniques and mass analysers allows the in-depth investigation 
of the human serum proteome. 
The two most common ionization sources for biomolecules are based on matrix-
assisted laser desorption/ionization (MALDI) or electrospray ionization (ESI). It is fair to 
state that at least in part MALDI and ESI provide complementary information, and that 
the method of choice depends on the application. The latter ionization is generally used to 
analyse compounds present in solution and has the advantage of on-line coupling with 
chromatography systems. ESI of peptides and proteins produces a broad distribution of 






Figure 1. General workflow for the MS analysis of human serum peptides and proteins.  
 
The charge state depends on both the composition of the liquid in which peptides 
and proteins are dissolved and their amino acid composition and structure. These 
multiply-charged ions are suitable for further MS identification experiments (i.e. MS/MS) 
that are based on the isolation and fragmentation of a particular ionized species 
(i.e. precursor ion). The preferred ions for MS/MS-analysis are (de)protonated species 
(i.e. [M+nH]n+ or [M-nH]n-), but also other precursor ions have been used for 
identification studies. The MS analysis of the fragment ions allows the identification of 
the primary sequence of the isolated peptide or protein. In so-called bottom-up proteomics 
studies, proteins are identified by digesting protein(s) into peptides with a proteolytic 
enzyme such as trypsin, followed by separation of the resulting peptides by RP-LC with 
continuous MS/MS “read-out” for each eluting peptide precursor. Peptide sequences are 
obtained from the corresponding MS/MS-spectrum with a database search tool, such as 




 Proteins identities (IDs) are then inferred from unique peptide sequence 
identifications. The utility of protein identification by database search depends upon the 
existence of a reference database that contains ideally all peptides of interest. This 
approach allows the identification of thousands of proteins in a single experiment [24]. 
However, it should be borne in mind that the presence of PTMs may affect the proteolytic 
efficiency of the enzyme, the recoveries from a clean-up procedure, retention time of the 
LC, and both the ESI the MS/MS efficiency. Thus, the identification of modified peptides 
by a bottom-up approach is not trivial. As an alternative approach and to overcome (some 
of) these problems, the interest for the analysis of proteins without any enzymatic 
digestion has tremendously grown the last few years [25]. This approach, referred to as 
top-down proteomics, allows the characterization of intact proteins from their MS/MS 
spectra [26,27]. Different proteoforms – all the different molecular forms in which the 
protein product of a single gene can be found, including changes due to genetic variations, 
alternatively spliced RNA transcripts and PTMs [28] – can be identified localizing 
differences in their amino acid sequences or PTMs. Top-down analysis requires mass 
spectrometers with very high resolving powers and mass accuracy (e.g. Orbitrap, 
Fourier transform ion cyclotron resonance (FTICR)). Unfortunately, ultrahigh resolution 
comes at the cost of longer analysis times, thus hampering application in traditional 
LC/MS/MS experiments. In general, ESI of an intact protein leads to highly charged ions 
with large isotopic distribution and different charge states. The fragmentation of intact 
proteins in an MS/MS experiment yields a large number of fragment ions, the isotopic 
distributions of which may overlap each other, thereby increasing the complexity of the 
spectra. In order to tackle this complexity, very high resolution measurements and 




characterization of intact proteins is mainly performed by direct infusion- (DI) ESI-
MS/MS analysis after off-line clean-up and/or fractionation procedures. However, the last 
generation Orbitrap and high resolution time-of-flight (TOF) mass analysers offer the 
sensitivity, the mass resolution and the acquisition speed needed for top-down proteomics 
on a LC time-scale [29].  
Tandem-MS or MS/MS of peptides and proteins can be performed in various 
ways using different fragmentation techniques [30]. Fragmentation by collision-induced 
dissociation (CID) occurs after acceleration of the ionized molecules by an electric field 
and collision with neutral gasses (e.g. helium, nitrogen or argon). Upon collision, part of 
the translational energy of the ionized molecules is converted into internal energy leading 
to the breakage of the peptide bonds and fragmentation of the precursor ion into smaller 
fragments. In a second and increasingly used dissociation process, electron-transfer 
dissociation (ETD) [31], low energy electrons are transferred from radical anions to 
multiply protonated molecules in the gas phase (i.e. [M+nH]n+) inducing random 
cleavages along the polypeptide backbone. Reactive radical anions are generated by 
reaction of neutral molecules of reagent (e.g. fluoranthene) and low energy electrons 
(i.e. lower than 1 eV) produced in a chemical ionization source after bombardment of a 
mediator gas (e.g. methane) with high energy electrons (i.e. 60-80 eV). The types of 
fragment ions obtained by CID and ETD depend on many factors including the amino 
acid sequence, the amount of internal energy, the charge state, the amount of radical 
anions, the reaction time, etc. As depicted in Figure 2, CID predominantly generates 






Figure 2. Peptide fragment ions observed in MS/MS spectra. The type of fragments 
generated in a MS/MS experiments depend on used fragmentation technique. Collision-
induced dissociation predominantly yields b- and y-type ions while electron transfer 
dissociation results in c- and z-type ions. 
 
One of major advantages of ETD in MS-based proteomics is the ability to 
localize the exact site of PTMs that can be missed by CID [33]. For example, CID of 
glycosylated peptides/proteins primarily leads to the fragmentation of the glycan structure 
with very low efficiency in the fragmentation of the polypeptide backbone. Instead, ETD 




property allows a better characterization of protein isoforms and PTMs, especially in top-
down experiments [34]. It has been shown that CID and ETD provide complementary 
information in terms of the primary sequence coverage of unmodified peptides and that 
the combination of these two methods in bottom-up experiments improves the total 
number of identified species [35]. In electron-capture dissociation (ECD) the multiply 
protonated ions overlap with “free” high energy electrons (released from a cathode) that 
results in a type of fragmentation that is similar to ETD experiments [36,37]. This 
technique has been developed in FTICR-MS and is often applied for the characterization 
of intact proteins by top-down MS/MS. 
The generation of multiply charged ions using ESI facilitates MS/MS-
experiments, but on the other hand complicates the mass spectrum and thus limits the 
analysis of complex mixtures. On the contrary, MALDI of peptides and proteins generates 
mainly singly charged ions (i.e. mainly [M+H]+ or [M-H]-) thus yielding MS spectra with 
a reduced number of overlapping species that are relatively easy to interpret [38]. 
In MALDI, the analyte is co-crystallized with an excess of a small, organic chemical 
compound (i.e. chemical matrix) that adsorbs laser energy and distributes this energy to 
the sample. This process induces a very rapid heating of the sample generating the 
vaporization of both the matrix and the analyte with as a consequence the removal of a 
certain amount of the sample (the so-called ablation). In conjunction with the ablation 
process the ionization of a minor fraction of matrix and analyte occurs. With high-end 
MALDI sources proteins in the concentration range of as low as attomoles can be 
detected. Apart from other factors the ionization efficiency depends on the used chemical 
matrix. Alpha-cyano-4-hydroxycinnamic acid (CHCA) is a small aromatic acid 




CHCA crystallizes in a homogeneous manner and provides MALDI-spots that allow 
automated MS acquisitions. Surface enhanced laser desorption/ionization (SELDI) is a 
variation of MALDI that is based on a chemically modified surface to selectively capture 
peptides and proteins from a complex mixture [39]. The sample preparation procedure 
(i.e. capture and washing) is performed directly on a modified target plate improving the 
throughput of the analysis. 
 
Time-of-flight mass spectrometers. In a TOF mass analyser, ions with different mass-to-
charge (m/z) ratios are separated in a flight tube based on their different flight times. 
To this end, all ions are accelerated to a defined kinetic energy (i.e. ½mv2) and introduced 
into the flight tube simultaneously (delayed extraction). The accelerated ions then travel in 
a field-free region to a multichannel plate (MCP) detector. The “heavier ions” travel 
slower than the “lighter ions” and thus will be detected sequentially. By also measuring 
ions (molecules) with a known m/z-value the instrument can be calibrated through simple 
correlation of the flight time with the m/z-value. The mass resolution (i.e. ∆mass/mass) of 
a linear TOF mass analyser depends on the time interval in which ions with identical m/z-
values reach the MCP detector. Factors that determine this interval are temporal 
distribution, spatial distribution and energy distribution of the ions. In modern mass 
analysers these factors are reduced through the implementation of specific technologies or 
configurations. For example, in reflectron TOF analysers the effect of the initial kinetic 
energy distribution on the mass resolution is counter-balanced using an electrostatic field 
for ion reflection. The reflectron, or ion mirror, thus allows compensating small ion 
energy differences by adjusting voltages. As a result, ions are more focused in time and 




values, because in the reflectron configuration the transmission efficiency is decreased. 
Reflectron mode spectra are often referred to as high resolution profiles, with typical 
resolving powers of between 7,000 and 10,000 [40]. TOF instruments are “no scanning” 
and fast (i.e. low duty cycle) mass analysers that allow high-throughput measurements 
when combined with MALDI- or ESI sources. TOF analysers have been used in 
combination with both MALDI and ESI sources to analyse human serum peptides and 
proteins [41,42]. Linear MALDI-TOF MS allows the analysis of large intact proteins 
while reflectron MALDI-TOF MS is usually employed to analyse endogenous serum 
peptides or proteolytic fragments from larger proteins.  
 
Fourier Transform Ion Cyclotron Resonance (FTICR) mass spectrometers. The basis 
of an FTICR mass spectrometer consists of an analyzer (ICR) cell that resides in a strong, 
homogeneous magnetic field. At present, for MS-purposes magnets are commercially 
available with field strength up to 15 tesla, and development of 21T systems is on-going 
[43]. In an FTICR experiment, ions are trapped in an ICR cell using a front- and back-
trapping electrode, followed by detection of their cyclotron frequency by two opposite 
detection electrodes in combination with two opposite excitation electrodes. 
Time schedules are crucial for proper control of any FTICR-MS or MS-MS experiment, 
consisting of ion quench/ion introduction, ion selection, ion dissociation, ion excitation, 
and ion detection [44,45]. 
Ion cyclotron movement, as a result of Lorentz force, is measured as a frequency that 






ϖc= (qB0) / m 
 
In this initial condition, the ion cyclotron orbital phases are random and the cyclotron 
radius is too small to induce a detectable image current on the detection plates. Thus, the 
ions are accelerated to wider cyclotron orbits applying a uniform electric field 
(excitation), directed perpendicular to the magnetic field direction, and rotating at the 
cyclotron frequency (typically >10 kHz) of ions of a particular m/z-value (i.e. resonant). 
The final cyclotron radius is directly proportional to both the electric field strength and the 
time of the irradiation and is inversely proportional to the magnetic field strength. 
The excitation process leads to the spatial coherency of the ions making their detection 
possible. Ions of a wide m/z-range can be simultaneously excited using a broadband 
waveform. The image current generated after the excitation of the ions, decays in time and 
is generally referred to free induction decay (FID) transient. The FID resulting from the 
detection of ions with different m/z-values is a superposition of sine waves. At this point, 
Fourier transform is applied to resolve the FID and generate a frequency-domain spectrum 
that is further converted into a mass spectrum. The strength of the magnetic field affects 
many spectral characteristics. For example, the mass resolving power and mass 
measurement accuracy increase linearly with increasing field strength while the maximum 
number of ions that can be confined without coalescence of their FTICR signals increases 
quadratically.  
FTICR analysers have been used in combination with both MALDI and ESI 
sources to analyse human serum peptides and proteins [46,47]. The main benefits of using 
this technology are (a) the ultrahigh mass resolving power that allows the analysis of large 




precision that allow a more reliable identification of the detected species; (c) a wide 
dynamic range that is favourable for the detection of low abundant components.  
  
Peptide and protein profiling of human serum samples. Like other components in 
human serum, proteins may be used for the prognosis, diagnosis and monitoring of a 
certain disease (e.g. cancer, diabetes, atherosclerosis). In this context, both automated and 
high-throughput sample preparation methods and MS approaches have been developed to 
measure protein levels in biological samples with the analytical robustness required for 
clinical application [48]. Driven by the urgent need of biomarkers for the early detection 
of severe diseases such as cancer, MS is on its way to mature into a clinical diagnostic 
tool [49]. Numerous peptide and protein profiling studies by either SELDI- or MALDI-
TOF-MS approaches have been reported for the discovery of disease-specific human 
serum signatures aiming for clinical diagnostics. Many of these studies were motivated by 
the early success published by Petricoin and co-workers in 2002. These investigators 
reported a serum proteomics pattern generated by RPC16 SELDI-TOF-MS that allowed 
the detection of ovarian cancer and the discrimination between healthy women and 
patients [50]. And indeed, over the last ten years, more disease-specific peptide and 
protein profiles related to other diseases could be identified through similar SELDI- or 
MALDI-TOF-MS methods [51,52]. However, also drawbacks of this approach became 
clear. First, only high-abundance serum proteins and their proteolytic fragments 
(i.e. peptides) were identified in the profiles [41]. Second, the identified discriminant 
proteins were not cancer-specific and in many cases appeared to be involved in the acute 
phase and inflammatory response [53,54]. Third, the standardization of sample collection 




As a consequence, none of proposed serum peptide signatures has been approved for 
routine diagnostics yet. 
Due to the biological variability in human serum samples and the resulting 
proteomics profiles profiling studies require a high number of samples for analysis and 
evaluation to obtain reliable statistical results. Time-consuming or tedious sample 
preparation procedures (e.g. gel electrophoresis) and MS methods (e.g. LC-MS/MS) are 
not suitable for high-throughput analysis. Therefore, a robotic platform for sample clean-
up and separation of complex protein mixtures is needed that provides a high degree of 
standardization and consequently low analytical variation. Solid-phase extraction (SPE) 
has been successfully implemented using ZipTip pipette tips, cartridges or magnetic 
beads in automated sample preparation protocols for MS-based proteomics. In particular, 
the use of (disposable) magnetic beads (MBs)-based procedures leads to a fast and robust 
fractionation of human serum proteins. Proteins can be separated with high selectivity 
using different chemically functionalized beads such as reversed-phase material (RPC4, 
RPC8, RPC18). As an alternative, functionalized cartridges can be applied: these have a 
higher loadability (i.e. quantity of proteins that can be processed) thus providing larger 
fraction volumes suitable for further protein separation or (additional) direct infusion 
experiments.  
Proteomic profiling studies are based on the comparison of hundreds (or even 
thousands) of signatures detected in hundreds of samples obtained from different 
individuals. After the acquisition of the MS profiles a series of data processing steps is 
required to extract the information needed for statistical analysis. These steps include a 
baseline correction, smoothing, peak-picking, internal calibration or peak alignment, and 




Data processing becomes more robust with improved quality of the profiles. Moreover, 
high quality data lead to a more reliable statistical analysis. In this context, resolving 
power, dynamic range, mass measurement accuracy and precision of the mass analyser are 
parameters that define the quality of the MS spectrum. The first proteomic profiling 
studies were performed on low resolution linear TOF mass analysers that detected 
peptides and proteins as broad peaks in a wide m/z-range. Later, high resolution reflectron 
mode TOF analysers were used to achieve isotopic resolution, however at a narrower 
m/z-range. Furthermore, the accuracy of SELDI/MALDI-TOF mass measurements is 
affected by the heterogeneity of the crystalized sample (i.e. chemical matrix and analytes) 
and both an external and an internal calibration (or alignment) are needed for robust 
comparisons of the profiles. Such differences in “height” of the sample on the MALDI 
target plate are less of a problem when applying MALDI-FTICR MS. Nevertheless, 
probably primarily due to the costs of this high-end platform, it has been rarely used for 
profiling of human serum peptides and proteins. However, following the latest 
developments of FTICR-MS (e.g. magnet production, more efficient ion transmission, cell 
improvements), the use of this technology has grown and the beneficial aspects have also 
become clear in clinical proteomics. Especially the ultrahigh resolution and the sub-ppm 
mass accuracy that are achieved with FTICR mass analysers have shown to be particularly 
useful for the identification of intact proteins and the localization of PTMs.  
 
Aim of this thesis. In this thesis, the development and application of novel MALDI-
FTICR-MS methods are described. These methods were used for the acquisition of 
ultrahigh resolution profiles containing (highly) abundant endogenous serum peptides and 




FTICR-MS results in a more robust and comprehensive analysis of the human serum 
degradome. This allows the identification of for instance cancer-related biomarker 
signatures, as is exemplified with serum samples from a pancreatic cancer cohort. 
The thus obtained proteomic signatures could be used for the accurate discrimination of 
healthy from diseased individuals. The developed MALDI-FTICR-MS methods were 
further applied to characterize small proteins fractionated by high-throughput and 
automated sample preparation protocols. Finally, identification of (large) polypeptides is 
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In order to balance the speed of analytical sample preparation procedures with mass 
spectrometry (MS)-based clinical proteomics the application of high-throughput robotic 
systems for body fluid workup is essential. In this paper we describe the implementation 
of various solid-phase extraction (SPE) sample preparation protocols on two different 
platforms, namely: 1) Magnetic bead-based SPE of peptides and proteins from body fluids 
on a Hamilton liquid handling workstation; 2) Cartridge-based SPE on a SPARK 
Symbiosis system. All SPE protocols were optimized for MS-based proteomics and 
compared with respect to obtained peptide- and protein profiles. Throughput numbers that 
were achieved in a 24 hour time frame for the sample workup procedures were more than 







Proteomics has matured into a standard technology and with that interest has broadened 
from studying fundamental biological processes to screening large patient cohorts in 
clinical research [1]. Improved and more detailed genetic knowledge of various biological 
processes or organisms is now widely used in proteomics research [2;3]. The last decade 
sample throughput in MS-based proteomics has increased enormously due to the 
development of highly automated and robust mass spectrometers and improved speed in 
data handling and -processing. As a consequence, the analytical methods that involve 
peptide- and protein profiling of body fluids require high-throughput approaches. It should 
be stressed that sample workup is an essential part in all proteomics workflows because of 
the large complexity of any biological material [4-6]. In order to handle sample 
complexity and obtain full coverage multidimensional separations have been reported 
[7;8]. However, such approaches are not feasible for large screening studies taking into 
account time, costs and robustness. Most biomarker discovery studies that have reported 
on candidate peptides and proteins that were found to correlate with the presence and/or a 
stage of a certain disease were based on relatively small numbers of samples. 
Not surprisingly, a large majority of these discoveries could not be validated and did not 
make it into a diagnostic clinical assay [9;10]. Thus a high-capacity pipeline is needed to 
perform screening studies of clinical cohorts containing at least 1,000 different individuals 
[11]. Such a high-throughput workflow consists of robust and relatively fast sample 
processing and preparation (resulting in a reduced complexity) as well as automated MS 
[1;12]. Moreover, high-end MS in combination with specific sample workup allows 
mapping of modifications such as glycosylation and phosphorylation [13;14]. 
In this paper we present two automation platforms for SPE-based sample 
preparation and subsequent MS-measurements. Automation of sample preparation not 
only increases sample throughput but also improves robustness by eliminating human 
errors. Here, two different instrumental setups are described: The first one involves 
magnetic bead-based SPE, whereas the second SPE-setup is based on column-like 
cartridges. Both setups aim for peptide- and protein profiling of body fluids. For this 
purpose a subset of proteins and peptides is captured from body fluids such as serum or 
urine using an SPE approach. The captured components are measured on a mass 
spectrometer to obtain a “profile” (mass spectrum) of the body fluid [15]. Pattern analysis 
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of these profiles allows the classification of individuals into groups (e.g. healthy versus 
diseased). In general, these methods consist of incubation-, washing- and elution steps. 
In addition, a protocol is described that involves spotting of samples onto a MALDI-target 
plate for analysis on for instance a MALDI time-of-flight (TOF) or MALDI Fourier 
Transform Ion Cyclotron Resonance (FTICR) system. We have chosen to implement the 
first application on a Hamilton liquid-handling workstation. Advantages of this robotic 
system are the flexibility in deck layout, user-friendly programming software and the 
possibility to include in-house developed and third party consumables or equipment. 
The second application has been implemented on a SPARK Symbiosis SPE system, 
specifically adapted to increase sample throughput. The advantages of this system are the 
availability of a wide range of different cartridges and the ability to keep the samples at 
4°C during sample storage and after elution. 
 The general availability of functionalized magnetic beads for peptide- or protein 
profiling is decreasing, or has even been discontinued in the case of (polymeric) reversed-
phase (RP) C18-beads. Other players have entered the market by supplying magnetic 
beads based on silica material that are currently under investigation in our group. 
Furthermore, the magnetic bead protocol results in peptide- or protein eluates that are 
“optimized” for MALDI-MS measurements while in some instances direct infusion ESI-
MS is the preferred MS method, e.g. to obtain multiply charged species that are more 
suitable for MS/MS-fragmentation. For these reasons an alternative SPE system was 
considered. This paper describes the implementation and comparison of both systems. 
 
MATERIALS AND METHODS 
Consumables and reagents. All microtitration plates (PCR-plates) were obtained from 
Greiner (Alphen a/d Rijn, The Netherlands). Functionalized magnetic beads were either 
purchased from Bruker Daltonics (weak cation exchange (WCX); Bremen, Germany) or 
from Invitrogen (reversed-phase (RP) C18; Breda, The Netherlands). The elution buffer 
for WCX magnetic beads was a 130 mM ammoniumhydroxide solution (J.T. Baker, 
Deventer, The Netherlands) and the stabilization buffer consisted of 3% trifluoroacetic 
acid (TFA; Sigma, St. Louis, USA) in water. MALDI matrix α-cyano-4-hydroxycinnamic 





acetone:ethanol 1:2. Magnets were purchased from Webcraft GmbH 
(http://www.supermagnete.de/; Gottmadingen, Germany). 
 
Serum samples. Serum samples were obtained from healthy volunteers at the Leiden 
University Medical Center (LUMC). Samples were collected, anonymized and processed 
according to a standardized protocol: all blood samples were drawn by antecubital 
venapuncture while the individuals were seated and had not been fasting. The samples 
were drawn in an 8.5 cc Serum Separator Vacutainer Tube (BD Diagnostics, Plymouth, 
UK) and within maximally 4 hours centrifuged at room temperature at 1000 g for 10 
minutes. The samples were kept in sterile 500 μl barcode labeled polypropylene tubes 
(TrakMate, Matrix TechCorp.) at -80ºC until further use. 
 
SPE using magnetic beads. For each (biological) sample fresh magnetic beads were 
used. The RPC18-beads were first activated by a three-step washing with a 0.1% TFA 
solution. Then, the samples were added to the activated beads and incubated for 5 minutes 
at room temperature. The beads were washed again three times with 0.1% TFA and 
peptides were eluted with a 1:1 mixture of water and acetonitrile. 
For the application of WCX-beads, the samples were added directly to the beads together 
with binding buffer since no activation was needed. The beads were washed three times 
with washing buffer and eluted with a high pH elution buffer, which was prepared as 
described in ‘Consumables and reagents’. Thus obtained eluates were mixed with 
stabilization buffer to acidify the sample. 
Two microliters of each (stabilized) eluate were mixed with 15 microliters of a MALDI 
matrix solution in a 384-well PCR plate. Then, 1 microliter of this mixture was spotted in 
quadruplicate onto a MALDI-target plate (Bruker Daltonics). 
 
SPE using cartridges. For each (biological) sample a new cartridge was used. Cartridges 
were pre-washed with 1 ml 100% acetonitrile and equilibrated with 1 ml 1% acetic acid / 
2% acetonitrile (wash solvent) prior to sample application. Serum samples were diluted 4 
times with 0.1% acetic acid and 100 µL of the diluted serum was applied to the cartridge 
with 1 ml wash solvent. The cartridges were washed with 2 ml wash solvent and eluted 
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with 100 µL 50% acetonitrile / 0.1% acetic acid. After elution the tubing was rinsed with 
500 µL wash solvent before proceeding to the next sample. 
 
Target plate spotting and mass spectrometry. The protocol for spotting onto a MALDI-
target plate is part of the other two procedures described above. The implementation will 
be described in the Results and Discussion section. MALDI-TOF experiments were 
performed on an UltraFlex II (Bruker Daltonics) either operating in positive reflectron 
mode in the m/z-range of 600–4,000 or in positive linear mode in the m/z-range of 1000-
11000. The spectra were acquired using FlexControl software ver. 3.0 (Bruker Daltonics). 
A Smartbeam 200 Hz solidstate laser, set at a frequency of 100 Hz, was used for 
ionization. A profile, or summed spectrum, was obtained for each MALDI-spot by adding 
20 spectra of 60 laser shots each at different rasters. To this end, FlexControl software 
decided on-the-fly whether or not a scan was used for the summed spectrum. For 
reflectron mode acquisitions, a resolution higher than 2,000 was required. Peaks were 
detected using the SNAP centroid peak detection algorithm with signal-to-noise threshold 
of 1 and a “TopHat” baseline subtraction. All mass scans not fitting these criteria were 
excluded. For linear mode acquisitions, a resolution higher than 100 was required and 
peaks were detected using the centroid peak detection algorithm with signal-to-noise 
threshold of 2 and a “TopHat” baseline subtraction. The measurement of a MALDI spot 
was finished when 1200 laser shots had been summed in one profile. FlexAnalysis 
Software 3.0 (Bruker Daltonics) was used for visualisation and data processing. 
 MALDI-FTICR experiments were performed on a Bruker 15 tesla solariX™ 
FTICR mass spectrometer equipped with a novel CombiSource [16]. The MALDI-FTICR 
system was controlled by Compass solariXcontrol software and equipped with a Bruker 
Smartbeam-II™ Laser System that operated at a frequency of 500 Hz. The “medium” 
predefined shot pattern was used for the irradiation. Each mass spectrum was obtained 
from a single scan of 600 laser shots using 512 K data points. Typically, the target plate 
offset was 100 V with the deflector plate set at 180 V. The ion funnels operated at 100 V 
and 6.0 V, respectively, with the skimmers at 15 V and 5 V. The trapping potentials were 
set at 0.60 V and 0.55 V, the analyzer entrance was maintained at -7 V, and side kick 





excitation power was 28% with a pulse time of 20.0 µs. MALDI-FTICR profiles were 
obtained from the same target plate that had been used for the MALDI-TOF acquisitions. 
 
RESULTS AND DISCUSSIONS 
Implementation of SPE using magnetic beads on the robotic liquid handling system. 
The robotic system for automated liquid handling is built up from three units (Figure 1A). 
Currently, this system is used for (1) in-gel and in-solution digestions, (2) desalting of 
samples using ziptips, and (3) magnetic bead based SPE for peptide- and protein profiling. 
In this study data is reported from the third application, which involves the unit depicted 
on the right-hand side of Figure 1A. This unit consists of a two-arm Hamilton STARplus 
robotic workstation that is equipped with eight independently controlled 1 ml pipetting 
channels, a 300 µL 96 channel pipetting head, an 8+1 channel nanospotter, a 96-well 
magnet, a vacuum system, a heated/cooled shaker, a temperature controlled carrier and a 
plate CORE-gripper. Description of the second and third unit (left-hand side and middle 
of Figure 1A) is outside the scope of this work. 
For the application of magnetic bead based SPE it was necessary to develop 
specific labware that was not readily available from the supplier. For example, to prevent 
evaporation of volatile solvents from the supplied open reagent containers, special 
containers have been implemented with automated sliding lids to open and close on 
demand. In addition, a wireless and non-fixed mini-camera that can be picked-up by one 
of the eight 1 ml pipetting channels has been implemented for quality control purposes. 
Finally, a specific magnet plate incorporating 96 individual magnets to accommodate 
96-well plates was in-house developed. With this magnet different sample workup steps 
can be performed as will be described in the following paragraph. 
In MS-based clinical profiling studies proteins and peptides are isolated from a 
biological fluid (blood, urine, CSF) using SPE material, which is normally used in a 
cartridge or column-like format or as paramagnetic beads. In the here described automated 
system paramagnetic beads coated with a variety of functionalities, are applied to extract 
various subsets of peptides and proteins. The platform allows multiplexing, i.e. a sample 
plate can be processed with different types of magnetic beads, either simultaneously or 
sequentially. The deck layout for this protocol is shown in Figure 1B. 
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The various protocols for the different bead types have an identical workflow in 
terms of “order of events”, however slightly differ with regard to the number of activation 
cycles, wash cycles and incubation times and the specific buffers used. All protocols for 
the extraction procedures provided by the manufacturer for manual processing were 
adapted and further optimized to allow implementation on the robotic system. Initially, 
these optimizations have been described on a previous 8-channel liquid handling platform 
(http://www.hamiltonrobotics.com/fileadmin/user_upload/prodb/app_notes/Proteomics/B
R-0504-01_PeptideExtraction_for_ProteinProfiling_01.pdf). However, for the current 
platform these protocols were further adjusted to obtain an even higher throughput. In 
short, each protocol consists of a binding step, several washing steps and an elution step. 
Optionally there might be an activation and/or equilibration step, and a stabilization step 
of the eluate. All eluates are collected in a fresh PCR-plate and then spotted in 
quadruplicate onto a target plate for further analysis by MALDI-TOF-MS and/or MALDI-
FTICR-MS. In order to reduce loss of magnetic beads to a minimum PCR-plates were 
used throughout the protocol. These plates allow for maximum aspiration of solvents with 
a minimal residual volume in the wells and minimal disturbance of the magnetic bead 
pellet through a smaller surface to height ratio in comparison with other types of 
microtitration plates. 
 Obviously, the manipulation of magnetic beads requires a magnet for capturing. 
Ideally, in a 96-well PCR plate all magnetic beads are captured at the bottom of each well 
upon using a magnet. Different types of commercially available magnets to accommodate 
such 96-well plates were tested on the Hamilton system, namely magnets in ring-, bar- 
and pin form. Unfortunately, in our hands none of these magnets allowed suitable 
implementation in the robotic system due to “off-center” or “well-above-the-bottom” 
capturing of magnetic beads in a PCR plate. As a result of non-optimal capture proper 
resuspension of magnetic beads was not possible and the SPE-cleanup of serum samples 
failed. Therefore, a magnet block was in-house developed with a single magnet at the 
bottom of each well, resulting in optimal capture of beads. Proper resuspension of the 
bead pellet needs to be performed without the magnet. This implicates that two deck 
positions are required for processing one sample plate. Therefore, an electronically 
controlled height-adjustable magnet was designed to allow collection and resuspension of 





The here described SPE-protocols based on magnetic bead fractionation were 
implemented in the year 2008. Since then, more than 15,000 different serum samples have 
been processed in biomarker screening studies [17-23]. These studies included statistical 
validation tests. From the results of the 96-channel system it was concluded that the 
reproducibility of the peptide- and protein profiles obtained from MALDI-TOF-MS was 
better than in the case of manual sample processing.  
Typically, the coefficient of variation (CV) of the peak areas in the profiles was 
on average 15% when processing biological serum sample replicates, and for some 
specific peptides even below 5%. Note that this value results from a combination of 
variation in the SPE-procedure itself, the MALDI-spotting and MALDI-TOF 
measurement. This aspect is further discussed in the last paragraph of this section 
(comparison of beads and cartridges).  
 
Implementation of online SPE using cartridges on the Symbiosis. Basically, a 
Symbiosis system consists of one autosampler (Reliance), one High Pressure Dispenser 
(HPD) and one Automated Cartridge Exchange (ACE) unit. In Figure 1C, the setup of our 
customized Symbiosis system is shown. In this setup three Reliance systems are combined 
with two HPD units, each equipped with two syringes, and two ACE units. Two Reliance 
systems are used as an autosampler (left- and right-hand side of Figure 1C) and the third 
Reliance acts as a fraction collector (middle of Figure 1C). The fraction collector is 
reached by both systems in an alternating way: when one system is in the “load position”, 
i.e. equilibrating and washing a cartridge (left-hand side in Figure 1C), the other one is in 
the “elute position” (right-hand side in Figure 1C). Note that the cartridge is swapped 
from the left clamp to the right clamp in the ACE unit on the left-hand side upon elution, 
and vice-versa for the cartridge in the second ACE. Moreover, for each sample a new 
cartridge is applied, and the used cartridge is placed back into the storage container. 










Figure 1. Systems setup. Picture of both sample preparation systems, consisting of a 
Hamilton Microlab® STAR, a Hamilton SWAP, an automated CHRIST vacuum centrifuge 
and a Hamilton Microlab® STARplus (A), a photo and schematic representation (B) of the 
Microlab® STARplus deck layout used for magnetic bead based protein profiling and a photo 
with flow-scheme (C) of the Symbiosis system. To carry out a protocol on the Microlab® 
STARplus with optimal use of deck space and without user-intervention stacks of pipette tips 
are needed. This storage of tips on the deck is further indicated as “Tip-stacking” (Ts) 
positions. To allow for tip pickup within a certain protocol one rack of tips is initially 
transferred to a so-called “Tip-working” (Tw) position. TCC: Temperature Controlled 
Carrier; Tw10: tip work sequence 10 microliter tips; Tw50: tip work sequence 50 microliter 
tips; Tw300: tip work sequence 300 microliter tips; Tw1000: tip work sequence 1000 
microliter tips; Ts10: tip stack 10 microliter tips; Ts50: tip stack 50 microliter tips; Ts300: tip 
stack 300 microliter Tips; Tmix: spare position for all tip types to be used by 96-channel head; 
Tr1, Tr2, Tr3: empty racks for tips to be re-used; MB: Magnetic beads; WP: working plate; 
MP: mixing plate for mixing sample and MALDI-matrix; SP: sample plate; StP: eluent 
storage plate; SLC: Sliding Lid Containers for volatile solvents; MALDI: MALDI-target 
plate; RV: reagent vessels; WT: waste and tool carrier. Tools include CORE-gripper and 
CORE-camera (CAM); SN: service carrier nano-head for washing and waste. 
 
 
 Both paramagnetic beads and the cartridges are available with a wide variety of 
functionalities. However, cartridges can also be specifically packed with any solid phase 
material of choice, making the availability of such material the only limiting factor. In this 
study six out of eight functionalities from the SPARK method development kit were 
tested with respect to peptide- and protein isolation from serum samples, as well as three 
other functionalities, namely: CN-SE, C2-SE, C8 EC-SE (End Capped), C18 HD (High 
Density), Resin GP (General Phase), Resin SH (Strong Hydrophobic), PLRP, C18-OH 
and C18-EC. A general protocol was used for all cartridges. In short, the cartridges were 
activated with acetonitrile and equilibrated with wash solvent. Serum samples were 
diluted 4 times with 0.1% acetic acid and applied to the cartridges using wash solvent. 
The cartridges were washed and eluted with elution solvent. The eluates were collected as 
100 µL fractions. The resulting eluates were spotted in quadruplicate using the Hamilton 
STARplus as described below. 
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 Figure 2 (inset) shows a typical FTICR-MS profile of SPE eluates, such as 
obtained with samples processed with the nine cartridges mentioned above. Based on the 
number of features (peaks) in the spectrum and the total signal intensity in both the low- 
and the high-mass range, the C8 EC-SE, C18-HD and C18-EC cartridges performed best 
and to a lesser extent also the C2-SE in the high-mass range. Preliminary results also 
indicated that the eluates from the C18-EC cartridges performed best in direct infusion 
FTICR-MS experiments, making these cartridges the type of choice for future 
experiments. 
 Using these C18-EC cartridges, four samples were processed in eightfold and 
spotted in quadruplicate onto a MALDI-target plate. For each processed sample two spots 
were used for MALDI-FTICR-MS measurements in the low mass range (1000-3700 Da) 
and two spots were used for MALDI-FTICR-MS measurements in the high mass range 
(3.5-10kDa), resulting in 16 spectra for each sample in both mass ranges. For 23 peaks of 
known composition and present in all spectra [16;24], the intensities expressed as area 
under the curve were averaged over the 16 spectra. The intensities were normalized 
against the total intensity of the 17 (low-mass range) and 6 (high-mass range) peaks, 
respectively. The results are depicted in Figure 2. It can be seen that the intra-sample 
reproducibility (standard deviation) is dependent on the peptide itself (i.e. the m/z-value), 
and in some cases this error is even larger than the inter-sample variation (e.g. at m/z-
value 1465). However, in general the standard deviations are within acceptable limits and 
allow accurate comparison between peptide intensities in different serum samples. For 
example, the peptide intensity at m/z = 1778.023 is two-fold higher in sample 4 compared 










Figure 2. Repeatability and Reprocucibility of the cartridge-based SPE method. Peptides 
used for this analysis are observed as [M+H]+ at monoisotopic m/z values: 1206.6 = 
EGDFLAEGGGVR; 1350.6 = SGEGDFLAEGGGVR; 1465.7 = DSGEGDFLAEGGGVR; 1518.7 = ADS(-
H2O)GEGDFLAEGGGVR; 1536.7 = ADSGEGDFLAEGGGVR; 1616.7 = ADSpGEGDFLAEGGG VR; 
1739.9 = NGFKSHALQLNNRQI; 1778.0 = SKITHRIHWESASLL; 1896.0 = RNGFKSHALQLN NRQI; 
2021.1 = SSKITHRIHWESASLLR; 2271.1 = SRQLGLPGPPDVPDHAAYHPF; 2553.1 = SSSYSKQ 
FTSSTSYNRGDSTFES; 2768.2 = SSSYSKQFTSSTSYNRGDSTFESKS; 2931.3 = 
SSSYSKQFTSSTSYNR GDSTFESKSY; 3156.6 = NVHSGSTFFKYYLQGAKIPKPEASFSPR; 3190.4 = 
SSSYSKQFTSSTSYNRGDSTFESKSYKM; 3261.5 = SSSYSKQFTSSTSYNRGDSTFESKSY KMA; 
4280.5= NVHSAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDHAAYHPF; 5902.4 = 






Implementation of a MALDI-target plate spotting protocol on the robotic liquid 
handling system. A spotting protocol for MALDI plates has been developed previously 
(http://www.hamiltonrobotics.com/fileadmin/user_upload/prodb/app_notes/ 
Proteomics/BR-0302-01_MALDITargetSpot.pdf); however this protocol included a 
washing step on the MALDI target. Since our procedures result in purified samples such a 
washing step was not needed anymore. To this end, we compared two methods of matrix 
and sample deposition on the MALDI-target: 1) Premixing sample with matrix in a 
384-well plate and 2) deposition of sample on a MALDI target plate followed by 
application of matrix with the nanospotter. The two methods differ in sample to matrix 
ratio and the final concentration of organic solvent. For the first method the sample to 
matrix ratio was 2:15 and the organic solvent concentration was 94% while for the second 
method the sample to matrix ratio was 10:4 and the organic solvent concentration was 
64%, when calculated for a sample composition containing 50% acetonitrile as is the case 
for most of the applications described in this paper. This ratio is of influence on the drying 
speed and crystal formation. The premixing method was found to perform consistently 
better than the nanospotter method. In principle it would be possible to reverse the second 
method (apply sample instead of matrix with the nanospotter). This would change the 
sample to matrix ratio and the final organic solvent concentration, but processing times 
would increase dramatically. Moreover, to prevent sample carry-over disposable tips are 
to be preferred over washable tips. Depending on the method applied before spotting, 
using only a single spot for each sample will not always result in a good spectrum.  
Using α-cyanohydroxycinnamic acid (CHCA) as the MALDI matrix and a 
Bruker AnchorchipTM an optimal spot is a very thin uniform layer which is slightly larger 
than the anchor (Figure 3A). Causes for non-ideal spots could e.g be the absence of 
analytes in the sample or extract, resulting in very dense spots with the size of the anchor 
(Figure 3B) or, in case of magnetic bead purification, the presence of magnetic beads on 
the MALDI target caused by incomplete separation of beads from the eluate, resulting in 
brown spots (Figure 3C). Furthermore, aberrant spot volumes, caused for instance by 
droplets at the outside of the tips, may result in different crystal formation and 







Figure 3. Examples of MALDI spots. (A) Optimal spot: thin homogeneous matrix layer, 
which is larger than anchor. (B) Small spots almost the size of the anchor, due to absence or 
(very) low concentration of analytes. (C) Brown spots: presence of magnetic beads due to 
incomplete separation of magnetic beads from eluate. (D) One very large spot due to the 
presence of a droplet on the tip during spotting. Also visible are magnetic beads (brown color) 
and an inhomogeneous matrix layer due to changed evaporation conditions (lower organic 
solvent concentration). 
 
Figure 4. Wireless camera mounted on a pipetting channel (A) top-view showing the CORE-




Theoretically it would be possible to check the quality of the spots and the 
envisaged quality of the spectra by imaging and automated evaluation of the images. 
For this purpose it would be possible to use a camera mounted on the Hamilton 
STARplus, as described in an application note on the Hamilton website 
(http://www.hamiltonrobotics.com/fileadmin/user_upload/prodb/app_notes/Genomics/BR
-0506-01-EasyPick_ColonyPicking.pdf). However, this is a serious investment. Therefore, 
an affordable system was developed which, in addition, is not fixed to the robot, but is 
placed on the deck as separate labware. To implement this, a commercially available 
wireless mini camera was mounted in a frame, together with a battery and LEDs for 
illumination. To grab the camera the Hamilton’s CORE technology was used. For this 
purpose a CORE head, similar to a tip-head, was also included in the frame. Furthermore, 
a switch was integrated which activates the camera when this is picked up and stops it 
when placed back on the deck (Figure 4). So far, no software is available which allows 
automated image evaluation, but we foresee that general software for this purpose will 
become available in the future. 
 
Comparison of MALDI-FTICR profiles obtained from magnetic beads-based SPE or 
cartridge-based SPE. The same samples from the reproducibility test described above 
were also processed with C18 magnetic beads. Here, the comparison of the bead-
processed samples with the cartridge-processed samples is based on MALDI-FTICR 
profiles, although similar profiles were obtained using MALDI-TOF-MS (data not 
shown). Recently, we have reported on the beneficial effects of ultrahigh resolution MS in 
terms of determined mass measurement errors and alignment of data [16]. Typical 
examples of these precision profiles are depicted in Figure 5a, in which a so-called low 
mass and high mass spectra are shown. The comparison of eluates from C18 magnetic 
beads to those of C18-EC cartridges is illustrated in Figure 5b, where peak area CVs (four 
samples, eight independent workups each) are given for a set of known peptides (same as 
in Figure 2). At a first glance, especially the low mass region seems different between the 
two SPE protocols. However, upon careful analysis it was found that on average the same 
peptides are captured by both the cartridges and the magnetic beads, although for some 







Figure 5. Comparison of magnetic bead-based SPE with cartridge-based SPE. Spectra (A) 
and average normalized intensities (B). Peptides used for this analysis are the same as in 
Figure 2. 
 
extent by the cartridges, while m/z 2021.2 and 3156.7 were isolated in higher amounts by 
the magnetic beads. Similarly, in the high mass region differences were observed for the 
signal at m/z 5905.4. From Figure 5b it becomes clear that the peak area CVs are often 
similar for both the magnetic beads and the cartridges. Note that for some of the peptides 
the two workup protocols yield results with different efficiency and reproducibility. 
For these peptides the less efficient method usually exhibits the largest variation. 
It is obvious that biologically relevant differences should be considered with regard to the 
determined CV of each specific peptide.  
In summary, precision profiles obtained from the same sample after work-up 
using the here described two SPE-protocols show a large amount of overlap in a 
qualitative analysis, i.e. the same peptides are captured by both procedures. From these 
results we conclude that the C18 cartridges provide a suitable alternative for C18 
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magnetic beads. Nevertheless, for some species large differences in the absolute amounts 
(ratios) are observed. Whether or not these intensity differences have an effect on 
classification of samples of specific patient cohorts is currently under investigation. 
 
CONCLUSIONS  
The implementation of the sample preparation processes on automated liquid handling 
platforms, as described in this paper, allows to both speed up the analysis of a large 
number of samples but also to eliminate errors. Apart from the throughput, the latter 
aspect is essential for application in clinical diagnosis where standardization and quality 
control (QC) are pivotal in meeting good laboratory practice (GLP) requirements [25]. 
In combination with the previously described automated MALDI-target loading and the 
high-throughput MS-based methods developed in our group this workflow is a next step 
towards implementation of proteomics in a clinical setting [26;27]. 
 In this paper, two sample preparation techniques based on SPE on a highly 
automated platform are described. It was found that the cartridge-based Symbiosis system 
is a suitable alternative for the magnetic bead-based sample preparation and cleanup. 
In view of the fact that the production of specific types of beads has been discontinued 
this is an important aspect. Furthermore, the use of cartridges increases flexibility in 
sample preparation, since the cartridges can be packed with virtually any desired solid 
phase material. The peptides captured with C18-SPE material by both techniques are 
similar, although the capture efficiency may differ for each peptide. Furthermore, it was 
shown that the standard deviations for both the magnetic beads and the cartridges were 
very similar in inter- as well as intra-sample comparisons. As discussed in this paper, the 
CV of the intensity of a certain peak in magnetic bead profiles was often well below 10% 
when processing biological serum sample replicates, and on average about 15%. Based on 
the results presented here we expect this to be the same for the cartridges, which requires 








A movie of the CORE-Camera in action can be found on 
http://www.lumc.nl/con/1040, then navigate to ‘biomolecular mass spectrometry/Mass 
spectrometry-based clinical proteomics/methods’. 
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Many biomarker discovery studies are based on matrix-assisted laser desorption/ionisation 
(MALDI) peptide profiles. In this study, 96 human serum samples were analysed on a 
Bruker solariXTM MALDI Fourier transform ion cyclotron resonance (FTICR) system 
equipped with a 15 tesla magnet. Isotopically resolved peptides were observed in 
ultrahigh resolution FTICR profiles up to m/z 6500 with mass measurement errors 
(MMEs) of previously identified peptides at a sub-ppm level. For comparison with our 
previous platform for peptide profile mass analysis (i.e. Ultraflex II) the corresponding 
time-of-flight (TOF) spectra were obtained with isotopically resolved peptides up to 
m/z 3500. The FTICR and TOF systems performed rather similar with respect to the 
repeatability of the signal intensities. However, the mass measurement precision improved 
at least 10-fold in ultrahigh resolution data and thus simplified spectral alignment 
necessary for robust and quantitatively precise comparisons of profiles in large-scale 
clinical studies. From each single MALDI-FTICR spectrum an m/z-list was obtained with 
sub-ppm precision for all different species, which is beneficial for identification purposes 
and interlaboratory comparisons. Furthermore, the FTICR system allowed new peptide 
identifications from collision-induced dissociation (CID) spectra using direct infusion of 







Mass spectrometry (MS) has emerged as a key technology for molecular profiling of 
biological samples. Nowadays this versatile and high-end analytical tool is applied in 
(pre)clinical studies to identify and quantify proteins, lipids, or metabolites [1–3]. 
The first strategy is commonly referred to as MS-based proteomics and is widely applied 
to identify and quantify proteins in for instance studies on cancer biology [4–6]. One way 
of performing an MS-based proteomics experiment is to map a set of (poly)peptides in a 
single spectrum, i.e. a profile. The continuous efforts to find new prognostic or diagnostic 
biomarkers have stimulated the use of such profiles in clinical settings. In the early days, a 
single low-resolution mass spectrum derived from an individual's body fluid was used for 
comparative studies. However, a profile of a complex mixture is most informative when 
recorded on an ultrahigh resolution instrument such as a Fourier transform ion cyclotron 
resonance (FTICR) mass spectrometer, as was early recognised for the analysis of 
peptides, glycans or even crude oil [7–11]. Identifications of compounds are also more 
confident from ultrahigh resolution profiles. Unfortunately, it soon became clear that 
profiles reflected only a subset of the complex mixture and that online chromatographic 
separation in combination with electrospray ionisation (ESI)-MS would allow the samples 
to be analysed in greater depth [12,13]. Profiling studies became unpopular and were 
criticised because of their problems with reproducibility and validation [14]. In this 
context, the importance of standardisation in sample workup, measurement and data 
processing and evaluation has been stressed [15–17]. Thus, MS profiles can be highly 
reproducible provided each procedure in the workflow is carefully and correctly applied 
[1]. In addition, matrix-assisted laser desorption/ionisation (MALDI)-MS of peptides 
remains unrivalled with respect to acquisition speed and automation strategies [18]. 
Following the current developments in ultrahigh resolution MS, mass measurement at 
higher precision improves the alignment of multiple spectra that are needed for 
comparative analysis [19,20]. Here we demonstrate a robust method for peptide profiling 
using a commercially available MALDI-FTICR system equipped with a novel front-end 
and a 15 tesla magnet. This work builds on recent developments of MS systems and 
measurement strategies to meet the challenge of complexity inherent to biological 
samples. The high-mass measurement precision significantly aids data analysis workflows 
in discovery studies and is a key step towards robust and standardised high-throughput 
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Sample collection and serum peptide isolation. The protocols for both the collection of 
human blood samples and for serum peptide isolation have been described previously 
[17]. Informed consent was obtained from all patients and the Leiden University Medical 
Center (LUMC) Medical Ethical Committee approved the studies. Briefly, blood samples 
were collected in 10 mL BD Vacutainer tubes (containing a clot activator and a gel for 
serum separation) from patients and healthy volunteers by antecubital venipuncture and 
centrifuged within 1 h. Serum was then transferred into a 1 mL cryovial and stored at 
-80 °C until further aliquotting. To this end, 96 cryovials were thawed and serum was 
distributed over eight racks using an eight-channel liquid-handling robot (Hamilton, 
Bonaduz, Switzerland). Each rack was stored again at -80 °C and thawed only for the 
automated peptide isolation procedure. Serum peptides were isolated in a fully automated 
fashion using reversed-phase (RP)C18-functionalised magnetic beads. In this study, 
10 mL of commercially available RPC18 Dynabeads (Invitrogen, Carlsbad, CA, USA) 
was used for the analysis of 5 mL serum. The manufacturer's protocol was followed for 
the activation, wash, and desorption steps of the RPC18 beads, with adjustments and 
optimisations to allow implementation on a 96-channel liquid-handling Hamilton 
STARplusW pipetting robot. Shortly, RPC18 beads were washed with a 0.1% 
trifluoroacetic acid solution and peptides were eluted using a 50% acetonitrile solution. 
The eluates obtained in this last step were transferred into a 96-well plate (i.e. eluate plate) 
and mixed with stabilisation buffer. A portion of these eluates (2 mL) was used for 
MALDI spotting while the remainder was frozen and stored at -80 ºC for later tandem 
mass spectrometry (MS/MS) experiments. MALDI spotting was performed on the 
96-channel liquid handling robot by mixing 2 mL of the sample eluates with 10 mL of an 
α-cyano-4-hydroxycinnamic acid solution (0.3 g/L in ethanol/acetone 2:1). Each sample 
was spotted in quadruplicate onto a MALDI AnchorChip (600 mm; Bruker Daltonics, 






MALDI-TOF-MS. MALDI-TOF experiments were performed on an UltraFlex II (Bruker 
Daltonics) either operating in positive reflectron mode in the m/z range of 600–4000 or in 
positive linear mode in the m/z range of 1000–6500. The spectra were acquired using 
FlexControl software version 3.0 (Bruker Daltonics). A Smartbeam 200 Hz solid-state 
laser, set at a frequency of 100 Hz, was used for ionisation. A profile, or summed 
spectrum, was obtained for each MALDI spot by adding 20 spectra of 60 laser shots each 
at different rasters. To this end, FlexControl software decided on-the-fly whether or not a 
scan was used for the summed spectrum. For reflectron mode acquisitions, a resolution 
higher than 2000 was required. Peaks were detected using the SNAP centroid peak 
detection algorithm with signal-to-noise (S/N) threshold of 1 and a ‘TopHat’ baseline 
subtraction. All mass scans not fitting these criteria were excluded. For linear mode 
acquisitions, a resolution higher than 100 was required and peaks were detected using the 
centroid peak detection algorithm with S/N threshold of 2 and a ‘TopHat’ baseline 
subtraction. The measurement of a MALDI spot was finished when 1200 laser shots had 
been summed in one profile. FlexAnalysis Software 3.0 (Bruker Daltonics) was used for 
visualisation and data processing. 
 
Internal calibration of MALDI-TOF serum peptide profiles. Prior to the measurement 
of the serum peptide samples, the MALDI-TOF system was externally calibrated using a 
commercially available peptide mix (Bruker Daltonics). All MALDI-TOF serum peptide 
profiles were baseline subtracted and internally calibrated using six previously identified 
peptides (see Results section and Fig. 3a). The TopHat algorithm was used for the 
baseline subtraction while the Centroid Algorithm, with a S/N threshold of 5 and a height 
of 80%, was used for the peak detection. 
 
MALDI-FTICR-MS. MALDI-FTICR experiments were performed on a Bruker 15 tesla 
solariX™ FTICR mass spectrometer equipped with a novel CombiSource (Bruker 
Daltonics, depicted in Fig. 1). The MALDI-FTICR system was controlled by Compass 
solariXcontrol software and equipped with a Bruker Smartbeam-II™ laser system that 
operated at a frequency of 500 Hz. The ‘medium’ predefined shot pattern was used for the 
irradiation. Each mass spectrum was obtained from a single scan of 600 laser shots using 
512 K data points. Typically, the target plate offset was 100 V and the deflector plate was 
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180 V. The ion funnels operated at 100 Vand 6.0 V, respectively, with the skimmers at 15 
and 5 V. The trapping potentials were set at 0.60 and 0.55 V, the analyzer entrance was 
maintained at -7 V, and side kick technology was used to further optimise peak shape and 
signal intensity. The required excitation power was 28% with a pulse time of 20.0 ms. 
MALDI-FTICR profiles were obtained from the same target plate that had been used for 
the MALDI-TOF acquisitions. Two acquisition settings were used to obtain profiles in the 
low-mass and high-mass range, for which only the different parameters are overviewed in 
Table 1. 
 
Internal calibration of MALDI-FTICR serum peptide profiles. DataAnalysis Software 
4.0 SP 3 (Bruker Daltonics) was used for the visualisation and the calibration of the 
spectra. Prior to the measurement of each MALDI plate the FTICR system was externally 
calibrated using a commercially available peptide mix and a protein mix (Bruker 
Daltonics). The spectra were then internally calibrated using the same six peptides as in 
MALDI-TOF profiles (see Results and discussion section, Fig. 3a). Peaks were detected 
using the FTMS algorithm with a S/N threshold of 5 and using the centroid for peak 
position with a percentage height of 85. An exclusion mass list was used to filter out all 
the peaks not included in the evaluation of the methods. 
 
Direct infusion ESI-FTICR-MS/MS for peptide identification. The eluates obtained 
from the RPC18-magnetic bead workup were used for MS/MS experiments (see section 
‘Sample collection’). To this end, eluates from 96 different samples were pooled and 
ultrafiltrated using a 30 kDa filter (Amicon Ultra 0.5 mL; Millipore). The filtrate was 
concentrated by lyophilisation before RPC18-LC/MS analysis on a splitless nanoLC-Ultra 
2D plus system (Eksigent, Dublin, CA, USA) equipped with a PepMap C18 trap column 
(300 µm i.d., 5 mm length; Dionex, Sunnyvale, CA, USA) and a ChromXP C18 analytical 
column (300 µm i.d., 15 cm length; Eksigent). Here, 1 min manual fraction collection was 
performed at a flow rate of 4 mL/min, with a gradient of 4% to 44% acetonitrile in 0.05% 
formic acid buffer. Then, the 35 fractions were analysed on the Bruker 15 tesla solariX 
FTICR mass spectrometer (Fig. 1) controlled by Compass solariXcontrol software after 
mixing them with 100 mL of spray solution (50:50 MeOH/H2O + 0.1% formic acid). 




experiments were performed using the quadrupole for precursor ion selection (with an 















Figure 1. Schematics of the Bruker 15 tesla solariXTM FTICR system equipped with a 
CombiSource, used for both MALDI precision profiling experiments as well as for direct 
infusion ESI peptide identification studies. 
 
 
Table 1. Instrument parameters that differed between low- and high mass acquisitions using 




Compass solariX control Low mass acquisition High mass acquisition 
Mass range m/z 1,013 – 3,500 m/z 2,026 – 6,500 
Time of Flight 1.300 ms 3.000 ms 
Quadrupole filter Mass m/z 1,540 m/z 2,500 
DC Extract Bias (hexapole 
 
0.6 V 0.7 V 
DC Bias (hexapole 2) -12 V -25 V 
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RESULTS AND DISCUSSION 
 In this study, both MALDI-TOF and MALDI-FTICR profiles were obtained 
from the same serum samples of 96 individuals using fully automated and standardised 
protocols for collection of human blood samples as well as solid-phase extraction (SPE) 
with RPC18-functionalised magnetic beads as previously described [17,21,22]. In Fig. 2, 
typical examples of MALDI peptide profiles are summarised. Figure 2(a) shows a low-
resolution linear mode TOF spectrum, as would be common in the early days of peptide 
profiling [21]. It is well known that in such a profile, peptides are observed as single broad 
peaks that only allow the determination of an average mass of the peptide. In the 
corresponding high-resolution reflectron spectrum, the isotopic peaks are resolved and 
thus measured independently, as is illustrated for the species at m/z 3265 (Fig. 2(b), inset 
III). Such monoisotopic peptide mass values are advantageous for identification purposes 
and have become the standard in peptide profiling [22]. Recently, the potential of a high-
resolution profile has been exploited in terms of analysing isotope distributions and 
internal correlations, and applied as a quality control (QC) parameter [17]. 
In this study, the same set of 96 different serum peptide samples was also 
measured on a 15 tesla MALDI-FTICR system. These FTICR profiles were obtained 
using two different acquisition settings in quick succession, i.e. for optimal coverage of 
peptides in the low-mass range as well as in the high-mass range. Typical examples of 
such ultrahigh resolution profiles are given in Figs. 2(c) and 2(d). All peptides in these 
spectra were isotopically resolved, with a resolving power 56 000 at m/z 6093 (Fig. 2(d), 
inset VI). The isotopic resolution of the peptides present in the profile improves the 
information regarding the chemical composition and allows further QC in clinical studies 
[17]. On average, the resolving power at m/z 3265 in the MALDI-TOF reflectron mode 
was 11 000 (Fig. 2(b), inset III), whereas in the corresponding FTICR profiles the 
resolution of this peptide was 52 000 (Fig. 2(c), inset V). Moreover, the ultrahigh 
resolving power provided by the MALDI-FTICR system resulted in the detection of 









Figure 2. MALDI peptide profiles were obtained on both a TOF and an FTICR system, 
depicted in red and blue, respectively. The peptides were solid-phase extracted from human 
serum samples. (a) Low-resolution linear mode MALDI-TOF profiles were recorded up to m/z 
6500 with all peptides observed as single peaks (inset I). (b) High-resolution reflectron mode 
MALDI-TOF profiles were recorded up to m/z 4500 with all peptide signals isotopically 
resolved (insets II and III). (c) A typical example of a low mass range MALDI-FTICR profile. 
The ultrahigh resolving power allows the detection of four overlapping peptides that could not 
be resolved in reflectron TOF data (comparing insets II and IV). (d) A typical example of a 
high mass range ultrahigh resolution MALDI-FTICR profile. (e) Venn diagram depicting the 
number of observed features in FTICR and reflectron TOF profiles. 
 
This is exemplified for the signal at m/z 1421: the isotopic distribution observed 
in the TOF profile suggests overlapping, nonresolved species (Fig. 2(b), inset II), which is 
confirmed in the FTICR spectrum that resolved four different species (Fig. 2(c), inset IV), 
that can thus be independently quantified. A detailed evaluation on the number of detected 
peaks, or features, with at least a relative intensity of 0.01% compared to the base peak 
and a S/N ratio higher than 10 in both TOF and corresponding FTICR profiles resulted in 
190 and 315 features, respectively. The results are summarised in Fig. 2(e), in which the 
features are divided into equidistant parts of the m/z range of 1000 to 4500. The Venn 
diagram shows that the number of the features detected in the MALDI-TOF spectra 
dramatically decreased along the m/z range, whereas in the corresponding FTICR profiles, 
the distribution of features over the considered m/z range was much more homogeneous. 
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In other words, most peptides in reflectron TOF spectra were profiled at the lower m/z 
range and in FTICR profiles all three parts of the m/z range contained more than 
50 features. In order to evaluate the repeatability of peptide mass measurements as well as 
the corresponding peak intensities in more detail, replicates of an in-house prepared serum 
sample standard (obtained from a pool a serum samples) were analysed. From this sample 
48 MALDI spots were measured in reflectron TOF mode, 48 spots were measured on the 
new FTICR system using the low-mass acquisition settings, and 48 spots were used to 
obtain high-mass FTICR profiles. In the TOF profiles 24 peptides were selected for a 
detailed evaluation, whereas in the low-mass and high-mass FTICR profiles 36 and 
21 peptides were used, respectively. The standard deviation of 48 mass measurements at 
48 different spots was calculated for each of the considered peptides after internal 
calibration using known MALDI profile peptides [23]. In the MALDITOF profiles this 
standard deviation varied from 0.70 to 7.7 ppm, with an average of 3.0 ppm. In the low-
mass and high-mass MALDI-FTICR profiles this standard deviation varied from 0.19 to 
1.0 ppm (average 0.51 ppm) and 0.25 to 2.2 ppm (average 1.1 ppm), respectively. In 
addition, the repeatability of the intensity measurements was determined from this dataset 
and results are provided in Supplementary Tables S1, S2 and S3 (see Supporting 
Information). It was found that the coefficient of variation (CV) was on average 16% in 
the TOF profiles (varying from 12 to 29% for 24 different m/z-values), 19% in the low 
mass FTICR profiles (varying from 9 to 33% for 36 different m/z-values), and 17% in the 
high mass FTICR profiles (varying from 11 to 26% for 21 different m/z-values). 
From these data it was concluded that the repeatability of the intensity measurement was 
rather similar for TOF (Ultraflex II) and FTICR (solariX). Aiming for high-throughput 
screening of clinical samples, a representative set of 96 human serum samples was spotted 
in quadruplicate on a MALDI target plate after SPE workup. From this plate, 
384 MALDI-TOF spectra were obtained as well as 192 corresponding ‘low-mass’ and 
192 ‘high-mass’ FTICR profiles. After a selection procedure based on the presence of 
calibrant peptides at a predefined S/N level 301 MALDI-TOF and 314 MALDI-FTICR 
spectra remained [17]. The m/z-values in the profiles were compared to a previously 
reported list of ‘MALDIMS profile peaks’[23]. Six of these identified peptides were 
selected for internal calibration, with calculated m/z-values of monoisotopic peaks of 




3-16, P02671), 1616.6594 (FPA 1-16 + P, P02671), 2021.1039 (complement C3f 
fragment, P01024), 2931.2915 (fibrinogen alpha (FGA) chain precursor 576-601, 
P02671), and 3261.4641 (FGA chain precursor 576-604, P02671). These six peptides with 
13 other (unidentified) peptides were selected for further evaluation of their MME and 
corresponding standard deviation for each individual spectrum. The results were 
summarised for all selected spectra and are depicted in Fig. 3(a). At a first glance the 
differences between TOF and FTICR spectra are as predicted, i.e. the TOF (red) errors 
dominate over the FTICR (blue) errors. It can be seen that the average MME of the 
peptides in 301 TOF profiles varied from -4.5 to 4.6 ppm and in 314 FTICR profiles from 
-0.8 to 0.9 ppm. Note, however, that some of the MMEs are at a low-ppm level in 
reflectron mode TOF profiles, and sometimes even lower than in corresponding FTICR 
profiles. However, the average mass measurement error only informs us about the 
robustness of the instrument and its calibration. It is the precision of the mass 
measurement that is crucial for alignment, integration and quantitation. Here the benefit of 
using FTICR is more obvious, as the standard deviation of the MME for peptides 
observed in both TOF and FTICR profiles is at least 10-fold better in the ultrahigh 
resolution spectra. An improved precision is of great value for profiling studies since it 
simplifies analysis and makes spectral alignment more accurate and robust. Alignment of 
spectra across all samples and individuals is essential for valid comparisons of profiles in 
clinical studies. As an example, the results of the standard alignment procedure (see 
Experimental section) of the peptide at m/z 1518.68 detected in both TOF and FTICR 
profiles are shown in Fig. 3(b). Note that this alignment was performed on profiles from 
96 different individuals and thus included large intensity differences of each peptide up to 










Figure 3. (a) Comparison of mass measurement errors of known peptides in TOF and FTICR 
profiles. The errors and corresponding standard deviations were determined from replicate 
measurements of 96 different serum samples. The peptides indicated with an asterisk were 
used for internal calibration. The peptide identities are as follows: 1206.6=G.EGDFLAEGGGVR; 
1350.6=D.SGEGDFLAEGGGVR; 1465.7 =A.DSGEGDFLAEGGGVR; 1518.7=ADS(-H2O)GEGDFLAEGGGVR; 
1536.7=ADSGEGDFLAEGGGVR; 1616.7 =ADSpGEGDFLAEGGGVR; 1739.9=R.NGFKSHALQLNNRQI.R; 
1778.0=S.SKITHRIHWESASLL.R; 1865.0 = SSKITHRIHWESASLL.R; 1896.0=G.RNGFKSHALQLNNRQI.R; 
2022.1=SSKITHRIHWESASLLR; 2271.1= S.SRQLGLPGPPDVPDHAAYHPF.R; 
2553.1=K.SSSYSKQFTSSTSYNRGDSTFES.K; 2768.2 =K.SSSYSKQFTSSTSYNRGDSTFESKS.Y; 
2932.3=K.SSSYSKQFTSSTSYNRGDSTFESKSY.K; 3157.6=R.NVHS 
GSTFFKYYLQGAKIPKPEASFSPR.R; 3191.4=K.SSSYSKQFTSSTSYNRGDSTFESKSYKM.A; 3262.5=K.S 
SSYSKQFTSSTSYNRGDSTFESKSYKMA.D; 3278.5=K.SSSYSKQFTSSTSYNRGDSTFESKSYKMoxA.D. 
(b) Comparison of alignment of MALDI-TOF and FTICR profiles, exemplified for the 
monoisotopic peptide signal at m/z 1518.68. Spectra were obtained from 96 different serum 
samples, all spotted in quadruplicate on a MALDI AnchorChip target plate. Different colors 
are applied for the individuals and serum aliquots to indicate heterogeneity in disease state 






Moreover, it should be mentioned that the alignment of FTICR spectra was 
performed much faster and with fewer (no) errors compared to TOF data. An additional 
advantage of the improved precision relates to peak identification. When assuming a 
normal distribution of MMEs in a specific set of profiles, it can be reasoned that the exact 
mass of the species lies with 95% certainty within two standard deviations from the 
measured mass. Provided the m/z-values of unknown peaks are determined at a sub-ppm 
precision level, the identification window in a database search can also be limited to such 
a level [19,24]. The MALDI-FTICR precision profiles presented here of human serum 
peptides contain more than 100 different peptides, all with a measured m/zvalue at 
sub-ppm precision. It is well recognised that a similar mass precision of a large amount of 
peptides can be obtained from an LC/MS platform with high-end mass analysis, such as 
the Orbitrap or an ESI-FTICR system [25,26]. Note, however, that an LC/MS approach 
requires much more measurement time per sample and as a result the compatibility with 
large cohorts is challenging. The solariX-FTICR system was also used to perform MS/MS 
experiments. To this end, peptide mixtures were directly infused in ESI mode, isolated in 
the Q and fragmented using CID gas in the hexapole collision cell (see Fig. 1).These 
peptide mixtures were obtained after suitable sample cleanup from the magnetic bead 
eluates (as described in the Experimental section). Five new peptides could be identified 
from MS/MS experiments, namely EGDFLAEGGGV (from fibrinopeptide alpha chain5-
15, uniprot P02671), AcGEDAAQAEKFQHPG (from serum deprivation-response protein 
2-15, O95810), pyroQAGAAGSRMNFRPGVLS (from inter-alpha-trypsin inhibitor H4 
650-666, Q14624), AcSETSRTAFGGRRAVPPNNSNAAEDDLPTVELQGVVPR (from 
factor XIIIa 2-60, P00448), and TFGSGEADC336(C482)GLRPLFEKKSLEDKT 
ERELLESYIDGR (from prothrombin 328-363, P00734). Note that the latter peptide 
contains a cysteinylation at cysteine 336 (indicated between parentheses) that originates 
from the disulfide bridge to cysteine 482. All these assignments were carried out with sub-
ppm MMEs on both the selected precursor ion as well as the fragment ions (data not 
shown). Note that the FTICR provides low ppm MMEs (i.e. precise data) that allow an 
accurate overlap between species observed in MALDI profiles and those determined in 
ESI spectra, such as previously reported with a 2 ppm window [27]. In the current study 
this window of overlap between ESI and MALDI data was even lower than 1 ppm, e.g. 
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0.33 ± 0.48 ppm for the peptide 650-666 from inter-alphatrypsin inhibitor H4, and 
-0.34 ± 0.67 ppm for the peptide 2-60 from factor XIIIa. 
 
CONCLUSIONS  
In this study, we show that a combination of highly standardised sample workup protocols 
with ultrahigh resolution FTICR-MS generates serum peptide profiles with very low 
MMEs. Following the current developments in ultrahigh resolution MS, mass 
measurement at higher precision improves the alignment of multiple spectra that are 
needed for comparative analysis. Moreover, MALDI-FTICR spectra provide m/z-values at 
sub-ppm precision of all species present in the profiles. From replicate measurements on 
multiple MALDI spots of an in-house prepared serum sample standard it was concluded 
that coefficients of variance (CVs) of peak intensities were similar in TOF and FTICR-
spectra. A pool of the serum samples was further analysed by direct infusion ESI-FTICR-
MS/MS experiments, which resulted in new peptide identifications for five m/z-values. 
Ultrahigh resolution peptide profiling builds on recent developments of MS systems and 
measurement strategies that provide low MMEs that significantly aid data analysis 
workflows in discovery studies. Such high precision is essential for robust and 
standardised high-throughput screening of hundreds to thousands of patient samples. 
 
SUPPORTING INFORMATION 
Supporting information may be found in the online version of this article. 
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In this study, we have implemented a new quality control (QC) parameter for peptide 
profiling based on isotopic distributions. This QC parameter is an objective measure and 
facilitates automatic sorting of large numbers of peptide spectra. Peptides in human serum 
samples were enriched using reversed-phase C18-functionalized magnetic beads using a 
high-throughput robotic platform. High-resolution MALDI-TOF and ultrahigh resolution 
MALDI-FTICR mass spectra were obtained and a workflow was developed for automated 
analysis and evaluation of these profiles. To this end, the isotopic distributions of multiple 
peptides were quantified from both MALDI-TOF and MALDI-FTICR spectra. 
Odd peptide isotope distributions in TOF spectra could be rationalized from ultrahigh 
resolution FTICR spectra that showed overlap of different peptides. The comparison of 
isotope patterns with estimated polyaveragine distributions was used to calculate a QC 
value for each single mass spectrum. Sorting these QC values enabled the best MALDI 
spectrum to be selected from replicate spots. Moreover, using this approach spectra 
containing high intensities of polymers or other contaminants and lacking peptides of 
interest can be efficiently removed from a clinical dataset. In general, this method 








In the past decade, discovery studies in clinical proteomics have evolved synergistically 
with the technological progress made in mass spectrometry (MS). The growth in the field 
of MS-based proteomics [1, 2] has been driven by the introduction of new identification 
techniques [3, 4] and improvements in the resolution, mass accuracy, robustness, and 
dynamic range of modern mass analyzers [5– 8]. From the early days, serum peptide- and 
protein profiling has played a major role in clinical studies for biomarker discovery, 
aiming at identifying differences in peptide- and protein levels in serum of healthy and 
diseased individuals [9 –13]. Peptide and protein patterns can change as a result of disease 
and are thus helpful in both early detection and monitoring the development of the 
disease. However, serum is a very complex mixture of biomolecules and, therefore, 
requires appropriate sample workup. In addition to the complexity, the peptide and protein 
profiles of serum are usually dominated by highly abundant species (the tip of the iceberg) 
[14]. Different strategies have been followed to reduce the biological complexity of 
human serum samples and multiple methods and technologies have been developed for 
the purpose of sample workup [15–19]. The combination of protein and peptide extraction 
using functionalized magnetic beads with matrix-assisted laser desorption/ionization 
(MALDI) MS has been widely used for profiling studies [20 –22]. One of the advantages 
of this approach is that automation of both solid-phase extraction (SPE) and MS allows 
high-throughput screening. Also, for each serum sample, fresh disposable magnetic beads 
are used, thus avoiding carry-over that may occur when other techniques such as liquid 
chromatography (LC) are used. Moreover, magnetic beads with a different functionality 
allow protein- and peptide enrichment based on different chemical-physical interactions, 
thus broadening the range of components covered. Several studies have focused in detail 
on sources of variance in profiling experiments and the necessity of standardization in 
sample collection and preparation has been demonstrated [23–25]. Robotic liquid 
handling has the advantage of better reproducibility of the SPE and a greatly increased 
throughput. Robotic platforms enable a fully automated use of magnetic beads and ensure 
the control of each step in the extraction protocol [26 –28]. In addition, the high speed of 
data acquisition of MALDI MS allows the analysis of thousands of samples in a realistic 
time period. The application of statistical analysis for the evaluation of the high number of 
data generated using this strategy, finally enables a more confident identification of 
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possible biomarkers. In profiling studies, the most commonly used mass analysis in 
combination with MALDI is time-of-flight mass spectrometry (TOF-MS) [29 –31]. 
Following the current developments in high-resolution mass spectrometry, MALDI 
coupled with Fourier transform ion cyclotron resonance (FTICR-MS) has been applied for 
the same purpose [32, 33]. The high-resolution and low or even sub-ppm mass 
measurement errors result in more confident peptide and protein assignments. In this 
study, we compared peptide profiles using the two MS-platforms indicated above, i.e., 
MALDI-TOF and MALDI-FTICR. With respect to large-scale mass spectrometric 
proteomic or peptidomic profiling experiments, the quality control (QC) of both the 
workflow and the data yielded is an arduous task. Variations can occur pre-analytically 
(blood collection, clotting time, storage conditions), in the analytical workflow, and in the 
data acquisition (MS experiments). The human eye is extremely good at differentiating 
multiple pictures, e.g, peptide profiles. However, the visual inspection of all acquired 
spectra would be time-consuming and subjective. For this reason, various QC procedures 
and tools have been developed that allow (automated) evaluation of peptide and protein 
MS profiles [34 –38]. Generally, the signal to noise ratio and/or the threshold of the noise 
level are taken into account, whereas in MALDI MS protein and peptide profiling the 
reproducibility of the signal intensity is rigorously evaluated [39,40]. The use of a highly 
robust protocol including replicate measurements for each sample allows further 
standardization. The evaluation of noise levels of different datasets (e.g, different MALDI 
plates) is more cumbersome and prone to bias. In this study, we describe a novel QC 
approach for the automatic selection of mass spectra, based on peptide isotopic 
distributions. To this end, the previously used model amino acid averagine was used to 
carry out detailed comparisons [41]. A recently developed integration method was used to 
obtain intensity values for each isotope signal within a given distribution [42]. We will 
show that this QC parameter can clearly discriminate good and poor peptide spectra. 
 
MATERIALS AND METHODS 
Blood Collection and Serum Handling. Blood samples were collected from patients and 
healthy volunteers by antecubital venipuncture while the person was seated. Informed 
consent was obtained from all patients, and the Leiden University Medical Center 




carried out under supervision of the Department of Surgery at the LUMC. It is outside the 
scope of this paper to give a detailed description of the various patient cohorts. Subsets of 
the data will be reported elsewhere. Within 1 h after collection of blood in a 10 mL BD 
vacutainer tube (containing a clot activator and a gel for serum separation) the sample was 
centrifuged for 10 min at 1500 x g. The serum was then transferred to a 1 mL 
polypropylene cryovial, frozen, and stored at -80 °C. Each cryovial was thawed only once 
and divided over eight 50 µL Matrix 2D barcoded storage tubes (Thermo Fisher Scientific 
Inc., Hudson, NH, USA) using an 8-channel Hamilton pipetting robot. These tubes were 
then distributed over eight different 96-sample matrix latch racks, thus yielding eight 
identical Matrix racks containing 96 different serum samples. These racks were frozen 
again at -80 °C and a rack was thawed only once for the automated peptide capture 
procedure. The sample thawing time, i.e., the time between taking a rack out of the freezer 
and the starting time of the peptide isolation procedure (next section), was between 30 and 
60 min for all serum samples. This high degree of standardization in sample handling and 
sample thawing-time in combination with the use of the 96-channel pipetting robot 
ensured identical (robust) and simultaneous treatment of all serum samples in the peptide 
isolation procedure. 
 
High-Throughput Peptide Isolation with RPC18 Dynabeads and MALDI Spotting. 
The isolation of peptides from human serum was performed using reversed-phase 
C18-functionalized magnetic beads [11, 26, 27]. For each sample, a fresh suspension of 
paramagnetic monodisperse beads was used and all 96 serum samples in one Matrix rack 
were incubated with the same lot-number of beads. In this study 10 µL of commercially 
available RPC18 Dynabeads (Invitrogen, Carlsbad, CA, USA) was used for the analysis 
of 5 µL of undiluted human serum. The activation, wash, and desorption steps of the 
RPC18 beads were based on the manufacturer’s protocol; however, the protocol was 
adjusted to enable an optimal implementation on a 96-channel Hamilton STARplus 
pipetting robot (Hamilton, Bonaduz, Switzerland). In short, a plate containing 96 magnets 
was designed and built in-house to accommodate a 96-well PCR microtiter plate (MTP) 
and to allow for optimal settlement of the magnetic beads at the bottom of each well. 
Furthermore, it was found that additional activation steps were needed, since automated 
pipetting does not allow the removal of all liquid from the pulled-down magnetic beads. 
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Thus, for optimal removal of preservatives during the activation step, the RPC18 beads 
were washed three times with 50 µL of water. For similar reasons, after binding of the 
peptides to the RPC18 beads three wash steps with 50 µL of a 0.1% trifluoroacetic acid 
solution were carried out. Finally, the eluates obtained in the peptide desorption step 
(performed with a 50% acetonitrile solution) were transferred to a 96-well plate and 
mixed with stabilization buffer. A portion of these eluates (2 µL) was used for MALDI-
spotting while the remainder was frozen and stored at -80 °C for future analysis. 
The 96-channel Hamilton STARplus pipetting robot was used for mixing of sample 
eluates with MALDI matrix, followed by spotting on a MALDI target plate. To this end, 
2 µL of the stabilized eluate was transferred into a fresh 384-well MTP and mixed with 
10 µL of α-cyano-4-hydroxycinnamic acid (0.3 g/L in ethanol:acetone 2:1). Four MALDI 
spots of each eluate were obtained after quadruplicate spotting on a MALDI AnchorChip 
(600 µm; Bruker Daltonics, Bremen, Germany) using 1 µL of the eluate/matrix mixture 
for each spot. 
 
MALDI-TOF and -TOF/TOF Mass Spectrometry. After MALDI spotting, the target 
plate was immediately stored in a storage chamber (RT, 5% oxygen, 95% nitrogen), until 
transfer into the MALDI-TOF instrument by a CRS F3 robotic arm (Thermo Fisher 
Scientific Inc., Marietta, OH, USA), as a fully automated plate loader [43]. In this way, all 
MALDI-TOF measurements were carried out within 12 h after spotting on the 96-channel 
robot. All MALDI-TOF experiments were performed on an UltraFlex III (Bruker 
Daltonics) operating in positive reflectron mode in the m/z range of 600–4000. 
The spectra were acquired using FlexControl software ver. 3.0 (Bruker Daltonics) with 
identical data acquisition parameters. A SmartBeam 200 Hz solidstate laser, set at a 
frequency of 100 Hz, was used for ionization. A profile, or summed spectrum, was 
obtained for each MALDI-spot by adding 20 spectra of 60 laser shots each at different 
rasters. FlexControl software decided on-the-fly whether or not a scan was used for the 
summed spectrum. To this end, a resolution higher than 2000 was required. Peaks were 
detected using the SNAP centroid peak detection algorithm with signal-to-noise threshold 
of 1 and a “TopHat” baseline subtraction. All mass scans not fitting these criteria were 
excluded. The measurement of a MALDI spot was finished when 1200 laser shots had 




4000 and externally calibrated using a commercially available peptide mix (Bruker 
Daltonics). FlexAnalysis Software 3.0 (Bruker Daltonics) was used for visualization and 
initial data processing. For identification, the LIFT-TOF/TOF spectra were recorded on 
the same Bruker Ultraflex III TOF/TOF mass spectrometer. No additional collision gas 
was applied. Precursor ions were accelerated to 8 kV and selected in a timed ion gate. 
The fragments were further accelerated by 19 kV in the LIFT cell, and their masses were 
analyzed after the ion reflector passage. 
 
Peak Alignment in MALDI-TOF Serum Peptide Profiles. The workflow for processing 
peptide profiles is depicted in Figure 1. After external calibration using a commercially 
available peptide mix, the maximum observed mass shift in the 384 spectra varied from 
~0.1 Da at m/z 1500 to 0.2 Da at m/z 4000. Before carrying out the alignment a baseline 
subtraction of all spectra was performed. To allow the alignment of all 384 spectra from 
one MALDI target plate, at least three peptides at different m/z values were needed for 
internal calibration. To compensate for the possible absence of one or two peptides in a 
spectrum, the following five peptides were selected based on a manual inspection of a few 
spectra, namely m/z 1465.8, 1778.1, 1865.2, 2602.5, and 2931.5, with a tolerance window 
of 100 ppm for the m/z 1465.8 peak increasing up to 300 ppm for the highest m/z value 
(FlexAnalysis 3.0). 
 
Determination of Peak Intensities Using Xtractor. All MALDI-TOF and the MALDI-
FTICR spectra were exported as DAT (.dat) and XY (.xy) files, respectively. In both 
formats (ASCII), all m/z values with corresponding intensities (i.e., data points) were 
reported. The simple Xtractor tool was used to determine the intensity of each user-
defined peak [42]. To this end, a certain m/z window was defined for each peak included 
in a so-called reference file, thus allowing Xtractor to sum all the intensities of the data 
points within the defined bin. The bin size for all peaks in the MALDI-TOF spectra was 
fixed at ±0.49 Da, the bin size for the peaks in the MALDI-FTICR spectra varied from 
±0.02 Da at m/z 1465.8 to ±0.08 Da at m/z 2931.5. In this way, single intensity values for 
each isotopic peak within any isotope distribution were obtained. Importantly, Xtractor 
generates uniform data (peak) arrays regardless of spectra content (Xtractor is an open 




Figure 1. Overview of three sequential processing methods for the generation and evaluation 




Calculation of Peak Intensities in Peptide Isotope Distributions. The observed peptide 
isotopic distributions were compared with those obtained from the polyaveragine model 
as explained in Results and Discussion section. The theoretical isotopic distribution of a 
polyaveragine peptide was calculated using chemcalc (www.chemcalc.org). 
The elemental composition used for the calculation of peak intensities of each individual 
isotope reflected a singly protonated polyaveragine peptide molecule with integer 
numbers for all indices of the atoms C, H, N, O, and S. In a similar way, the theoretical 
isotopic distribution of the peptide at m/z 1465.8 was calculated after identification of this 
peptide using MALDI-TOF/TOF. Note that each individual isotope within a distribution 
was considered as one single peak, as described earlier by Rockwood et al. [44] Thus, by 
using the jcamp file from chemcalc, all calculated intensities within the isotopic fine 




MALDI-FTICR Mass Spectrometry. All MALDI-FTICR experiments were carried out 
on a Bruker Daltonics apex-ultra 9.4 tesla FTICR mass spectrometer. This instrument was 
equipped an Apollo II dual ion source, two ion funnels, a selection quadrupole in the 
front-end, and an Infinity ICR cell. For the purpose of comparing FTICR-measurements 
with results obtained from the TOF, manual MALDI-spotting was carried out from a 
frozen 96-well eluate plate. After thawing the RPC18 eluates at room-temperature, 2 µL 
of each eluate was transferred into a 384-well plate and mixed with 10 µL of α-cyano-4-
hydroxycinnamic acid (0.3 g/L in ethanol:acetone 2:1). Finally, 1 µL of this mixture was 
manually spotted on a MALDI Anchor-Chip (600 µm) in duplicate using a standard 
Gilson P2 pipette. In this way, 192 spots of 96 different samples were obtained. These 
spots were measured on the FTICR using a SmartBeam 200 Hz solid-state laser, operated 
a frequency of 100 Hz. The irradiation spot size was ~200 µm. The ions generated from 
50 laser shots were accumulated in the hexapole and then transferred through the 
quadrupole to the collision cell. This process was repeated eight times on different raster 
spots. The 450 laser shots accumulated in the collision cell were then transferred to the 
ICR cell for mass analysis. The quadrupole was set to an m/z of 400 and RF amplitude of 
3000 Vp-p. Each spectrum was generated by accumulation of eight scans with 512 K data 
points. All data were acquired using the Bruker ApexControl software and evaluated 
using Bruker DataAnalysis software. 
 
 
RESULTS AND DISCUSSION 
Peptide Isotope Distributions in MALDI-TOF Spectra. The workflow for sample, 
profile, and data processing is depicted in Figure 1. One of the aims of this study was to 
demonstrate the use of peptide isotopic distributions of peptides for quality control 
parameter. For illustration, the isotopic patterns of the five ubiquitous peptides used for 
alignment are shown in Figure 2. While the selection of these five peptides was an 
arbitrary process, no software is available that yields a better result without the need of 
user-defined input parameters. One of these peptides was identified, namely m/z 1465.8, 
as a fragment of fibrinogen α-chain (P02671, peptide DSGEGDFLAEGGGVR). 
Previous reports corroborate this identification [45]. Using the elemental composition of 
this peptide the theoretical isotopic distribution was calculated (see the Materials and 
Methods section). It should be emphasized, however, that identification of the peptides is 
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not necessary for the evaluation of isotopic distributions, but clearly becomes important at 
the stage a biomarker candidate has been detected. Different strategies, followed by 
adjustments, have been proposed for the estimation of isotopic distributions of 
unidentified peptides [36, 46, 47]. In this study, we used the “averagine” model, proposed 
by Senko et al. to construct peptides from a hypothetical average amino acid [41]. This is 
sufficient for the estimation of isotopic distribution of unknown peptides since we are not 
searching for the best fit, but only need to discriminate between peptide and nonpeptide 
(e.g, polymer, matrix cluster) distributions. The estimated values of the five peptides are 
depicted in Figure 2. These are obtained by first transferring a peptide m/z value into a 
neutral mass (i.e., [m/z value–proton–water]), then dividing this number by the exact mass 
of averagine (i.e., 111.0543 Da), and multiplying the result with the indices of the 
molecular formula of averagine (i.e., C4.9384H7.7583N1.3577O1.4773S0.0417). Finally, 
one “water-molecule” and a proton are added to create the corresponding “polyaveragine” 
molecular formula and m/z value. Due to rounding of the indices, the m/z values of the 
observed peptide and the corresponding polyaveragine are not identical. It is clear from 
Figure 2 that the isotopic patterns of the five peptides used for alignment were in good 
agreement with the polyaveragine distributions. A quantitative evaluation of these isotope 
distributions will be given in the next section. Differences with estimated distributions 
may be indicative of the presence of peptides that contain post-translational modifications 
(PTMs) or metal cations, or may point at overlapping peptides. Two examples of the latter 
cause of aberrant isotopic distributions are revealed in Figure 3a. Here, the isotope 
distributions of two peptides present in some of the MALDI-TOF profiles did not match 
those of the corresponding polyaveragine peptides. Subsequent high-resolution FTICR 
mass analysis of the same m/z values clearly showed overlap of two different peptides. 
Further analysis showed that the weighted sum of two estimated polyaveragine 
distributions (with a mass difference of one Da) matched the distributions observed in the 
TOF spectra. Differences with estimated distributions can be also indicative of sample 
contamination, such as polymers [48]. An example of MALDI-FTICR spectrum that 
contains polymer Tinuvin-622 is shown in Figure 3b. The comparison of the isotopic 
distribution of the polymer at m/z = 1732 with that estimated from a polyaveragine peptide 









Figure 2. (a) MALDI-TOF peptide profile obtained from human serum after sample workup 
using RPC18-functionalized magnetic beads. (b) Observed isotopic distributions of five 
peptides chosen for alignment of all serum peptide profiles. The horizontal lines at the top of 
the peaks represent the calculated values of the corresponding polyaveragine peptides. 
(c) Profile processing results in a QC value for each individual mass spectrum. First, the 
intensity of each isotope peak is determined using Xtractor. Then, after normalization, the 
observed intensities are compared with those estimated from the polyaveragine peptide. For a 
more accurate determination of the deviation, the random noise variance is taken into 
account. Finally, the sum of thus obtained deviations for all considered peptides represents the 





Figure 3. (a) Examples of deviations from the polyaveragine model due to overlap of different 
peptides. Left panel: enlarged part of a MALDI-TOF human serum peptide profile showing 
odd isotopic distributions. Middle panel: calculated isotope distributions of the corresponding 
polyaveragine peptides. Right panel: enlarged part of the MALDI-FTICR mass spectrum of 
the same spot reveals the presence of overlapping peptides 1 and 2 that cause the odd isotopic 
distribution in the MALDI-TOF spectra, and overlapping peptides 3 and 4. (b) Example of 
deviation from the polyaveragine model due to different peak identity. A MALDI-FTICR 
spectrum dominated by polymers of tinuvin-622 (poly-(N-β-hydroxyethyl-2,2,6,6-tetramethyl-
4-hydroxy-piperidinyl succinate). The enlarged part shows the isotopic distribution of the 
polymer m/z 1732 and the isotopic distribution calculated from a polyaveragine peptide with 




Quality Control Based on Peptide Isotope Distributions. The intensities of the 
observed peaks in each peptide isotope distribution were determined using Xtractor 
(see the Materials and Methods section). As an example, for the peptide at m/z 1865.22 
the intensity of the monoisotopic was determined as the sum of all measured values at 
m/z 1865.22 ± 0.49, the intensity of the second isotope was determined as the sum of all 
measured values at m/z 1866.22 ± 0.49, and so forth (Figure 2). The window of 0.49 Da 
was chosen to ensure total quantification of each isotope. This window of 0.49 Da does 
not reflect the actual peak width, i.e., the resolution of the peptides in the MALDI-TOF 
spectra varied from about 7000 at m/z 1465.8 and about 10,000 at m/z 2931.5. It should be 
noted that the density of data points decreases with increasing m/z values in a TOF 
spectrum. As a result, the number of data points within each bin differs between different 
peptides. However, within one peptide isotopic pattern, the number of data points is the 
same for each single isotopic peak, at least for the five peptides considered here. Three 
intensity values were obtained for all five peptides previously discussed in the spectral 
alignment part using the Xtractor tool. All isotope intensities were then normalized using 
the sum of the first three intensities within the distribution. These intensities were 
compared with the corresponding abundances in a polyaveragine isotopic distribution, as 
previously described by Palmblad et al. [49]. Here, the total signal variance is taken into 
account in the parameter σ2m. In the aforementioned study, carried out using electrospray 
ionization (ESI) FTICR-MS, σ2m contained two terms, namely, experimental signal 
variance, which was approximately proportional to signal strength, and noise variance, 
which was constant. In MALDI spectra; however, every single laser shot yields a different 
amount of ions. As a result, the noise levels are not constant. In general, in the MALDI-
TOF experiments performed in this study the noise variance decreased at increasing 
m/z values, whereas the opposite was true for the MALDI-FTICR spectra. For the purpose 
of biomarker discovery and subsequent validation a detailed evaluation of noise variance 
is pivotal. In this respect, various studies have been reported to determine sources of 
variance and to provide tools for quantification [14, 25, 31, 34]. The aim of this work is 
the development of a new tool for evaluation of spectral quality to improve future 
biomarker discovery studies. To this end, for further calculations the total signal variance 
σ2m was estimated as follows. For one single MALDI target plate the noise levels in TOF- 
and FTICR profiles were determined for each of the five considered peptides as an 
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average from 10 different samples (summarized in Table 1). Thus, σ2m was considered 
constant at a specific m/z value for each sample on one MALDI target plate. Based on 
visual inspection of the spectrum, an “empty” m/z region was selected for each peptide 
used for alignment to calculate a corresponding σ2m value. Using these σ2m values the 
deviations between estimated and observed isotopic distributions were determined and 














in which P and M are the number of peptides and isotopes considered per peptide, 
respectively; I*m(est.) and I*m(obs.) are the intensities of the estimated and observed 
isotopic peaks normalized for the sum of the intensities of the first three isotopic peaks in 
the corresponding isotopic distributions; the σ2m value is the random variance noise 
calculated in a small set of analyzed spectra. 
As an example, the QC values of 384 mass spectra (quadruplicate spots of 96 different 
serum samples on one MALDI target plate) are depicted in Figure 4. Note that a low QC 
value corresponds with a high quality spectrum. For most samples with a high quality 
profile, a similar QC value was observed for the four replicates, as exemplified for S21 in 
Figure 4. From this it was be concluded that MALDI-spotting followed by mass analysis 
showed good repeatability. QC based on isotopic distribution is a powerful tool for the 
evaluation of samples that yield low quality spectra. In some cases, only one out of four 
spectra was poor, as exemplified for S83, in other cases three out of four replicates were 
poor (e.g, S4 and S49). For this reason it is proposed to select the “best” spectrum of each 
sample for statistical analysis, i.e., with the lowest QC value. In cases that all four 
replicates yielded empty spectra (e.g, S58) or showed poor QC values (indicated with 
circled sample codes in Figure 4) the sample was excluded from further analysis. 
Applying the selection of one high quality spectrum for each sample ensures standardized 
further statistics, whereas upon considering all replicate spots the final profile is obtained 
after averaging of two, three or four spectra. 
Another way to evaluate the similarity of multiple MALDI profiles is using the dot-




In such a comparison, all signal is taken into account, including background peaks. 
The quality of spectra has been evaluated in detail counting the number of peaks in each 
replicate measurement [50]. Note that the number of peaks in a spectrum may be high as a 
result of contaminants and as such is earmarked “good quality”. The same problem will 
arise upon using total ion intensities, which is exemplified in Figure 5. Here, the FTICR 
spectrum of no. 3 contains mostly polymers with high signal-to-noise ratios and will result 
in a false positive. As an alternative, peak picking algorithms are widely used to determine 
intensities of specific compounds in a spectrum. In combination with peak picking the 
quality of one single isotope distribution can be determined using the “sophisticated 
numerical annotation procedure” or SNAP (Bruker). When summarizing the SNAP 
quality factors of the five selected peptides, a similar trend as in our proposed quality 
values was observed. However, the extraction of SNAP quality factors from large 
numbers of mass spectra is time-consuming due to necessary peak picking and 
deconvolution of each spectrum. Moreover, in the case of a low quality spectrum these 
processes are often not robust and make automation more difficult. When manually 
applying SNAP on the same five peptides used for alignment, out of the four replicates in 
Figure 4, the same profiles were selected as low quality. 
 
Comparative Analysis of MALDI-TOF and MALDI-FTICR Spectra. For the purpose 
of comparing TOF and FTICR serum peptide profiles, the same 192 spots on a MALDI 
target plate were measured both on a MALDI-TOF and a MALDI-FTICR instrument. 
The QC value for each TOF spectrum as well as for each FTICR spectrum was 
determined according to eq 1. The results are plotted in Figure 5 after sorting. Here, it can 
be observed that a small fraction of the spectra showed a drastically increased QC value 
that is indicative for a poor spectral quality. It was verified that all TOF-spectra of 
MALDI-spots with high QC value also yielded low quality FTICR-spectra. In other 
words, trend analysis of both TOF- and FTICR data resulted in a similar selection of low 
quality data. It is important to note that the choice of a cut-off point in Figure 5 will be 
different for each MALDI target plate considered. Any chosen cut-off point for the 
discrimination between the high and the poor quality spectra based on QC values will 
introduce false-positive and false-negative results. For a quantitative analysis, the 
normalized intensities estimated from the polyaveragine peptides, the average ratios of the 
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isotopic distributions and their coefficients of variation were evaluated for the five 
peptides discussed earlier (see Figure 2) and the results are summarized in Table 1. In this 
evaluation, the 
50 MALDI-TOF and the 50 MALDI-FTICR mass spectra with lowest QC values were 
selected from the results obtained from 192 peptide profiles in Figure 5. It can be seen 
from Table 1 that the observed isotope ratios were in good agreement with those estimated 
from the polyaveragine distribution. For example, the averaged isotope ratio of the first 
and the second peak in the distribution of the peptide at m/z 1865 was 1.1 in the TOF 
spectra and 1.0 in the FTICR, which is in good agreement with the estimated value of 1.0 
from the polyaveragine peptide with m/z 1886. The results in Table 1 show that the 
coefficients of variation of the first isotope ratios were within 6% and 13% for MALDI-
TOF and MALDI-FTICR, respectively. With respect to the possibility of overlap of 
multiple peptides, it was observed from MALDI-FTICR data that the m/z regions of the 
five peptides manually selected for the QC method contained a singly species. Finally, if 
in the serum, glycopeptides would be present in which the contribution of the glycan part 
is relatively large, these would be lost upon the RPC18 extraction. This leaves inherent 
deviations from the polyaveragine peptide as the only explanation for different isotopic 
distributions in the five peptides. Thus, the observed deviations can be attributed to the 







Figure 4. (a) Histogram of 384 QC values of 96 human serum samples measured in 
quadruplicate with MALDI-TOF. The low values (short bars) indicate high quality spectra 
while a negative value is automatically assigned when an empty spectrum is recorded. Based 
on these QC values it was found that from the total batch of recorded peptide profiles, 
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63 spectra were of poor quality, i.e., 16% of the data were not suitable for further analysis. 
The cut-off point is indicated with an arrow in the plot. For seven samples, all four replicates 
yielded a poor quality spectrum (indicated with a circle over the sample code). As a result, 
when taking into account only the spectrum with the highest quality for each sample, 93% of 
the data were of high quality and included for further analysis. (b) Two examples of four 
replicate MALDI-TOF spectra of samples S21 and S83. The calculation of the QC values for 
each of these peptide profiles allowed the selection of one spectrum for further analysis. 
Ordering according to the QC method resulted in sample 23 in 4-1-2-3 and in sample 83 in 
4-2-3-1. Ordering according to the sum of SNAP quality factors of the same five peptides 





Figure 5. Plot of QC values derived from 192 MALDI-TOF and MALDI-FTICR human 
serum peptide profiles. These 192 profiles were obtained from 96 different samples after 
duplicate spotting on a MALDI target plate. The QC values are calculated applying eq 1 to the 
isotopic distributions of five peptides selected in Figure 2. After sorting the MALDI spot 





Table 1. The averages of the normalized intensities of the isotope peaks and the coefficients of 
variation, calculated from the isotopic distribution of five different peptides, are reported. The 
data were calculated using 50 MALDI-TOF and 50 MALDI-FTICR mass spectra with the 
lowest QC-values obtained from the measurements of 96 human serum peptide samples 
(see Figure 4). The σ2m is the averaged random noise variance measured in sub-set of MALDI-
TOF and MALDI-FTICR in m/z windows of 5 Da near the monoisotopic peak of each peptide 
and containing only background signal. 
 
CONCLUSION 
In this study, the isotopic distributions of a small set of peptides were used as a quality 
control parameter for the evaluation of MALDI-TOF and MALDI-FTICR spectra. 
This novel QC method allows a semi-automated selection of a good spectrum from 
replicate measurements of one sample and for the removal of low quality spectra from 
further statistical analysis, which is necessary for large-scale study. The isotopic 
distributions of five peptides (present in all serum samples) were determined and 
evaluated in both high-resolution MALDI-TOF and ultrahigh resolution MALDI-FTICR 
spectra. The selected isotope patterns were compared with polyaveragine distributions to 
calculate a quality control value for each single mass spectrum. Sorting the obtained QC 
values allowed the selection of the best MALDI spectrum from replicate spots and the 
removal of low quality spectra from further data analysis. Examples of odd peptide 



































































































1.4E11 2943.5 0.24 0.40 0.36 
 
* Peptide identified as a fragment of α-chain fibrinogen (P02671). The normalized intensities, calculated 




isotope distributions in MALDI-TOF spectra could be rationalized from corresponding 
ultrahigh resolution FTICR profiles that showed overlap of different peptides. As was 
earlier shown and has been discussed by other groups, multiple factors can invalidate the 
results of peptide profiling studies. To obtain a confident result, the full workflow of a 
profiling study should be highly standardized. The novel QC parameter used in this study 
is objective and facilitates further data analysis in large scale clinical studies. The 
proposed QC value can be determined for any isotopically-resolved MALDI-profile, i.e., 
this method is independent of the type of instrument, the manufacturer, or the software 
used for data processing. The use of this parameter in combination with other quality 
criteria that take into account signal-to-noise, reproducibility, and baseline threshold 
should result in a better selection of high-quality spectra. The integration of all such 
metrics for quality evaluation into one single method is under development. 
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The continuous efforts to find new prognostic or diagnostic biomarkers have stimulated 
the use of mass spectrometry (MS) profiles in a clinical setting. In the early days (about 
one decade ago), a single low-resolution mass spectrum derived from an individual’s body 
fluid was used for comparative studies. However, a peptide profile of a complex mixture 
is most informative when recorded on an ultrahigh resolution instrument such as a Fourier 
transform ion cyclotron resonance (FTICR) mass spectrometer. In this study we show the 
benefits of the ultrahigh resolving power and the high mass accuracy and precision 
provided by an FTICR mass spectrometer equipped with a 15-tesla magnet. The ultrahigh-
resolution data not only allow assignment of fragment ions with high charge states 
(4+, 5+) but also enhance confidence of human serum peptide identifications from tandem 
MS experiments. This is exemplified with collision-induced dissociation (CID) and 
electron transfer dissociation (ETD) data of middle-down-sized endogenous or protein-








Mass spectrometry- (MS-) based proteomics is a principal platform in systems biology, 
that is, the integrated approach of different technical disciplines to study the physiological 
processes in a cell or tissue [1–3]. The diagnosis of a disease or monitoring new medicines 
in a (pre)clinical setting can be performed either through (theoretically) full proteome 
analysis or by molecular profiling of large cohorts of biological samples. Nowadays, the 
first approach is technically feasible, however at low throughput [4]. In the latter high-
throughput approach the relevant differences between numerous peptides and proteins are 
mapped in affected tissues or body fluids of healthy and diseased individuals [5, 6]. 
To this purpose differential analyses of protein expression patterns in cells, tissue, or body 
fluids such as plasma or cerebrospinal fluid (CSF) are performed. These patterns can 
change as a result of disease and are thus helpful in both early detection and monitoring 
the development of the disease. Additionally, detection of biomarkers can also play a 
significant role in prevention. Proteomic approaches have been successfully used to obtain 
information on the state of protein circuits inside tumor cells and at the tumor-host 
interface [7]. Moreover, the analysis of peripheral blood (serum samples) for biomarkers 
has emerged as a promising tool for cancer diagnostics, disease monitoring, and 
prognostication of the patient. Unfortunately, many biomarker discovery profiling studies 
have not provided sufficient information on the identity of the peptides or proteins of 
interest. One reason for this incompleteness is the technical limitation of the used 
MS-platform with respect to resolving power and MS/MS capabilities. In this work we 
show the benefits of using high-end Fourier transform ion cyclotron resonance (FTICR) 
MS for identification of human serum peptides. These benefits are even more clear when 
taking into account that many of these peptides are endogenous or result from protein 
degradation. 
 
Ultrahigh Resolution and- Precision Provided by FTICR. It is well established that the 
sub-ppm mass accuracy of Fourier transform ion cyclotron resonance mass spectrometry 
(FTICR-MS) improves the result and increases the confidence of identifications [8, 9]. 
Previously, we have shown that a combination of highly standardized sample workup 
protocols with FTICR precision profiles results in very low mass measurement errors 
(MMEs) [9]. Moreover, FTICRMS is a powerful tool in tackling sample complexity due 
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to its ultrahigh mass resolution characteristics [10]. Several recent instrumental and 
software developments (improved electronics and computer technology) have made 
FTICR-MS accessible to a broader research community, including the life science area 
and the clinic. With suitable control and proper calibration, high field FTICR-MS 
routinely achieves an MME lower than 1 ppm [11, 12]. At very high fields, such as in 
recently available 15-tesla instruments, MMEs at a ppb level can be reached. 
The confidence in peptide and protein identifications improves significantly with 
increasing mass accuracy, especially if mass accuracies below 1 ppm are reached. 
Moreover, an increased mass accuracy assists in the identifications of peptides that are not 
in a database (e.g, unsequenced species, posttranslational modifications). The potential of 
sub-ppm mass accuracy allows for in-depth comparisons of complex peptide mixtures 
obtained from patient and control body fluids. In order to properly use accurate mass 
values obtained from modern high-end mass analyzers guidelines have been reported with 
respect to statistical mass accuracy [13]. 
 
Tandem MS Using Electron Transfer Dissociation. Peptide sequencing with electron 
transfer dissociation (ETD) MS/MS has proven to be an extremely powerful and 
complementary tool next to the widely used collision-induced dissociation (CID) [14, 15]. 
In a bottom-up proteomics workflow the peptide sequence coverage is often improved 
with combined CID and ETD fragmentation, either performed on-line in an alternating 
way or off-line in a sequential experiment [16, 17]. Initially, ETD was implemented on 
ion trap mass spectrometers and this is still the most commonly applied platform to 
perform peptide sequencing experiments. In the field of MS-based proteomics it is now 
well known that ETD is especially favorable for sequencing larger peptides with higher 
charge states (i.e., 3+, 4+), for middle-down and top-down proteomics, and for 
determining the location and identity of posttranslational modifications (PTMs) on peptide 
backbones [15]. Recent developments have enabled ETD experiments on ultrahigh-
resolution mass analyzers such as a time of flight (TOF), Orbitrap, and FTICR [15, 18, 
19]. In this work we will present both CID and ETD data obtained from an FTICR system 






MATERIALS AND METHODS 
Sample Collection and Serum Peptide Isolation. The protocols for both the collection 
of human blood samples and for serum peptide isolation have been described previously 
[9]. Informed consent was obtained from all patients and the Leiden University Medical 
Center (LUMC) Medical Ethical Committee approved the studies. Serum peptides were 
isolated in a fully automated and standardized fashion using reversed-phase (RP) 
C18-functionalized magnetic beads. In this study, 10 μL of commercially available 
RPC18 Dynabeads (Invitrogen, Carlsbad, CA, USA) was used for the analysis of 5 μL 
serum. The manufacturer’s protocol was followed for the activation, wash, and desorption 
steps of the RPC18 beads, with adjustments and optimizations to allow implementation on 
a 96-channel liquid handling Hamilton STAR plus pipetting robot [9]. 
 
ESI-FTICR-MS/MS. The eluates obtained from the RPC18-magnetic bead workup were 
used for MS/MS experiments (see sample collection). To this end, eluates from 96 
different samples were pooled and ultrafiltrated using a 30 kDa filter (Amicon Ultra 0.5 
mL; Millipore). The filtrate was concentrated by lyophilization before RPC18-LCMS 
analysis on a splitless nanoLC-Ultra 2D plus system (Eksigent, Dublin, CA, USA) 
equipped with a PepMap C18 trap column (300 µm internal diameter, 5 mm length; 
Dionex, Sunnyvale, CA USA) and a ChromXP C18-analytical column (300 µm internal 
diameter, 15 cm length; Eksigent). Here, one minute manual fraction collection was 
performed at a flow rate of 4 µL per minute, with a gradient of 4% to 44% acetonitril in 
0.05% formic acid buffer. Then, the 35 fractions were analysed using a Bruker 15 tesla 
solariX FTICR mass spectrometer equipped with a CombiSource, a quadrupole for 
precursor ion selection, a hexapole collision cell for CID, and an ETD source on a splitted 
octopole after mixing them with 100 µL of spray solution (50/50 MeOH/H2O 0.1% 
formic acid) [9]. Direct infusion electrospray ionisation (ESI) experiments were carried 
out at an infusion rate of 2 microliter per minute. The ion funnels were operated at 100 V 
and 6.0V, respectively, with the skimmers at 15V and 5V. The trapping potentials were 
set at 0.60V and 0.55V, the analyzer entrance was maintained at –7V, and side kick 
technology was used to further optimize peak shape and signal intensity. The required 
excitation power was 28% with a pulse time of 20.0 μs. MS/MS experiments were 
performed with the Q (quadrupole) at an isolation window of 10 mass units, followed by 
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either CID or ETD and fragment ion mass analysis in the ICR cell. For CID experiments, 
both the collision energy and the accumulation time in the hexapole collision cell were 
optimized for each precursor ion. Collision energies varied from 5 to 33V while the 
accumulation times varied from 1 to 5 seconds. For ETD experiments the ETD reagent 
accumulation time was fixed at 400 ms (fluoranthene from negative chemical ionization 
(NCI) source). The ETD spectrum was optimized by varying the reaction time (from 10 to 
100 ms, with an optimum at 50 ms), varying the peptide (analyte) accumulation time 
(depending on the precursor ion intensity), and modifying the mirror RF amplitude 
(280−300 Vpp). 
 
Data Analysis. It should be noted that the peptides that were sequenced in this work 
(obtained from human serum samples) were either endogenous peptides or breakdown 
products from serum proteins. This implies that any amino acid can be present at the 
C- and the N-terminus. As a consequence, the interpretation of MS/MS spectra was partly 
performed manually (de novo) and partly using software from Bruker Daltonics (Data 
Analysis, BioTools). With a manually determined part of the sequence (sequence tag) a 







Figure 1. ESI-FTICR-MS/MS spectra of an albumin peptide isolated from a human serum 







Figure 2. ESI-FTICR-MS/MS spectra of a prothrombin peptide isolated from a human 
serum sample, with sequence coverage in CID (a) and ETD (b). In order to exemplify the 
ultrahigh resolving power of the system the insets show the isotopic patterns of fragment ions 
at m/z 793 [y34(5+)] and at m/z 1028 [y35(4+)]. 
 
Figure 3. Summary of mass measurement errors of fragment ions in ESI-FTICR-MS/MS 
CID (a) and ETD (b) spectra of a prothrombin peptide isolated from a human serum sample. 
 
RESULTS AND DISCUSSION 
Matrix-assisted laser desorption ionization (MALDI) precision profiles of serum eluates 
were obtained using a state-of-the-art solariX-FTICR system equipped with a 15-tesla 
magnet [9]. Since the purpose of this study is to report peptide identifications, the 
discussion of such precision profiles is outside the scope of this work. Nevertheless, it 
should be emphasized that the accurate mass list of peptides obtained from precision 
profiles allowed a window of overlap between species observed in MALDI profiles and 
those determined in ESI spectra lower than 1 ppm. For a complex mixture such as serum 
peptides this can only be achieved in a single-step analysis (i.e., without the need for LC-
separation) using the ultrahigh resolving power of FTICR.  
The solariX-FTICR system was further used to perform MS/MS experiments aiming for 
peptide sequencing. To this end, peptide mixtures were directly infused in ESI mode, 
isolated in the Q, and fragmented through either CID or ETD. These peptide mixtures 
were obtained after suitable sample clean-up from the magnetic bead eluates and 
fractionation (as described in Section 2). As an example, the CID and ETD spectra of an 
albumin fragment (UniProt P02768, number 25–48) are shown in Figure 1. The ultrahigh 
resolving power of the FTICR allowed confident assignment of many fragment ions, 
resulting in a peptide sequence coverage of 87% (20 out of 23 peptide bonds) and 91% 
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from CID and ETD, respectively. From Figure 1 it follows that in the albumin peptide 
three bond cleavages were not observed upon CID, namely, between the amino acids S-E, 
H-R, and FK. In the ETD spectrum these bond cleavages, among others, were observed, 
stressing the complementarity of these two fragmentation methods. The complementarity 
is also valid vice versa; namely, bond cleavages between amino acids E-E and K-A were 
observed in CID and not in ETD. Furthermore, it is interesting to report on the signal 
intensities of the CID and ETD fragments of the peptide with MW 2754 Da: these varied 
from 4 × 10E6 to 4 × 10E8, with a precursor ion intensity of 5 × 10E8, and from 1 × 10E7 
to 3 × 10E8, with a precursor ion intensity of 3 × 10E9, respectively. This exemplifies the 
large dynamic range of the FTICR; that is, also the low abundant fragment ions are clearly 
detectable in an MS/MS spectrum. The second example of complementarity of CID and 
ETD fragmentation is presented in Figure 2, although not up to a total sequence coverage 
of 100%. The sequence coverage of the prothrombin peptide was 77% from the CID 
spectrum and 60% from the ETD-spectrum, whereas the combination of data resulted in 
89%. This peptide was identified as a fragment from prothrombin (UniProt P00734, 
number 328–363), namely, TFGSGEADC(C)GLRPLFEKKSLEDKTERELLE 
SYIDGR. Note that this peptide contains a cysteinylation at cysteine 336 (indicated 
between parentheses) that originates from the disulfide bridge to cysteine 482. Both the 
ultrahigh resolving power and the subppm MMEs of all fragment ions provided by the 
FTICR were essential for confident assignments. In the case of the CID spectrum 
especially, the charge states of most fragment ions obtained from the large precursor 
peptide with five protons could not have been resolved with relatively low-resolution 
instrumentation such as an ion trap mass spectrometer. This is exemplified by the insets in 
Figure 2, showing the isotopic patterns of fragment ions at m/z 793 [y34(5+)] and at 
m/z 1028 [y35(4+)]. The MMEs are overviewed in Figure 3. The average MMEs for the 
CID and ETD experiments of the peptide with MW 4210 Da were 0.01 ± 0.16 ppm and 
−0.03 ± 0.19 ppm, respectively. Again, the benefits of the large dynamic range (more than 
two orders of magnitude) of detecting fragment ions become clear from the following 
number: the signal intensities of the CID fragments of the peptide withMW4210 Da 
varied from 2.5×10E6 to 5×10E8, with a precursor ion intensity of 2 × 10E8, and the 
signal intensities of the ETD fragments of this peptide varied from 1 × 10E7 to 6 × 10E8, 
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Ultrahigh resolution MALDI-FT-ICR profiles were obtained from human serum samples 
that were processed using a fully automated RPC18-based magnetic bead method. 
Proteins were profiled from m/z value 6630 with a resolving power of 73000 up to 
m/z value 12600 with a resolving power of 37000. In this study, a detailed evaluation was 
performed of the isoforms of apolipoprotein C-III, i.e. the different mucin-type core 1 
O-glycans with the addition of one or two sialic acid residues. The MALDI-FT-ICR 
profiles are discussed with regard to reproducibility of the signal intensities as well as the 
accurate mass measurements. ESI-FTICR-MS/MS analyses of the same serum samples 







Human serum peptide and protein profiling by MALDI coupled with TOF-MS is a 
well-established discovery strategy for disease-related biomarkers [1]. Studies reported in 
the previous decade have resulted in a large number of candidate peptides and proteins 
that were found to correlate with the presence and/or a stage of a certain disease. 
However, most of these discoveries have not been translated into a diagnostic clinical 
assay [2–5]. The obvious explanation for this setback is the inherent lack of “depth” in 
profiling studies, i.e. of the existing ten orders of magnitude of concentration range in 
protein abundance, only the first three or four layers are mapped [5]. Another important 
reason for the hitherto disappointing outcome of MS-based biomarker studies relates to 
validation, as robustness of the analytical platform at high-throughput use is essential. 
It has been shown that the reproducibility of MALDI profiling methods improves using 
highly standardized sample collection and work-up protocols [6–9]. The use of a fully 
automated liquid-handling robotic platform results in reproducible SPE peptide 
purification steps as well as in robust MALDI spotting procedures; thus, standardizing the 
entire serum profiling workflow. Sample purification and/or separation procedures are 
needed prior to analysis by MS, because body fluids such as serum are highly complex 
mixtures. With each additional procedure that is included in the workflow, more effort is 
required to achieve good robustness of the analytical protocols. While MALDI profiling 
protocols include off-line peptide or protein purification methods [10], the application of 
LC together with ESI allows separation of peptide and proteins with on-line MS 
measurement. The separation efficiency of LC has led to both a larger number of profiled 
peptides and proteins and to a more quantitative analysis when triple quadrupole (Q) MS 
was used [11,12]. However, relatively low throughput is inherent to most LCMS methods, 
which makes the analysis of large sample cohorts difficult and thus impedes the process of 
biomarker validation. High-throughput approaches pose a large demand on LC equipment. 
Obviously, chromatographic runs can be shortened (to a certain extent) to alleviate the 
problem of running into weeks or even months of analysis time. Another way to tackle 
sample complexity involves the use of ultrahigh resolution instruments such as FT-ICR or 
Orbitrap R MS. These provide the highest mass measurement precision and accuracy and 
allow separation of peptides and proteins that would overlap in lower resolution mass 
spectrometers [13–15]. We recently reported serum peptide profiles (m/z range from 1000 
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to 6500 Da) with low parts per million (ppm) mass measurement errors (MMEs) obtained 
from an MALDI-FT-ICR system equipped with a 15 tesla magnet [16]. It was shown that 
the sub-ppm mass measurement precision improved the alignment of multiple spectra that 
are needed for comparative analysis and thus allowed a robust and standardized 
high-throughput screening of hundreds to thousands of patient samples. In almost any 
biomarker discovery study larger peptides and proteins are profiled by low resolution 
MALDI-TOF-MS. Unfortunately, because of the lower resolving power at higher masses 
as well as the intrinsic more complex isotopic distribution, such larger peptides and 
proteins are detected as broad peaks. In these cases, the identification and quantification 
of single species is very challenging with respect to robustness of the method. 
Moreover, when protein signals in profiles are isotopically resolved the mass differences 
between corresponding variants can be determined with great accuracy, thus allowing the 
determination of a point mutation or a PTM [17]. In the current study, we have used a new 
MALDI-FT-ICR method for profiling of large serum peptides and proteins in the mass 
range from 6000 to 15 300 Da with high sensitivity and high resolution. Based on the 
previously reported identifications in MALDI profiles, we focused on apolipoproteins that 
were observed in the current profiles, namely apolipoprotein C-I (Apo-CI), C-II (Apo-
CII), and C-III (Apo-CIII), including its glycosylated isoforms [1, 18, 19]. 
Apolipoproteins C (Apo-Cs) are present in blood associated, at different degrees, with 
various lipoproteins particles [20–22]. Several studies have been carried out in order to 
elucidate the role of Apo-Cs in the metabolism of lipoproteins and results have been 
comprehensively reviewed [23–25]. Briefly, Apo-Cs are involved in the metabolism of 
lipoproteins through the activation or inhibition of several triacylglycerol lipases and 
interaction with different lipoprotein receptors [26]. It is known that Apo-Cs levels are 
abnormal with certain diseases. For example, individuals affected by diabetes as well as 
those subjects with hypertriglyceridemia have increased concentration of Apo- CIIIs 
[27,28]. The risk of coronary heart disease has been also correlated with Apo-CIIIs levels 
in blood [29, 30]. Cohen et al. recently reported on an MALDI-TOF profiling study 
showing that Apo-CI and Apo-CIII extracted on C8-coated beads were significantly lower 
in serum samples of stomach cancer patients as compared to healthy individuals [31]. 
In addition, the glycosylation pattern of Apo-CIII is being used as a marker for certain 




IEF can be used to detect abnormalities in the biosynthesis of core 1 mucin-type 
O-glycans and reported that patients with CDG type IIe and IIf as well as part of patients 
with an unspecific CDG type II had hypoglycosylated Apo-CIII isoform profiles [32, 33]. 
Density gradient ultracentrifugation procedures have been applied for the separation of the 
lipoprotein particles containing Apo-Cs [34]. Other techniques such as delipidation, 2DE 
[35–37], IEF [38], and LC [39, 40] have been used to further purify and separate Apo-Cs. 
In the first approach, long centrifugation times are often required, thus decreasing the 
throughput of the analysis. Apo-Cs have been successfully extracted and profiled using a 
combination of SPE and MALDI-TOF MS [18, 19, 41–43]. In the present study, we 
perform magnetic bead (MB) based SPE of serum samples followed by the acquisition of 
ultrahigh resolution MALDI-FT-ICR profiles including Apo-CI, Apo-CII, and 
glycosylated Apo-CIII isoforms. 
 
MATERIALS AND METHODS 
Sample collection. Human blood samples were collected as previously described [44]. 
Briefly, blood samples were collected in 10-mL BD Vacutainer tubes (containing a clot 
activator and a gel for serum separation) from healthy volunteers by antecubital 
venipuncture and centrifuged for 1 h. Serum was then transferred to a 1-mL cryovial and 
stored at –80 °C until further aliquoting. To this end, 96 cryovials were thawed and serum 
was distributed over eight racks using an eight-channel liquid-handling robot (Hamilton, 
Bonaduz, Switzerland). Each rack was stored again at –80 °C and thawed only for the 
automated peptide isolation procedure. 
 
Serum protein isolation. Serum samples were anonymized before purification of proteins 
by SPE either based on magnetic beads (MBs) or on cartridges. Previously, it was shown 
that these two SPE protocols provided similar results for peptide isolation from serum 
[45]. In the cartridge-based protocol, serum samples were thawed at room temperature for 
1 h, diluted four times with 0.1% acetic acid and loaded (100 µL) on preconditioned 
C18-cartridges (SPARK). Each cartridge was washed with 2 mL of 1% acetic acid/2% 
acetonitrile (ACN) solution and peptides/proteins were eluted with 100 µL of a 50% 
ACN/0.1% acetic acid solution. This procedure was implemented on a customized 
SPARK Symbiosis SPE system, specifically adapted to increase sample throughput. The 
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MB-based protocol was performed for the purification of 96 serum samples from 
96 different individuals using a 96-channel liquid handling robot as described previously 
[16]. After both types of SPE methods, MALDI spotting was performed on the same 
liquid handling robot by mixing 2 µL of the sample eluates with 10 µL of an α-cyano-4-
hydroxycinnamic acid solution (0.3 g/L in ethanol/acetone 2:1). Each sample was spotted 
either in duplicate (MBseluates) or quadruplicate (cartridge eluates) onto an MALDI 
AnchorChip (600 µm; Bruker Daltonics, Bremen, Germany). Cartridge-based SPE was 
used for method optimization of the MALDI-FT-ICR experiments (Fig. 1), whereas MBs 
were used to evaluate the biological variation of the Apo-Cs isoforms that were stored at 
−80 °C for 6 months and thawed at room temperature prior to MALDI spotting (Fig. 3). 
For identification purposes, proteins were purified from serum samples by RPC4 SPE. 
Briefly, 300 µL of serum was diluted with 600 µL of a 0.05% formic acid (FA) solution, 
vortexed and kept at room temperature for 15 min for standardization reasons. The diluted 
serum was then loaded on a 1 mL BioSelect SPE C4 cartridge (Grace, Deerfield, Illinois, 
USA) that was prewashed two times with 900 µL of a 95% ACN/4.95% water/ 0.05% FA 
solution and preconditioned with 900 µL of a 0.05% FA solution. The cartridge was then 
washed three times with 900 µL of a 0.05% FA solution and the adsorbed peptides and 
proteins were stepwise eluted with 900 µL of 5, 10, 15, and 20% ACN solution. 
These five fractions were analysed by MALDI-FT-ICR-MS to determine which fractions 
contained the relevant apolipoproteins (data not shown). To this end, 1 µL of each of the 
RPC4 cartridge eluates was mixed with 15 µL α-cyano-4-hydroxycinnamic acid solution 
(0.3 g/L in ethanol/acetone 2:1) and 1 µL of the mixture was spotted on an MALDI 
AnchorChip. Direct infusion ESI-FT-ICR analysis was performed only on the RPC4 
cartridge fractions that contained the Apo-CIII isoforms. Prior to ESI-FT-ICR MS, 50 µL 
of each suitable eluate was diluted with 50 µL of a 95% ACN/4.95% water/0.05% FA 
solution and analyzed by direct infusion. 
 
MALDI- and ESI-FT-ICR MS. Both MALDI- and ESI-FT-ICR experiments were 
performed on a Bruker 15 tesla solariXTM FT-ICR mass spectrometer. The MALDI-FT-
ICR system was controlled by Compass solariX control software and equipped with a 
Bruker Smartbeam-IITM Laser System that operated at a frequency of 1000 Hz. 




spectrum was acquired from m/z values 6000 to 15000 and obtained from the average of 
ten scans of 150 laser shots each using 256 K data points. The random walk option was 
allowed on a diameter of 300 µm. Typically, the target plate offset was 100 V with the 
deflector plate set at 180 V. The ions were trapped and measured in the ICR cell using the 
Gated Trapping option. Both the front and the back trapping potentials were set to 1 V 
while the front and the back detection voltages were set to 0.4 and 0.45 V, respectively. 
The ramp time was 0.01 s. The required excitation power was 45% with a pulse time of 
15.0 µs. DataAnalysis Software 4.0 SP 3 (Bruker Daltonics) was used for the visualization 
and the calibration of the spectra while the IsotopePattern software (Bruker Daltonics) 
was used for the simulation of the isotopic distribution of the Apo-CIIIs isoforms. 
Direct infusion ESI-FT-ICR experiments were performed using the same instrumental 
settings described previously [46]. Briefly, a Q was used for precursor ion selection and a 
hexapole collision cell for CID. Direct infusion ESI experiments were carried out at an 
infusion rate of 2 µL/min. The ion funnels operated at 100 and 6.0 V, respectively, with 
the skimmers at 15 and 5 V. The trapping potentials were set at 0.60 and 0.55 V, the 
analyzer entrance was maintained at –7 V, and side kick technology was used to further 
optimize peak shape and signal intensity. The required excitation power was 28% with a 
pulse time of 20 µs. MS/MS experiments were performed with the Q at an isolation 
window of 10 mass units followed by CID and fragment ion mass analysis in the ICR cell. 
For CID experiments, both the collision energy and the accumulation time in the hexapole 
collision cell were optimized for each precursor ion. Collision energies varied from 5 to 
33 V while the accumulation times varied from 1 to 5 s. 
 
RESULTS AND DISCUSSION 
MALDI-FT-ICR serum profiles. A stringent protocol was used for the collection of 
human blood samples to allow for a valid evaluation of peptide and protein signals in 
MALDI profiles, and for later comparison of different patient cohorts in a 
high-throughput manner. All serum samples were processed through a fully automated 
and standardized workup procedure applying SPE with RPC18 functionalized MBs as 
described previously [45]. Then, for screening purposes, 1 µL of each serum eluate 
(i.e. obtained after SPE) was measured on an MALDI-TOF system and the remainder of 
the eluates was stored at –80 °C (data not shown). In this study, these serum eluates were 
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further used to obtain profiles of apolipoproteins. To this end, the eluates were thawed and 
anonymized, and then spotted onto an MALDI target plate after premixing with matrix 
solution using the same 96-channel liquid handling platform. MALDI-FT-ICR spectra 
(profiles) were obtained through an automated acquisition procedure on the solariXTM 
system (see Section 2). A typical example of an ultrahigh resolution MALDI-FT-ICR 
serum protein profile recorded from m/z values 6000 to 15000 is shown in Fig. 1. Note 
that all species (i.e. proteins) in the profile in Fig. 1 are isotopically resolved, with a 
resolving power of 73000, 51000, and 37000 at m/z values 6630, 9420, and 12607, 
respectively. Furthermore, a resolving power of 29000 for the signal at m/z 15193 was 
determined in the MALDI-FT-ICR protein profile obtained from an RPC4 cartridge 
eluate, as shown in the inset in Fig. 1 (note that this signal was not observed in the RPC18 
MALDI-FTICR protein profile). Recently, we have reported on ultrahigh resolution 
MALDI-FT-ICR serum peptide profiles up to m/z value 6500 from similar samples with 
identical workup. It was shown that MMEs of multiple MS acquisitions were at the 
sub-ppm level both for individual samples (repeatability) and for hundreds of different 
serum samples after alignment. Hence, these FT-ICR spectra were established as precision 
peptide profiles. In the current profile, the m/z range has been extended up to m/z value 
15000. From Fig. 1, it is evident that the use of an FT-ICR-system allows accurate mass 
analysis of small proteins in MALDI protein profiles because all species are fully resolved 
up to an m/z value of 12615 (or even at m/z value 15193, Fig. 1 inset). This was not 









Figure 1. Ultrahigh resolution 15T MALDI-FT-ICR protein profile obtained from human 
serum purified by RPC18 cartridge-based SPE. Proteins were profiled from m/z value 6630 
with a resolving power of 73000 up to m/z value 12600 with a resolving power of 37000. 
The inset shows an enlargement of an MALDI-FT-ICR protein profile obtained from an 
RPC4 cartridge eluate. The resolving power for the protein at 15193 m/z was 29000. This 
signal was not observed in the RPC18 MALDI-FT-ICR protein profile. The identification was 
performed by comparing the observed m/z values to previously reported lists of 
(proteolytically degraded) proteins (or polypeptides) (Table 1). The most abundant peaks were 
identified as O-glycosylated isoforms of apolipoprotein-CIII. ESI-FT-ICR MS/MS 
experiments confirmed the identity of both Apo-CI and Apo-CIII1 (Fig. 2). 
 
Moreover, possible peak overlap can be determined in ultrahigh resolution profiles, and 
peak intensities at high m/z values can be measured with greater precision [16]. 
Obviously, the more accurate mass differences between various species within one profile 
increase confidence levels of their identification (as will be further discussed at the end of 




Apolipoprotein identifications. Initially, all m/z values of species observed in the 
ultrahigh resolution high-mass MALDI-FT-ICR profile (Fig. 1) were compared to 
previously reported lists of (proteolytically degraded) proteins (or polypeptides) [1, 18, 
19]. From these lists it became clear that several apolipoproteins were present in the 
profile, such as the monoisotopic peak of apo-CI (calculated m/z value 6627.5131), the 
monoisotopic peak of apo-CIII (calculated m/z value 8689.1879), and the monoisotopic 
peak of apo-CII (calculated m/z value 8910.3856). A summary of all species in Fig. 1 that 
could be assigned based on known proteins is given in Table 1. The monoisotopic peak 
values in our data were in low ppm agreement with the previously reported 
O-glycosylated isoforms of Apo-CIII, with the remark that glycan linkages cannot be 
determined from the current experiments. These previously reported Apo-CIII isoforms 
consist of a single mucin-type core-1 disaccharide galactose linked to 
N-acetylgalactosamine (Galβ1–3GalNAc), as such, or include a terminal modification 
with one (NeuAcα2–3Galβ1–3GalNAc or Galβ1–3[NeuAcα2–6]GalNAc) or two 
(NeuAcα2–3Galβ1–3[NeuAcα2–6]GalNAc) sialic acid residues (or N-acetylneuraminic 
acid (NeuAc)). These three different isoforms of Apo-CIII are commonly referred to as 
Apo-CIII0, Apo-CIII1, and Apo-CIII2, respectively, the index pointing at the number of 
sialic acid residues bound to the protein as determined by IEF [32]. Note that in such an 
IEF profile the Apo-CIII0 band can include three different isoforms, namely 
nonglycosylated Apo-CIII, Apo-CIII with one GalNAc monosaccharide, and Apo-CIII 
with the GalNAc-Gal disaccharide. Since all these three species lack any sialic acids (and 
are thus referred to as Apo-CIII0), it has been proposed to add an index a, b, or c [43]. 
In this study we did not find any evidence for the presence of Apo-CIII0b (calculated m/z 
value 8963.3044) in any of the acquired MALDI-FT-ICR profiles of all measured serum 
samples (Fig. 1). Interestingly, a conflict in assignment of the m/z value 6627.5 in Fig. 1 
was noted, which was typed as Apo-CII by Tiss et al., whereas Hortin and Albrethsen 
reported Apo-CI. From our ESI-FT-ICRMS/MS data it was concluded that this species (in 
MALDI observed at m/z value 6627.5, in ESI selected as precursor ion [M+10H]10+) 







Figure 2. Enlarged parts of the CID spectra of Apo-CI (A) and Apo-CIII1 (B) obtained with 
direct infusion ESI-FT-ICR-MS/MS of serum samples that were purified by RPC4 cartridge-
based SPE. In both cases, the [M+10H]10+ precursor ion was selected in the quadrupole (Q) to 
perform MS/MS experiments. In the MS/MS spectrum of Apo- CIII1 (B) all fragment ions 
lack the O-glycan, unless indicated explicitly. 
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Table 1. List of identified proteins observed in RPC18 magnetic bead and RPC18 cartridge 
MALDI-FTICR serum profiles in the m/z-range of 6,000-15,000. Twelve out of 15 identified 
proteins belong to the apolipoprotein family including O-glycosylated isoforms of 
apolipoprotein-CIII. The identity of the two proteins written in bold, namely ApoCI (27-83) 










(fragment) Peptide sequences 


















8689.1879 P02656 ApoCIII0a (21-98) 
SEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQARGWVTDGFSS
LKDYWSTVKDKFSEFWDLDPEVRPTSAVA 




8760.2250 P02656 ApoCIII0a (21-99) 
SEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQARGWVTDGFSS
LKDYWSTVKDKFSEFWDLDPEVRPTSAVAA 




9054.3201 P02656 ApoCIII0c (21-98) 
SEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQARGWVTDGFSS
LKDYWSTVKDKFSEFWDLDPEVRPT(GalNAcGal)SAVA 




9282.8208 P02775 CTAP-III (44-128) 
NLAKGKEESLDSDLYAELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVI
ATLKDGRKICLDPDAPRIKKIVQKKLAGDESAD 




9416.4526 P02656 ApoCIII1 (21-99) 
SEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQARGWVTDGFSS
LKDYWSTVKDKFSEFWDLDPEVRPT(GalNAcGalneu5Ac)SAVAA 













Figure 3. Enlarged part of the ultrahigh resolution MALDI-FT-ICR protein profile obtained 
from human serum purified by RPC18 cartridge-based SPE. In this m/z range, Apo-CIII 
isoforms were identified as the most abundant peaks and Apo-CIII isoforms truncations 
(minus the C-teminal alanine), Apo-CII and the connective tissue-activating peptide III 
(CTAP-III) were observed at lower intensities. The upper inlets show the comparison between 
the observed isotopic distribution and those calculated from the amino acid sequences of the 
Apo-CIII isoforms (as indicated). The mass differences (365.13 and 291.10) between the 
Apo-CIII isoforms are in excellent agreement with the theoretical values (for HexNAcHex and 
NeuAc are 365.1322 and 291.0954 Da). The SDs of the mass differences were calculated from 
96 RPC18 MB-based MALDI-FT-ICR protein profiles. 
 
Furthermore, it should be stressed that the small glycoprotein Apo-CIII1 can actually be a 
mixture of two isomers, namely the sialic acid residue can be linked to either the terminal 
Gal or to the GalNAc (NeuAcα2–3Galβ1–3GalNAc or Galβ1–3[NeuAcα2– 6]GalNAc, 
respectively). The observed ESI-FT-ICR-MS/MS analysis is in full accordance with both 
structures (Fig. 2B). Therefore, no conclusions can be drawn from these data on the 
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relative contribution of these two isomers to the Apo-CIII1 species. Possibly electron 
transfer dissociation MS/MS experiments can differentiate between these two isomers 
[46]. As a final remark it becomes clear from MALDI-FT-ICR profiles that the mass 
difference between species nonglycosylated Apo-CIII, Apo-CIII0, Apo-CIII1, and 
Apo-CIII2 provides additional evidence for the peak identities. This is illustrated in Fig. 3, 
where the observed ∆m are 365.13, 291.10, and 291.10 Da, respectively (theoretical 
differences for HexNAcHex and NeuAc are 365.1322 and 291.0954 Da). Note that the 
mass difference of 0.02 Da corresponds to a MME of 2 ppm based on the mass of 
Apo-CIII1 (calculated m/z 9416.4526).  
 
Quantitative analysis of four apo-CIII isoforms. In order to evaluate the biological 
variation in abundance of the apo-CIII isoforms in human sera, we analysed the MALDI-
FT-ICR MS spectra obtained from 96 differentindividuals. A 96-well-plate containing 
RP18 MBs eluates and stored at –80C was thawed and each eluate was spotted in 
duplicate onto a MALDI target plate as described in Section 2. From this plate, 
192 spectra were obtained and visualized using the DataAnalysis software (Bruker). First, 
the technical variation in the Apo-CIII isoform distributions was determined from each 
pair of spectra (replicate spots). Recently, we reported in more detail on the technical 
variation of similarly obtained MALDI-FT-ICR profiles [45, 47]. It was found that the 
reproducibility of peak areas of peptides and proteins between 1 and 9 kDa varied for each 
signal, with on average a coefficient of variation of approximately 15%. In the current 
profiles, similar technical variation was observed upon considering duplicate 
measurements of the same sample. The spectrum with highest intensities was used for 
further evaluation. In Fig. 3, a typical MALDI-FT-ICR serum protein profile in the mass 
range of 8550–9820 m/z value is depicted. In this m/z range, Apo-CIII isoforms were 
identified as the most abundant peaks while Apo-CIII isoforms truncations (minus the C-
teminal alanine), Apo-CII and the connective tissue-activating peptide III were identified 
as minor components (Table 1). The high confidence in the identifications derived from 
literature search or obtained fromMS/MSanalysis follows from the observed isotopic 
distribution of the Apo-CIII isoforms when compared with those calculated from the 
amino acid sequence using the IsotopePattern tool (Bruker). As shown in the upper insets 




isoforms have a good match with each other. Further note the excellent agreement of the 
mass differences between the Apo-CIII isoforms with the theoretical values. To calculate 
those mass differences, the m/z values of the most abundant isotope peak in the observed 
isotopic distribution of each of the Apo-CIII isoforms were extracted using the MassList 
tool (Bruker), copied in an Excel sheet and compared with the most abundant isotope peak 
in the calculated isotopic distribution of the corresponding Apo-CIII isoform. Thus, the 
average and SD of the mass differences in 96 spectra were calculated.  
In order to evaluate the biological variation quantitative data on the abundances 
of the four species non-glycosylated Apo-CIII (Apo-CIII0a), Apo-CIII0c, Apo-CIII1 and 
Apo-CIII2 were obtained as follows. The signal intensity of the extracted m/z values was 
calculated using the Xtractor tool [16] and exported in an Excel sheet. These intensities 
are summarized in the box-plot depicted in Fig. 4. It is clear from this box-plot that 
significant variation is present in isoform abundances. This was confirmed through an 
ANOVA, which resulted in an F value of 87with a p-value less than 2×10–16. In view of 
the important role of apolipoproteins in various disease pathways and of the fact that the 
present analytical procedure allows high-throughput screening [45] while providing very 
detailed information, further studies are warranted. Therefore, future studies will be 
performed in which MALDI-FT-ICR profiling of the Apo-CIII isoforms will be applied in 
a clinical cohort. This requires a systematical evaluation of abundances and identities with 
















Figure 4. Box-plot of the signal intensities of Apo-CIII0a, Apo-CIII0c, Apo-CIII1, 
Apo-CIII2, as obtained from 96 ultrahigh resolution MALDI-FT-ICR protein 
profiles. Large biological variation in the abundance of the apolipoprotein-C 
isoforms in 96 different individuals is evident, ANOVA resulted in an F-value of 87 
with a p-value less than 2 × 10–16. 
 
CONCLUSIONS 
Peptide and protein profiles from human body fluids can be obtained from ultrahigh 
resolution MALDI instruments such as FT-ICR-MS with sub-ppm mass precision and 
four orders of magnitude in dynamic concentration range. Provided sample collection as 
well as SPE is performed according to highly standardized protocols these profiles hold 
great potential for screening (larger) cohorts of patient samples. Moreover, single species 
(e.g. proteins) in complex mixtures can be identified and quantified using ultrahigh 
resolution MS. In this study a fully automated RPC18-based magnetic bead method was 
applied for SPE of 96 different human serum samples. Proteins were profiled from 




of middle-down proteins in MALDI protein profiles since all species were fully resolved 
in this mass range. It was shown that isoforms of apo-CIII could be mapped, namely the 
ones with the different mucin type core 1 O-glycans including one or two sialic acid 
residues. No evidence was found for the presence of Apo-CIII-GalNAc (“truncated” 
mucin-type core 1) in any of the acquired MALDI-FT-ICR profiles of all 96 different 
serum samples. Finally, ESI-FT-ICR-MS/MS identified the species observed in the 
MALDI-profile at m/z value 6627.5 as the monoisotopic peak of apo-CI. 
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Apolipoprotein-CIII (apoCIII) is an abundant blood glycoprotein associated with 
lipoprotein particles. Three different glycoforms have been described, all containing a 
mucin-type core-1 O-glycosylation with either zero, one or two sialic acids. Changes in 
the relative abundance of these glycoforms have been observed in a variety of different 
pathologies. In this study, ultrahigh resolution 15T MALDI Fourier transform ion 
cyclotron resonance (FTICR) MS was used to analyze apoCIII isoforms in serum protein 
profiles. For this purpose, serum proteins were purified using both a fully automated 
RPC18-based magnetic bead method and an RPC4 cartridge-based solid phase extraction 
method. Six new apoCIII isoforms were identified with low-ppm mass measurement 
errors and ultrahigh precision. These were characterized by more complex glycan moieties 
which are fucosylated instead of sialylated. To confirm the glycan moiety and localize the 
glycosylation site top-down ESI-FTICR-MS/MS and bottom-up LC-ion trap MS/MS were 
used. A large variation in the presence and abundance of the fucosylated isoforms was 
found in a set of 96 serum samples. These findings of fucosylated apoCIII isoforms 
warrant further research to elucidate the implications these glycoforms may have for the 
plethora of studies where alterations in apoCIII have been linked to the development of 






Apolipoprotein-CIII (apoCIII) is a relatively small protein containing 79 amino acids. It is 
present in blood where it is associated with chylomicrons, very-low-density lipoproteins 
(VLDLs), low-density lipoproteins (LDLs), and high-density lipoproteins (HDLs) [1]. 
ApoCIII regulates the metabolism of lipoprotein particles through the inhibition of 
lipoprotein lipase thereby affecting the concentration of triacylglycerol in blood [2,3]. 
Therefore, high levels of apoCIII correlate with hypertriglyceridemia [4] and are 
associated with coronary heart disease and atherosclerosis [5]. ApoCIII has also direct 
pro-inflammatory effects on both monocytes and endothelial cells which may additionally 
contribute to atherogenic mechanisms [6]. Recently, a role for apoCIII in the development 
of type I diabetes has been demonstrated [7] and correlations between quantitative 
changes in the apoCIII levels and other diseases like ischemic and hemorrhagic stroke and 
stomach cancer have been described [8,9].  
ApoCIII is glycosylated at threonine-74 and three glycoforms have been described [10]. 
All share a mucin-type core-1 O-glycosylation, i.e. a galactose β1-3 linked to an 
N-acetylgalactosamine (Galβ1-3GalNAc). Two isoforms are further modified with either 
one or two sialic acid residues, respectively (Galβ1-3[NeuAcα2-6]GalNAc and NeuAcα2-
3Galβ1-3[NeuAcα2-6]GalNAc) [11]. The different apoCIII glycoforms are commonly 
referred to as apoCIII0c, apoCIII1 and apoCIII2, the index indicating the number of sialic 
acid residues. A small fraction of apoCIII is non-glycosylated (apoCIII0a) [10]. 
An abnormal profile of the different apoCIII glycoforms (i.e. hypoglycosylation) can be 
used for diagnosis of genetic defects in O-glycan biosynthesis [12,13]. Because of the 
association of apoCIII levels with many pathological conditions, there is considerable 
interest to measure the levels of apoCIII and its glycoforms in serum. For this purpose, 
several methods have been developed including isoelectric focusing, two-dimensional 
electrophoresis, high-performance liquid chromatography and matrix-assisted laser 
desorption ionization (MALDI) coupled with time-of-flight (TOF) mass spectrometry 
(MS) [14-21].  
In a few MS-based profiling studies novel serum apoCIII glycoforms have been suggested 
but the exact nature of the glycan composition remained undetermined [22,23]. Further 
support for the presence of additional apoCIII glycoforms comes from a recent study 
performed in our laboratory, in which aberrantly O-glycosylated apoCIII-derived peptides 
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were observed in urine from Schistosoma mansoni-infected individuals that were absent in 
non-infected individuals [24]. Although these peptides were presumably also 
O-glycosylated on Thr-74 (referring to the full length protein), the glycans on these 
peptides were completely different from the hitherto described  
O-glycosylation. Most importantly, these O-glycopeptides contained high levels of 
fucosylation but lacked sialylation.  
Recently, we developed a new high-throughput MALDI Fourier transform ion cyclotron 
resonance (FTICR) MS method for profiling of serum proteins with fully resolved 
isotopic distributions up to 15300 Da [25]. Novel aspects of this method are the improved 
resolving power, precision and mass accuracy of the mass measurements, resulting in a 
more robust and reliable comparison of multiple spectra. The application of this method 
resulted in a detailed map of the previously reported apoCIII glycoforms in human serum 
[25].  
In the current study, this MALDI-FTICR protein profiling method was used to explore the 
presence of additional apoCIII glycoforms in human serum. Both top-down and bottom-
up experiments were performed on partially fractionated apoCIII by direct infusion 
ESI-FTICR MS/MS and liquid chromatography (LC) ion trap (IT) MS/MS, respectively. 
This resulted in the identification of six new apoCIII glycoforms in human serum. 
These are characterized by more complex glycan moieties which are fucosylated instead 
of sialylated. Furthermore, the relative distribution of apoCIII glycoforms was evaluated 
in a set of 96 different samples. 
 
MATERIALS AND METHODS 
Sample collection. Human blood samples were obtained as previously described [26]. 
Briefly, blood samples were collected in 10 mL BD Vacutainer tubes (containing a clot 
activator and a gel for serum separation) from healthy volunteers by antecubital 
venipuncture and centrifuged within 1 h. Informed consent was obtained from all 
volunteers and the study was approved by the Medical Ethical Committee of the LUMC. 
Serum was then transferred to a 1 mL cryovial and stored at -80°C. For aliquoting, 96 
cryovials were thawed and serum was dispensed in a 96-tube rack using an eight-channel 
liquid-handling robot (Hamilton, Bonaduz, Switzerland). This rack was then stored again 




High-throughput serum protein RP-C18 solid-phase extraction. Serum samples were 
anonymized before protein purification by reversed-phase extraction (SPE) based on 
magnetic beads (MB’s) [27]. SPE was carried out as follows: the RPC18-beads were first 
activated by a three-step washing with a 0.1% trifluoroacetic acid (TFA) solution. Then, 5 
µL of each sample were added to the activated beads and incubated for 5 min at room 
temperature. The beads were washed again three times with 0.1% TFA and proteins were 
eluted with a 1:1 mixture of water and acetonitrile. The MALDI spotting was performed 
on the liquid handling robot by mixing 2 µL of the sample eluates with 10 µL of an 
α-cyano-4-hydroxycinnamic acid solution (0.3 g/L in ethanol/acetone 2:1). Each sample 
was spotted in duplicate onto a MALDI AnchorChip (600 µm; Bruker Daltonics, Bremen, 
Germany). 
 
Serum protein RP-C4 solid-phase extraction. For identification purposes, 
(apolipo)proteins were first fractionated from serum samples by acetonitrile (ACN) 
precipitation followed by RP-C4 SPE. Briefly, 100 µL of thawed human serum were 
diluted with 100 µL of deionized water in a 1.5 mL plastic tube (Eppendorf) and kept at 
room temperature for 15 min for standardization reasons. High molecular weight proteins 
were precipitated by adding 200 µL of ice-cold acetonitrile (ACN) and storing the tube for 
two hours at -20°C. After 15 min at room temperature, the sample was centrifuged 
(Eppendorf, Centrifuge 5415 R) at 16,100 rcf for 10 min. Then, 300 µL of the supernatant 
were transferred to a new 1.5 mL Eppendorf tube and diluted with 1200 µL of a 0.05% 
formic acid (FA) solution. For each sample four replicate extractions were performed and 
the total volume (6 mL) of depleted-diluted serum was loaded on a 1 ml BioSelect SPE 
C4 cartridge (Grace, USA) that was pre-washed twice with 900 µL of a 95% ACN / 
4.95% water / 0.05% FA solution and pre-conditioned with 900 µL of a 0.05% FA 
solution. The cartridge was then washed three times with of 900 µL of a 10% ACN / 
89.95% water / 0.05% FA solution and the adsorbed peptides and proteins were stepwise 
eluted with 900 µL of a 15%, 20%, 25% and 30% acetonitrile solution. Prior to ESI-
FTICR MS, 60 µL of each eluate was diluted with 40 µL of a  
95% acetonitrile / 4.95% water / 0.05% FA solution and analyzed by direct infusion ESI-
FTICR MS.  
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MALDI- and ESI-FTICR mass spectrometry. Both MALDI- and ESI-FTICR 
experiments were performed on a Bruker 15 Tesla solariX™ FTICR mass spectrometer 
equipped with a CombiSource as previously reported [25,28]. Briefly, the MALDI-FTICR 
system was equipped with a Bruker Smartbeam-II™ Laser System that operated at a 
frequency of 1000 Hz. Each mass spectrum was acquired from m/z-values 6,000 to 15,300 
and obtained from the average of 10 scans of 150 laser shots each using 256 K data points. 
The random walk option was allowed on a diameter of 300 µm. The ions were trapped 
and measured in the ICR cell using the Gated Trapping option. Both the front and the 
back trapping potentials were set to 1 V while the front and the back detection voltages 
were set to 0.4 and 0.45 V, respectively. The ramp time was 0.01 s. The required 
excitation power was 45% with a pulse time of 15.0 µs. 
Prior to the measurement of each MALDI plate the FTICR system was externally 
calibrated using a commercially available peptide mix and a protein mix (Bruker 
Daltonics). The spectra were then internally calibrated using the m/z-values 6631.5242, 
8765.2387, 8915.3993, 9130.3710, 9421.4644, 11729.7978 corresponding to the most 
intense isotope peak of apolipoprotein-CI (amino acids 27-83), apoCIII0a (21-99), 
apoCIII0a (23-99), apoCIII0c (21-99), apoCIII1 (21-99), and beta-2-microglobulin (21-19), 
respectively. DataAnalysis Software 4.0 SP 3 (Bruker Daltonics) was used for the 
visualization and the calibration of the spectra. After evaluation by manual inspection, the 
spectrum with highest signal intensities was selected from each duplicate spectra for 
further statistical analysis. Both the m/z-values and intensity values were visualized using 
DataAnalysis Software 4.0 SP 3 (Bruker Daltonics) and copied in a Microsoft Excel 
worksheet for further evaluation. Theoretical isotopic distributions were calculated using 
the Simulate Isotopic Pattern tool using similar resolving powers as obtained in the 
protein profiles. Direct infusion ESI-FTICR experiments were performed using the same 
instrumental settings described previously with some modification [28]. Briefly, a 
quadrupole (Q) was used for precursor ion selection and a hexapole collision cell for 
collision-induced dissociation (CID). Direct infusion electrospray ionisation (ESI) 
experiments were carried out at an infusion rate of 2 µL/min. The ion funnels operated at 
100 V and 6.0 V, respectively, with the skimmers at 15 V and 5 V. The trapping potentials 
were set at 0.60 V and 0.55 V, the analyzer entrance was maintained at -7 V, and side kick 
technology was used to further optimize peak shape and signal intensity. 
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The required excitation power was 19% with a pulse time of 10 μs. MS/MS-experiments 
were performed by CID and fragment ion mass analysis in the ICR cell. For these 
experiments, the collision energy, the accumulation time in the hexapole collision cell and 
the isolation window in the Q were optimized for each precursor ion. Collision energies 
varied from 5 to 23 V while the accumulation times varied from 1 to 10 s. 
 
Trypsin Digestion and LC-Ion Trap Mass Spectrometry. Serum samples were 
processed as described above and 300 µL of the 20% ACN eluate from the RP-C4-
cartridge was lyophilized. Proteins were subsequently reconstituted in 50 µL ammonium 
bicarbonate pH 7.9 and digested with trypsin. For this purpose, proteins were first reduced 
and alkylated using dithiothreitol (5 mM, 30 min, 56ºC) followed by iodoacetamide 
(15 mM, 30 min, RT, in the dark). Then, 50 ng trypsin (sequencing grade modified 
Trypsin, Promega, Madison, WI) was added and proteins were digested overnight at 37ºC. 
The digestion reaction was stopped using 2 µL of 5% TFA. The digests were then 
analyzed by LC-MS using an Ultimate 3000 RSLCnano LC system (Thermo Scientific, 
Sunnyvale, CA) coupled to an HCTultra ion trap mass spectrometer (Bruker Daltonics, 
Bremen, Germany). The samples were injected onto an Acclaim C18 PepMap100 
trapping column (100 µm×2 cm, 5 µm, 100 Å (Thermo Scientific) and washed with 100% 
A (3% ACN in 0.1% formic acid) at 5 µL/min for 6 min. Following valve switching, 
peptides were separated on an Acclaim C18 PepMapRSLC column (75 µm×150 mm, 2 
µm, 100 Å) at a constant flow of 300 nL/min. The peptide elution gradient was from 3 to 
40 % B (95% ACN in 0.1% formic acid) in 48 min followed by an increase to 65% B in 
10 min. The nanoflow LC was coupled to the mass spectrometer using a nano-
electrospray ionization source. The spray voltage was set at 1.2 kV and the temperature of 
the heated capillary was set to 165°C. Eluting peptides were fragmented by CID using 










MALDI-FTICR-MS profiling of serum apoCIII glycoforms. Recently, we developed a 
method for fully automated RPC18 magnetic beads-based 15T MALDI-FTICR-MS 
protein profiling in the mass range from 6000 to 15300 Da [25]. These spectra were found 
to be dominated by various apolipoproteins. In the current study, we used this method to 
explore the presence of new apoCIII glycoforms in serum samples of 96 healthy control 
individuals. Firstly, all hitherto characterized apoCIII (glyco)forms (apoCIII0a, apoCIII0c, 
apoCIII1 and apoCIII2) could be mapped in all 96 different samples with our ultrahigh 
resolution MALDI-FTICR protein profiling method (Table 1). Upon focusing in-depth on 
ions with low intensities in the mass range from 9690 to 10900 Da (Figure 1) it was noted 
that these spectra contained m/z-values that corresponded to the theoretical ones for the 
monoprotonated apoCIII isoforms assuming the same O-glycan structures as were 
identified on apoCIII-derived peptides in urines of Schistosoma mansoni-infected 
individuals, as overviewed in Table 1 [24]. These glycoforms have a more complex and 
fucosylated glycan structure and do not contain any sialic acid residues.  
It should be stressed that, although the monoisotopic peaks are generally not 
observed in these profiles, the isotopic distribution itself of each apoCIII isoform allows 
the accurate determination of its mass (Figure 1). Thus, a nominal mass difference of 
1 Da, e.g. the difference between two Fuc residues and one sialic acid, would be 
observable (see Figure S1 in the Supplementary Materials). This is further illustrated in 
Figure S1, S2 and S3 in the Supplementary Materials, where theoretical distributions are 
compared to observed ones and the most abundant isotope peak within a distribution is 
used for the calculation of the mass measurement error. The observed low mass 
measurement errors (MMEs) corroborated the identification of each glycoform [28 29]. 
The MMEs were in the low ppm range (0.2 – 3 ppm) in all 96 different samples; however 
it should be noted that in none of the profiles (corresponding to a single sample) all six 
different glycoforms were observed at the same time. If one would show only the “best 
examples”, the observed MME of each glycoform would be at a sub-ppm level. 
In all cases, i.e. for all different species in all 96 different serum profiles, the mass 
differences between the “known” apoCIII isoforms and “newly identified” ones was 




Table 1. Isoforms of apolipoprotein-CIII 
 






Frequency in 96 
serum samples  
   
apoCIII0a (-) 8765.2385 100% 
apoCIII0c (HexHexNAc) 9130.3708 100% 
apoCIII1 (HexHexNAcNeuAc) a 9421.4663 100% 
apoCIII2
 (HexHexNAcNeuAc2) b 9712.5618 100% 
apoCIII-Hex2HexNAc2Fuc3b, c 9933.6769 27% 
apoCIII-Hex3HexNAc3Fuc2 10153.7538 11% 
apoCIII-Hex4HexNAc2Fuc3 10258.7852 8% 
apoCIII-Hex2HexNAc4Fuc3 10340.8383 29% 
apoCIII-Hex3HexNAc3Fuc4 10445.8698 12% 
apoCIII-Hex3HexNAc5Fuc4 10852.0286 6% 
    
a Structure confirmed with ESI-FTICR-MS/MS in a previous study [25]. 
b Structure confirmed with ESI-FTICR-MS/MS. 










Figure 1. Top-down 15T MALDI-FTICR-MS identification of fucosylated apolipoprotein-
CIII isoforms in human serum. Human serum proteins were purified by RP-C18 magnetic 
bead-based SPE and profiled by MALDI-FTICR MS from m/z-value 6000 up to m/z-value 
15300 (top-right inset). In the enlarged part of four different protein profiles (A−D), 
isotopically resolved apolipoprotein-CIII glycoforms are shown in the m/z-range from 9690 to 
10900. Six fucosylated apolipoprotein-CIII isoforms were identified by accurate mass 
measurement and were observed with different frequency in the spectra obtained from 
different individuals (see Table 1). The observed isotopic distributions are in good agreement 
with the isotopic distribution calculated from the theoretical molecular formulas. 








In all 96 serum profiles, a large variation in the relative abundance of all the apoCIII 
glycoforms was observed. However, there was not only variation in the relative 
abundance of these species, but also in the frequency wherein a specific isoform was 
observed. (Table1). For example, the most frequently observed fucosylated apoCIII 
isoform (apoCIII-Hex2HexNAc4Fuc3) was found in 29% of the samples while  
apoCIII-Hex3HexNAc5Fuc4 was present in only 6% of the samples. For relative 
quantification purposes, we normalized the signal intensity of the fucosylated isoforms to 
that of apoCIII0a. As such, the relative signal intensities ranged from 9% (isoform 
apoCIII-Hex2HexNAc2Fuc3) to 3% (isoform apoCIII-Hex3HexNAc5Fuc4) with relative 
standard deviations (RSD) of 3% and 1%, respectively. 
In summary, we have shown that the combination of ultrahigh mass measurement 
precision and resolution, with concomitant low MMEs, allows the identification of new 
proteoforms [29]. As such, six multi-fucosylated apoCIII isoforms were identified in 
human serum samples. One of these contains a glycan with three hexoses, three  
N-acetylhexosamines and four fucoses (i.e. apoCIII-Hex3HexNAc3Fuc4) that was not 
reported in the previous study on urinary apoCIII-derived peptides from Schistosoma 
mansoni-infected individuals.  
 
Top-Down Identification of apoCIII glycoforms by direct infusion ESI-FTICR mass 
spectrometry. To further confirm the identification of intact forms of apoCIII, top-down 
MS/MS experiments were performed on fractionated apolipoprotein samples. For this 
purpose, serum samples were first depleted from high molecular weight proteins using 
organic precipitation. These samples were loaded on C4-cartridges, and the eluates 
obtained from the stepwise elution of serum peptides/proteins with 15, 20, 25, 30% 
acetonitrile solutions were measured by direct infusion ESI-FTICR-MS. The spectra 
obtained from the first three fractions (15, 20 and 25% acetonitrile) showed similar 
protein charge state distributions while the spectrum of the fourth fraction was different 
and dominated by the charge state distribution of apolipoprotein AI (ApoAI, data not 
shown). The apoCIII0a, apoCIII0c, apoCIII1 and apoCIII2 isoforms were observed with 
maximum signal intensity in the spectrum obtained from the second fraction. 
This spectrum is depicted in Figure 2a. Here, the most intense peaks were identified as 
apolipoprotein CI (apoCI) and apoCIII1. The exact m/z-value of the most abundant isotope 
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peak in the isotopic distributions of these two proteins was used to internally calibrate the 
ESI-FTICR MS spectrum. The enlarged parts of the ESI-FTICR spectrum (Figure 2b) 
show ion species (m/z 1215.1 ([M+8H]8+) and m/z 994.3 ([M+10H]10+)) corresponding to 
apoCIII2 and to apoCIII-Hex2HexNAc2Fuc3. Subsequently, CID experiments were 
performed on the ion at m/z 1215.1 ([M+8H]8+), of which the results are depicted in 
Figure 3a. Similar to the MS spectra, the isotopic distribution of each theoretical ion was 
used to assign CID fragments in MS2-spectra. Clear losses of two sialic acids, one hexose 
and one N-acetylhexosamine are observed. Moreover, the singly charged ions observed in 
the mass range from m/z-values 250 to 1095 match with the oxonium ions corresponding 
to the glycan composition of the apoCIII2 isoform (i.e. Hex-HexNAc-Neu5Ac2). 
In addition to the glycosidic bond cleavages, protein backbone fragments, such as the 
b77- and b78-ions with or without one N-acetylhexosamine, were observed. The CID 
spectrum of the ion at m/z 994.3 ([M+10]10+), corresponding to apoCIII-
Hex2HexNAc2Fuc3, is depicted in Figure 3b. Here, losses of three fucoses, two hexoses 
and two N-acetylhexosamines unambiguously identify the glycan moiety on this protein 
species. This is further supported by the oxonium ions observed in the mass range from 
m/z 450 to 850. In addition, the backbone fragmentation is similar to that of the apoCIII2 
isoform described above although in this case the b77- and the b78-ions are only observed 
with an N-acetylhexosamine. Finally, two fragment ions containing one hexose, one 
N-acetylhexosamine and three fucoses were observed. These ions most likely result from 
fucose rearrangements that can occur during CID fragmentation of multi-fucosylated 





Figure 2. Ultrahigh resolution 15T ESI-FTICR-MS of human serum apolipoproteins. (A) 
ESI-FTICR MS spectrum of human serum apolipoproteins fractionated by RP-C4 cartridge-
based SPE after the removal of large proteins by acetonitrile precipitation. The two most 
abundant proteins in the spectrum were identified as apoCI and apoCIII1. (B) Enlarged parts 
of the ESI-FTICR spectrum show less abundant proteins including ion species (i.e., m/z 1215.1, 
[M + 8]8+; m/ 994.3, [M + 10]10+) corresponding to apoCIII2 and to apoCIII-
Hex2HexNAc2Fuc3. These two species were further analyzed by top-down 15T ESI-FTICR 





Figure 3. Top-Down 15T ESI-FTICR-MS/MS of two O-glycosylated apolipoprotein-CIII 
isoforms. (A) CID-spectrum of apoCIII2 (m/z-value 1215.1; [M + 8]8+) obtained with direct 
infusion ESI-FTICR-MS/MS of serum samples after acetonitrile precipitation and RP-C4 
cartridge-based SPE (see Figure 2). Most of the intense peaks were identified as fragments 
resulting from the losses of sialic acids, hexose and N-acetylhexosamine from the glycan 
moiety (i.e., Hex-HexNAc-Neu5Ac2). Fragments resulting from protein backbone cleavages 
(i.e., b77* and b78*) were observed at low intensities with and without one N-acetylhexosamine. 
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In the top-right inset, the singly charged oxonium ions corresponding to the singly protonated 
glycan moieties are shown. All assigned CID fragments are reported in Table S1 in Supporting 
Information. (B) CID-spectrum of apoCIII-Hex2HexNAc2Fuc3 (m/z-value 994.3; [M + 10]10+) 
obtained with direct infusion ESI-FTICR-MS/MS of serum samples after acetonitrile 
precipitation and RPC4 cartridge-based SPE (see Figure 2). Most of the intense peaks were 
identified as fragments resulting from the losses of fucoses, hexoses and N-acetylhexosamines 
from the glycan moiety (i.e., Hex2HexNAc2Fuc3). Two fragment ions were identified as b77* 
and b78* ions with one N-acetylhexosamine, respectively. Three singly charged oxonium ions 
corresponding to singly protonated glycans were observed (top-right inset). All assigned CID 
fragments are reported in Table S2 in Supporting Information. Square and HexNAc, N-
acetylhexosamine; circle, hexose; triangle; fucose; diamond, N-acetylneuraminic acid; b77*, 
b77 without glycans; b78*, b78 without glycans. 
 
 
Figure 4. Bottom-Up LC-IT-MS identification of a fucosylated apolipoprotein-CIII isoform. 
CID-spectrum of a tryptic peptide from apoCIIIHex2HexNAc2Fuc3 (m/z-value 1183.5; [M + 
3]3+) obtained after liquid chromatography and ion trap MS/MS. Multiply charged ions were 
identified as fragments resulting from the loss of fucoses, hexoses and N-acetylhexosamines. 
Three singly charged oxonium ions corresponding to singly protonated glycans were observed 
in the low-mass region. One N-terminal fragment ion (i.e., b10) was observed without the 
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glycosylation while one C-terminal fragment ion (i.e., y11* with either a HexNAc, HexNAc-Hex 
or HexNAc-Hex-Fuc moiety) was observed. All assigned CID fragments are reported in Table 
S3 in Supporting Information. Square and HexNAc, N-acetylhexosamine; circle, hexose; 
triangle; fucose. y11*, y11 without glycans. 
 
Bottom-up identification by LC-IT Mass Spectrometry. To further substantiate the 
identification of fucosylated apoCIII isoforms in serum as derived from our MALDI-
FTICR MS and top-down ESI-FTICR MS analyses, a bottom-up approach was chosen. 
To this end, tryptic peptides were obtained from the RP-C4 20% acetonitrile fraction (see 
above) and these were analyzed by LC-IT mass spectrometry. An inclusion list was used 
to limit the CID experiments to precursor ions corresponding to one of the glycosylated 
tryptic apoCIII peptides (DKFSEFWDLDPEVRPTSAVAA-Hex2HexNAc2Fuc3), related 
to one of the fucosylated apoCIII isoforms identified by our top-down analysis (Figure 
3b). The CID spectrum obtained from the fragmentation of the triply-charged precursor 
ion at m/z 1183.5 is depicted in Figure 4. Clear losses of the fucoses, hexoses and 
N-acetylhexosamines are apparent. In addition, oxonium ions corresponding to the 
HexNAc-Hex element containing one or two fucoses were observed. Some peptide 
backbone cleavages were also apparent. In line with what has been observed previously 
[24] the most prominent fragments correspond to the cleavage between the aspartic acid 
and proline residue. The resulting C-terminal fragment ions without (y11* at m/z–value 
1097.6) and with either a HexNAc, HexNAc-Hex or HexNAc-Hex-Fuc moiety were 
clearly noticeable. This demonstrates that, similar to the known apoCIII glycoforms, the 




Apolipoprotein-CIII is one of the abundant serum glycoproteins and has been 
biochemically characterized approximately 40 years ago [2,10,11,31]. In these initial 
studies it already became evident that there are several different apoCIII glycoforms 
which are characterized by a different degree of sialylation. At that time, the apoCIII 
glycoforms were separated and analyzed using laborious and time consuming techniques 
which were later substituted by more elaborate and fast analytical methods, including 
mass spectrometry [1,15-17]. In the current study, we have used a combination of 
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ultrahigh resolution MALDI-FTICR MS, top-down ESI-FTICR-MS/MS and a bottom-up 
approach on tryptic glycopeptides to study the O-glycosylation of apoCIII in serum. 
In addition to the known glycoforms, this resulted in the characterization of new low 
abundant apoCIII isoforms, containing more complex, fucosylated glycan moieties, 
possibly similar to Lewis-type Fucα(1-2)Galβ(1-4)[Fucα(1-3)]GlcNAc or Galβ(1-
4)[Fucα(1-3)]GlcNAc) structures. 
Previously, MALDI-TOF and SELDI-TOF based methods have been used to study 
plasma/serum apolipoprotein profiles [8,9]. Although these techniques are very valuable 
to assign known peptides and proteins, these MS-systems lack the necessary resolution, 
mass accuracy and precision for a confident characterization of new species as is 
exemplified by earlier reports on apoCIII isoforms [22,23]. Here, the putatively identified 
novel apoCIII species at 9934 Da probably corresponds to the most prominent and 
frequently observed fucosylated apoCIII isoform (apoCIII-Hex2HexNAc2Fuc3) that we 
characterized in the current study. The application of our ultrahigh resolution MALDI-
FTICR method allowed the identification of six fucosylated apoCIII isoforms based on 
low-ppm precision of multiple profiles and corresponding low MMEs [29,32]. 
With increasing number of applications on an orbitrap system this approach is also coined 
as “high resolution/accurate mass (HR/AM)”. A top-down ESI-FTICR-MS/MS was used 
for further characterization of the new apoCIII isoforms. The CID-analysis on the 
apoCIII-Hex2HexNAc2Fuc3 isoform primarily resulted in glycosidic bond cleavages, 
which confirmed the glycan moiety. However, relatively few peptide backbone fragments 
were observed. This is a common phenomenon of CID-mediated glycopeptide/protein 
fragmentation and often hampers the correct assignment of the glycosylation site [33]. 
Other fragmentation techniques like electron-transfer dissociation (ETD) can overcome 
this problem provided the intensity of the precursor ion is sufficient for performing such 
experiments (which unfortunately was not the case for the currently reported species) 
[17,34]. We therefore have applied a bottom-up approach to localize the site of 
glycosylation. Although based on our data the exact position (Thr-74 orSer-75) could not 
be inferred, we strongly believe that, in line with previous reports,Thr-74 is the site of 
glycosylation. 
There has been significant interest for profiling different apoCIII glycoforms due to the 
association of apoCIII with many (patho)physiological conditions, for example 
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triglyceride levels [3] and the risk of cardiovascular diseases [5,6]. In the future, it would 
be indicated to include the newly identified fucosylated species in the analyses of 
ultrahigh resolution protein profiles and determine the relation between their quantitative 
changes and, for example, cardiovascular physiology. For the current study, all samples 
were controls from an in-house study cohort and there appeared to be a large variation in 
the presence of the fucosylated apoCIII isoforms, both qualitatively as well as 
quantitatively. Considering the quantification, no firm conclusion about the relative 
quantities of the different isoforms can be drawn from our data, primarily because we 
have no information about the relative ionization efficiency of the different isoforms. 
In spite of this, it appeared that the fucosylated isoforms are not the dominating isoforms. 
Notwithstanding, signal intensities of 50% of the major fucosylated isoform relative to the 
apoCIII2 have been frequently observed (Figure 1). Most of the glycan structures on the 
fucosylated serum apoCIII isoforms were previously found on apoCIII-derived peptides in 
urine of Schistosoma mansoni-infected individuals but not in urine from healthy 
individuals [24]. In that study, the full-length fucosylated isoforms were not detected 
using MALDI-TOF analysis, neither in the serum from infected nor in the serum from 
healthy individuals. Our new method opens possibilities for further exploration, in order 
to reveal whether the appearance of the peptides in the urine of infected individuals is 
related to altered serum levels of these glycoforms. Alternatively, it may be the result of 
specific proteolytic activity associated with Schistosoma mansoni-infection in 
combination with the incomplete removal of these degradation products in the urinary 
tract system. 
As stated above, the novel glycan structures of apoCIII most probably are attached to the 
same residue (Thr-74) as the hitherto identified apoCIII glycosylation. Mutagenesis of this 
site revealed that apoCIII glycosylation is not indispensible for the secretion and 
distribution of apoCIII over the different lipoprotein particles [35] and individuals 
carrying a Thr-74 to Ala-74 mutation are apparently asymptomatic although they showed 
elevated levels of apoCIII0 [36]. ApoCIII inhibits lipoprotein lipase (LPL) and the 
importance of O-glycosylation in relation to this was recently demonstrated in a study of a 
loss-of-function mutant in the GalNAc transferase GALNT2 [37]. ApoCIII is specifically 
glycosylated by this enzyme and the mutation results in higher serum levels of apoCIII0 
and lower levels of apoCIII1 and is associated with accelerated clearance of plasma 
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triglycerides. In accordance, desialylation of apoCIII abrogates the LPL-inhibitory effect. 
At present, we cannot make any prediction on the functional role of the newly identified 
apoCIII glycoforms but we envisage that their identification is essential for obtaining a 
comprehensive assessment on the structure-function relationship of this major serum 
glycoprotein. 
In conclusion, using a combination of MS-techniques, we have characterized a set of 
fucosylated apoCIII isoforms in serum. In comparison to the known mucin-type, core-1 
apoCIII glycosylation with different degrees of sialylation, these novel glycoforms are 
characterized by more complex, fucosylated glycan moieties. The here presented 
analytical protein profiling procedure allows high-throughput screening while providing 
very detailed information. This in combination with the fact that apolipoproteins play an 
important role in various disease pathways warrants further research. Here, we aim to 
elucidate the implications these glycoforms may have for the plethora of studies where 






















     
ApoCIII2* 1214.9519 (8+) 292.1027 (1+) 0.0001 0.34 
SA 292.1028 (1+) 495.1821 (1+) -0.0001 -0.20 
SAHexNAc 495.1820 (1+) 657.2349 (1+) -0.0001 -0.15 
SAHexNAcHex 657.2348 (1+) 948.3303 (1+) 0.0000 0.00 
SA2HexNAcHex 948.3303 (1+) 1096.5362 (8+) 0.0023 2.1 
ApoCIII0a 1096.5385 (8+) 1253.0403 (7+) 0.0001 0.08 
 1253.0404( 7+) 1461.7125 (6+) -0.0003 -0.21 
 1461.7122 (6+) 1110.7901 (8+) 0.0009 0.81 
b78(HexNAc) 1110.7910 (8+) 1101.9105 (8+) 0.0000 0.00 
b77(HexNAc) 1101.9105 (8+) 1121.9211 (8+) 0.0007 0.62 
ApoCIII(HexNAc) 1121.9218 (8+) 1282.0517 (7+) 0.0001 0.08 
 1282.0518 (7+) 1495.5591 (6+) -0.0005 -0.33 
 1495.5586 (6+) 1142.1777 (8+) 0.0005 0.44 
ApoCIII(HexNAcHex) 1142.1782 (8+) 1305.2021 (7+) 0.0002 0.15 
 1305.2023 (7+) 1522.5679 (6+) 0.0001 0.07 
 1522.5680 (6+) 1178.5647 (8+) 0.0002 0.17 
ApoCIII(HexNAcHexSA) 1178.5649 (8+) 1346.7871 (7+) -0.0004 -0.30 
 1346.7867 (7+) 1214.9516 (8+) 0.0003 0.25 
b78 1240.3197 (7+) 1240.3192 (7+) 0.0005 0.40 
 1446.8709 (6+) 1446.8712 (6+) -0.0003 -0.21 
b77 1230.1713 (7+) 1230.1711 (7+) 0.0002 0.16 
 1435.0317 (6+) 1435.0317 (6+) 0.0000 0.00 
ApoCIII(HexNAcSA) 1158.3086 (8+) 1158.308 (8+) 0.0006 0.52 
 1323.6351 (7+) 1323.6367 (7+) -0.0016 -1.2 
      



























     
apoCIII(HexNAc2Hex2Fuc3)* 994.2743 (10+) 994.2742 (10+) -0.0001 -0.10 
HexHexNAcFuc 512.1974 (1+) 512.1974 (1+) 0.0000 0.00 
HexHexNAcFuc2 658.2553 (1+) 658.2553 (1+) 0.0000 0.00 
HexHexNAcFuc3 804.3129 (1+) 804.3132 (1+) 0.0003 0.37 
apoCIII 974.8105 (9+) 974.8108 (9+) 0.0003 0.31 
 1096.5365 (8+) 1096.5362 (8+) -0.0003 -0.27 
apoCIII(2HexNAc) 918.0461 (10+) 918.0463 (10+) 0.0002 0.22 
apoCIII(HexNAc2Hex) 934.2515 (10+) 934.2516 (10+) 0.0001 0.11 
apoCIII(HexNAc2Hex2) 950.4569 (10+) 950.4569 (10+) 0.0000 0.00 
apoCIII(HexNAc2Hex2Fuc) 965.0630 (10+) 965.0627 (10+) -0.0003 -0.31 
apoCIII(HexNAc2Hex2Fuc2) 979.6678 (10+) 979.6684 (10+) 0.0006 0.61 
apoCIII(HexNAc) 997.3752 (9+) 997.3751 (9+) -0.0001 -0.10 
 1121.9214 (8+) 1121.9211 (8+) -0.0003 -0.27 
apoCIII(HexNAcHex) 1015.3812 (9+) 1015.381 (9+) -0.0002 -0.20 
 1142.1777 (8+) 1142.1777 (8+) 0.0000 0.00 
apoCIII(HexNAcHexFuc) 1031.6095 (9+) 1031.6097 (9+) 0.0002 0.19 
 1160.4355 (8+) 1160.435 (8+) -0.0005 -0.43 
apoCIII(HexNAcHexFuc2) 1047.8380 (9+) 1047.8383 (9+) 0.0003 0.29 
apoCIII(HexNAcHexFuc3) 1064.0669 (9+) 1064.067 (9+) 0.0001 0.09 
b78(HexNAc) 1110.7908 (8+) 1110.7901 (8+) -0.0007 -0.63 
b77(HexNAc) 1101.9080 (8+) 1101.9105 (8+) 0.0025 2.27 
      













Figure 3. Fragment ions observed in the CID Ion Trap MS/MS spectrum of a tryptic 

















     
Pep*-
HexNAc2Hex2Fuc3** 
1183.5 (3+)*** 1183.53 (3+)*** 0.03 25 
HexHexNAc 366.10 (1+) 366.14 (1+) 0.04 109 
HexHexNAcFuc 512.16 (1+) 512.20 (1+) 0.04 78 
HexHexNAcFuc2 658.24 (1+) 658.26 (1+) 0.02 30 
Pep-HexNAc 1292.61 (2+) 1292.62 (2+) 0.01 8 
Pep-HexNAc2 929.81 (3+) 929.77 (3+) -0.04 -43 
Pep-HexNAcHex 1373.61 (2+) 1373.64 (2+) 0.03 22 
Pep-HexNAcHexFuc 1446.65 (2+) 1446.67 (2+) 0.02 14 
Pep-HexNAcHexFuc2 1519.60 (2+) 1519.70 (2+) 0.10 66 
Pep-HexNAc2Hex 983.76 (3+) 983.79 (3+) 0.03 30 
 1475.08 (2+) 1475.18 (2+) 0.10 68 
Pep-HexNAc2HexFuc 1548.08 (2+) 1548.21 (2+) 0.13 84 
Pep-HexNAc2Hex2 1037.77 (3+) 1037.81 (3+) 0.04 39 
 1556.14 (2+) 1556.21 (2+) 0.07 45 
Pep-HexNAc2Hex2Fuc 1086.48 (3+) 1086.5 (3+) 0.02 18 
 1629.12 (2+) 1629.24 (2+) 0.12 74 
Pep-HexNAc2Hex2Fuc2 1135.14 (3+) 1135.18 (3+) 0.04 35 
 1702.13 (2+) 1702.27 (2+) 0.14 82 
b10  1283.58 (1+) 1283.56 (1+) -0.02 -16 
y11* 1097.61 (1+) 1097.59 (1+) -0.02 -18 
y12* 1212.55 (1+) 1212.62 (1+) 0.07 58 
y11*HexNAc 1300.63 (1+) 1300.67 (1+) 0.04 31 
y11*HexNAcHex 1462.65 (1+) 1462.73 (1+) 0.08 55 
y11*HexNAcHexFuc 1608.65 (1+) 1608.79 (1+) 0.14 87 
      
* Pep: DKFSEFWDLDPEVRPTSAVAA 
** Precursor Ion 






Figure S1, S2 and S3. Enlarged parts of MALDI-FTICR serum protein profiles. The 
observed and theoretical isotopic distribution is shown for each fucosylated apoCIII isoform 
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Mass spectrometry-based (clinical) proteomics has been widely applied as a technology to 
find and validate disease-specific protein signatures. MALDI-based peptidome profiles 
provide a suitable platform for classification of body fluids or tissues, albeit at the cost of 
being unable to observe low abundant species. Here we show that a fully automated 
one-step solid-phase extraction serum sample cleanup in combination with fast MALDI 
acquisition and ultrahigh precision 15 tesla FTICR readout provides a powerful, fast and 
robust approach for obtaining biomarker signatures. This is exemplified for a cohort of 
pancreatic cancer patients. Specific “early cancer” symptoms such as pain, jaundice or 
weight loss are often not experienced, thus delaying diagnosis of the disease. 
Novel markers for early diagnosis of pancreatic cancer are therefore urgently needed. 
A total of 273 serum samples, distributed over a calibration and validation set, was 
processed and mass analyzed within a time frame of 24 hours. In both sets sensitivity and 
selectivity values were well above 85%. In these “next-generation” MALDI peptidome 
profiles all species up to 9 kDa were isotopically resolved. Finally, it is noted that the low 
ppm mass accuracy of peptides and proteins observed between 1 and 9 kDa in the FTICR 





Pancreatic cancer (PC) is the fourth (females) and fifth (males) leading cause of cancer 
death in developed countries, with a relatively low annual incidence of 5.4 cases per 
100,000 females and 8.2 cases per 100,000 males [1]. Patients often die within the first 
half year after diagnosis, or have an extremely poor prognosis with an overall five-year 
survival rate of less than 5% [2]. When surgical resection is possible, five-year survival 
rates improve to approximately 25%. Unfortunately, when the first symptoms appear most 
tumors are at an advanced stage and their surgical resection would not improve the 
prognosis [3;4]. Molecular biomarkers that detect PC at an early stage with high 
sensitivity and specificity would thus be highly beneficial. At the moment, the only used 
blood marker for detecting and following PC in the clinic is the mucin-associated 
carbohydrate antigen CA 19-9. This marker, however, often fails in detecting small, 
resectable cancers [5]. Consequently, like in other cancer biomarker studies, serum 
proteomics has become a popular approach to find new markers for PC, since blood is a 
rich and powerful source of biomarkers in general and samples can be collected in a 
minimally invasive way. The discovery of serum biomarkers is mainly performed by mass 
spectrometry (MS)-based proteomics methods [6]. One of these involves the comparison 
of serum protein profiles in a “case versus control” manner by matrix-assisted laser 
desorption/ionization - time of flight (MALDI-TOF) MS [7]. Such profiles (i.e. mass 
spectra) contain hundreds of features (or peaks), of which the presence and intensity can 
depend on the physiological and pathological condition of the individual. The statistical 
analysis of serum peptide and protein profiles obtained from both control and diseased 
individuals allows the identification of a set of features, or a so-called biomarker 
signature, that can be valuable in understanding the specific disease. Moreover, the 
biomarker signature may provide leads to further exploit diagnostic and therapeutic 
potential. Encouraging results have been obtained using profiling strategies [8-10]. 
Nevertheless, the route to clinically applicable protein assays faces various types of 
challenges [11;12]. With regard to the selected methodology, for MS-based peptide 
profiling approaches the problems can be categorized as follows. First of all, multiple 
profiling studies have shown to lack reproducibility and could not be validated. 
In this context, standardization of the protocols used for serum sample collection and for 
peptide and protein purification is pivotal [10;13;14]. The use of a fully automated high-
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throughput platform for sample processing based on solid-phase extraction (SPE) has 
been shown to minimize variation and to improve robustness of the method [15]. 
Secondly, previous MS-acquisitions such as performed on surface-enhanced laser 
desorption/ionization (SELDI) platforms were not robust and yielded poor accuracies. 
In addition, identification of peptides or proteins was cumbersome, or not possible at all in 
these early profiling studies. However, with current equipment these issues can be 
considered obsolete. The use of internal standards in combination with modern mass 
analyzers now allows precise quantitation and detailed characterization of peptides in 
high-throughput profiles [16;17]. Thirdly, similar peptide profiles were found for various 
diseases, implying that the features were not specific. On the other hand, it has been 
postulated that well-defined degradation of highly abundant proteins into peptides 
(“degradome”) can result in tumor-specific serum peptidome patterns [18].  
Recently, we reported a protein profiling study for PC performed on a fully automated 
SPE-based serum processing platform [19]. Proteins were first isolated with weak cation 
exchange (WCX) magnetic beads (MBs) using a 96-channel liquid handling robot, 
followed by acquisition of linear mode MALDI-TOF profiles in the range of 1 to 12 kDa, 
and evaluation via linear discriminant analysis with double cross-validation. This resulted 
in a discriminating WCX-profile for PC with a sensitivity of 78% and a specificity of 89% 
in the calibration set with an area under the curve (AUC) of 90%. These results were 
validated with a sensitivity of 74% and a specificity of 91% (AUC 90%). However, an 
obvious disadvantage of low resolution MS profiles is the fact that (poly)peptides and 
proteins are measured as broad peaks, thus leading to one of the earlier mentioned 
problems on peak identification. In a second profiling study using the same PC cohort, 
serum samples were processed with reversed-phase (RP) C18 MBs, and resulting peptides 
were measured with high-resolution reflectron mode MALDI-TOF MS yielding 
isotopically resolved profiles up to 4 kDa. For statistical evaluation, a list of 42 different 
peptides was compiled from which a discriminating profile for PC could be defined, with 
an area under the curve (AUC) of 92% (98%) a sensitivity of 76% (95%) and specificity 
of 91% (100%) in the calibration (validation) set. Although the identity of most of these 
peptides was known or elucidated, it became clear that multiple peptides still overlapped 
at the resolving power of approximately 11,000 [20]. The effect of increased resolving 




cyclotron resonance (FTICR) MS, a platform that has proven to be extremely powerful for 
the analysis of complex mixtures, such as oil, organic matter and plasma [21-23]. 
With proper control, mass resolving powers higher than 100,000 (at m/z-value 1,000 with 
1s transient) and low or sub-ppm mass measurement errors can be routinely obtained 
[24;25]. We have previously developed a MALDI-FTICR workflow on a commercially 
available platform equipped with a 15 tesla magnet that allows high-throughput and fully 
automated profiling of human serum peptides and proteins with isotopic resolution up to 
15,000 Da [26;27]. By following this approach, in comparison to high resolution TOF 
analyzers the spectrum alignment is more accurate and the quantification of peptides more 
robust due to the improved mass measurement precision. In this study this MALDI-
FTICR workflow in combination with SPE-based sample cleanup with RPC18-
functionalized MBs was applied for the analysis of a clinical cohort. Here, “next-
generation” MALDI-FTICR peptide and protein profiles were generated using serum 
samples obtained from PC patients and control individuals (258 samples in total). 
Classification performances of both the calibration and validation set were compared to 
those previously obtained from the same PC cohort, either processed with different MBs 
or measured on a different mass analyzer. Discriminating peaks (i.e. a biomarker 
signature) defined from the calibration set were validated using an independent 
case-control group. Finally, the low ppm mass accuracy provided by the MALDI-FTICR 
platform narrows the search window for de novo identifications of peptides and proteins 
in the profiles. 
 
MATERIALS AND METHODS 
Patients and sample collection. For the calibration set, serum samples were obtained 
from 49 patients with PC prior to surgery, and from 110 (age- and gender-matched) 
healthy volunteers (“controls”) over a time period ranging from October 2002 until 
December 2008 at the outpatient clinic of the Leiden University Medical Center (LUMC), 
the Netherlands. Healthy volunteers were partners or accompanying persons of included 
patients. For the validation set, serum samples were obtained from 39 patients and 
75 healthy (age- and gender-matched) volunteers over a time period ranging from January 
2009 until July 2010. Patients were selected candidates for curative surgery, thus no 
patients with primary irresectable tumours were included. All surgical specimens were 
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examined according to routine histological evaluation and the extent of the tumor spread 
was assessed by TNM (TNM Classification of Malignant Tumors) classification. 
Informed consent was obtained from all subjects and the study was approved by the 
Medical Ethical Committee of the LUMC. All samples were collected and processed 
according to a previously reported standardized protocol [9]. Briefly, blood samples were 
drawn by antecubital venipuncture while the individuals, who had not been fasting prior to 
any invasive procedure, were seated. The samples were collected in an 8.5 mL Serum 
Separator Vacutainer Tube (BD Diagnostics, Plymouth, UK) and maximally within 4 h at 
room temperature were centrifuged at 1000 g for 10 min. Serum samples were then 
distributed into sterile 500-µL barcode labelled polypropylene aliquots (TrakMate; Matrix 
TechCorp.) and stored at -80°C. All serum samples were thawed on ice once and 
randomly placed in barcode labelled racks in an 8-channel Hamilton STAR® pipetting 
robot (Hamilton) for automated aliquotting into 60-µL daughter tubes. The aliquots were 
stored in 96-tubes racks at -80°C until further sample processing. Samples from the 
calibration and the validation set were distributed over three 96-tubes racks as following: 
one full 96-tube rack for both the calibration and validation set and one partially-filled 96-
tube rack with 63 samples from the calibration set and 18 samples from the validation set. 
Identical processing steps were followed for the two sample sets.  
 
High-throughput RPC18-MB chromatography and MALDI spotting. The isolation of 
peptides from human serum was performed using RPC18-functionalized MBs as 
previously described [27]. In short, RPC18-MBs were first activated by a three-step 
washing with a 0.1% TFA solution. Then, for each sample 5 µL of serum was added to 
the activated beads and incubated for 5 min at room temperature. The beads were washed 
again three times with 0.1% TFA and peptides were eluted with a 1:1 mixture of water 
and acetonitrile. Two microliters of each (stabilized) eluate were mixed with 10 μL of an 
α-cyano-4-hydroxycinnamic acid MALDI matrix solution in a 384-well PCR plate. 
Then, 1 μL of this mixture was spotted in quadruplicate onto a 600 µm Anchor-Chip™ 
MALDI-target plate (Bruker Daltonics). The so-called RPC18 eluates from the calibration 
and the validation set were spotted onto three 384-spots MALDI-target plate as following: 
96 eluates from the calibration set and 96 eluates from the validation set were spotted in 




sets were spotted in quadruplicate onto the same MALDI-target plate. This SPE- and 
MALDI-spotting procedure requires approximately 3 hours per plate of 96 samples. 
  
MALDI-FTICR mass spectrometry and data processing. MALDI-FTICR experiments 
were performed on a Bruker 15 tesla solariX™ FTICR mass spectrometer equipped with a 
novel CombiSource (Bruker Daltonics). The MALDI-FTICR system was controlled by 
Compass solariXcontrol software and equipped with a Bruker Smartbeam-II™ laser 
system that operated at a frequency of 200 Hz. The ‘medium’ predefined shot pattern was 
used for the irradiation. Two acquisition settings, namely low-mass method (LM) and 
high-mass method (HM), respectively, were used to optimize both the sensitivity and 
resolving power in the mass range from 1013 to 3700 Da and in the mass range from 3500 
to 10000 Da, respectively. These methods were optimized as previously described with 
some modification [27]. For both methods, each mass spectrum was obtained from the 
sum of 10 scans of 150 laser shots each and using 512 K data points. Typically, the target 
plate offset was 100 V with the deflector plate set at 180 V. The ion funnels operated at 
100 V and 6.0 V, respectively, with the skimmers at 15 and 5 V. The analyzer entrance 
was maintained at -7 V, and side kick technology was used to further optimize peak shape 
and signal intensity. The trapping potentials were set at 0.60 and 0.55 V for the LM and at 
0.95 and 0.80 for the HM. The required excitation power was 28% with a pulse time of 
20.0 µs. The two acquisition settings differentiate for the trapping potentials (LM, 0.6 and 
0.55 V; HM, 0.95 and 0.80 V), the required excitation power (LM, 25%; HM, 28%) and 
pulse time (LM, 10 µs; HM, 20 µs), the time of flight to the ICR cell (LM, 1.350 ms; HM, 
2.700 ms) and the quadrupole filter mass (LM, m/z 1300; HM, m/z 2500). For each 
spotted sample, two duplicate spots were measured using the LM and the other two using 
the HM. Approximately 4.5 hours were needed to measure 384 MALDI spots 
(i.e. originating from 96 different serum samples). DataAnalysis Software 4.0 SP 5 
(Bruker Daltonics) was used for the visualization and the calibration of the spectra. Prior 
to the measurement of each MALDI plate the FTICR system was externally calibrated 
using a commercially available peptide mix and a protein mix (Bruker Daltonics). 
The spectra obtained using the LM were internally calibrated only when used for 
identification purposes. The m/z-values used for the internal calibration of the LM and the 
HM are reported in Table S1 in the Supplementary Material section. Peaks were 
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determined using the FTMS algorithm with a signal-to-noise threshold of 3 and using the 
centroid for peak position with a percentage height of 80.  
 
Peak selection and quantification. Protein and/or peptide signals in RPC18 profiles were 
quantified as follows. First, based on visual inspection of the profiles, 457 and 670 peaks 
were selected for the LM and HM spectra, respectively, for further analysis. To this end, a 
so-called reference file was compiled for both types of profiles in such a way that for each 
selected peak the m/z-value, a peak number and an m/z-window were reported. In the LM 
profiles, this m/z-window ranged from 0.015 to 0.166 Da while in the HM it ranged from 
0.05 to 0.31 Da reflecting the peak width along the spectra. Then, the in-house developed 
Xtractor tool was used to determine the intensity of each user-defined peak. This open 
source tool generates uniform data (peak) arrays regardless of spectral content 
(http://www.msutils.org/Xtractor). MALDI-FTICR profiles were exported as XY (.xy) 
files, all containing m/z values with corresponding intensities. Although peptide and 
proteins were measured up to 10,000 Da using the HM method, the peak selection was 
limited to 9043.3 Da. The analysis of the spectra in the m/z-range from 9043.3 to 10000 is 
on-going and the results will be presented in a separate study.  
 
Statistical analysis. Peak intensities were transformed using the logarithmic function, 
followed by calculation of the mean of peak intensities obtained from replicate spectra. 
The intensities of isotope peaks belonging to the same peptide were further summed to 
reduce the number of features and time needed for further analysis. For each sample, 196 
and 291 peak intensity values were obtained for the LM and HM, respectively, and were 
used for statistical analysis. To this end, logistic regression ridge shrinkage (LRRS) 
analysis was applied to the calibration sets (i.e. LM and HM data from the calibration set) 
in order to calibrate two diagnostic rules for the classification of the serum sample either 
as case or control. Each sample was assigned to the group for which the probability was 
higher. The prediction rules obtained from the application of LRRS on the calibration sets 
were applied to the validation sets (i.e. LM and HM data from the validation set). 
Thus, each sample was classified and the results were compared with known disease 
status. The classification probabilities assigned to each sample using the LM and HM data 




on the combination of the Logit transformed probabilities obtained for validation sets. 
This analysis involves the recalibration of the validated diagnostic rule. For each analysis 
error rate (error = the amount by which an observation differs from its expected value), 
sensitivity, specificity and area under the curve (AUC) were calculated. The error rates are 
based on the sensitivity and specificity values, assuming a prior class probability of 0.5 for 
each group. Receiver-operating characteristic (ROC) curves with the true-positive rate 
(sensitivity) were plotted in function of the false-positive rate (1-specificity) for different 
cut-off points of a parameter. Each point on the ROC curve represents a 
sensitivity/specificity pair corresponding to a particular decision threshold. The area under 
the ROC curve (AUC) is a measure of how well a parameter can distinguish between 
groups (diseased/healthy). Univariate discriminate analysis was performed to determine 
which peak varied the most between case and control groups. This study was limited to 
peaks of which the absolute weighted discriminant coefficient was higher than 0.1 in the 
multivariate discriminant analysis used to calibrate the discriminant models. Finally, a t-
test was performed on a selection of peaks for the calibration sets only. 
 
RESULTS  
MALDI-FTICR-MS peptide and protein profiling. Serum samples of PC patients as 
well as control individuals were processed simultaneously using a previously described 
fully automated and standardized SPE-based RPC18-MB protocol [15]. Thus obtained 
MB eluates were spotted onto a MALDI target plate in quadruplicate. Two types of 
ultrahigh resolution peptide and protein profiles were then acquired applying an 
automated acquisition procedure on the MALDI-FTICR system (see Materials and 
Methods section). Two out of four spots were used to obtain a so-called low mass (LM) 
profile (m/z-values from 1013 to 3700) and the remaining two spots were used to generate 
a so-called high mass (HM) profile (m/z-values from 3500 to 10,00). In total, 273 serum 
samples were analyzed in this way, thus yielding 1,092 profiles. A typical example of 
both an LM and HM MALDI-FTICR profile is depicted in Figure 1 (upper panel). It was 
verified that all peptides and (small) proteins were measured with isotopic resolution 
through all the spectra, with typical resolving powers varying from 130000 
(m/z 1039.6727) to 46000 (m/z 3523.7664) in the LM spectra and from 150000 
(m/z 3680.8709) to 33000 (m/z 9744.6054) in the HM spectra (as plotted in Figure 2A). 
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As a result, a large number of peptides or proteins that would overlap in high resolution 
MALDI-TOF MS were measured as distinct features by MALDI-FTICR MS. Two 
examples of resolved species are shown in Figure 2B, one for the LM and one for the HM 
profiles. The ultrahigh resolving power allowed the accurate quantification of the selected 
peptides and proteins in all the spectra. After manual inspection of the profiles, 457 and 
670 peaks for the LM and HM, respectively, were selected for statistical analysis. 
After taking into account isotopic peaks from the same species, 196 peptides remained 
from the 457 selected peaks in LM spectra and 291 peptides or proteins remained from the 
670 selected peaks in HM spectra. Peptides and proteins were detected with signal 
intensities that typically ranged over two orders of magnitude. For example, 
Fibrinopeptide alpha chain (2–16) (at m/z-value 1465.6554) was often observed as the 
most intense peptide, and was 304 times more intense than Complement C4-A (1337–
1350) (at m/z-value 1626.8459) detected with a signal-to-noise ratio (S/N) of 6.6, in a 
typical spectrum. Thus, peptides observed with low S/N were also evaluated. 
For example, the peptide identified as oxidized Fibrinogen beta chain (45-71)(m/z 
2898.5334) (see Serum peptide identification by accurate mass difference measurement 
section) was observed in the spectra in the calibration set with an averaged S/N 9.6 with a 
standard deviation (SD) of 6.4, while the highly intense Complement C3f fragment 
peptide (at m/z-value 2021.1039) was observed with an averaged S/N of 2035 with an SD 
of 345. As a final remark, from 12 out of 1,032 profiles the quality was insufficient for 

















Figure 1. Ultrahigh resolution 15T MALDI-FTICR peptide and protein profiles obtained 
from human serum after RPC18 magnetic bead-based SPE (upper panel). Using two different 
acquisition settings, optimized for the low-mass and high-mass range, peptides and proteins 
were isotopically resolved up to 10 kDa. For statistical analysis, logistic regression ridge 
shrinkage analysis was used to find changes in the peptide and protein profiles obtained from 
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healthy individuals and pancreatic cancer patients. A weighted discriminant coefficient was 
assigned to each detected peptide or protein according to its discriminant property in the way 
that the higher the value of the discriminant coefficient the higher the case probability (middle 
panel). Identifications of the most discriminating peptides and proteins were based on 
previously reported peptide IDs or on accurate mass measurement of mass differences in the 
spectra (lower panel). Note that these identifications need further confirmation by MS/MS-
data. 
 
Statistical analysis. The signal intensities of all selected peaks were determined in all 
serum profiles using the Xtractor tool described in the Materials and methods section. 
As shown in Figure 2A, the m/z-windows in the reference files were fine-tuned according 
to the resolving power calculated for each m/z-value. The presence of different peptides 
with close masses was also taken into account as well as the mass measurement precision 
(see Figure 2B). The optimization of this m/z-window allowed the accurate quantification 
of all peaks selected from the spectra. Thus obtained peak intensity values were then used 
for statistical analysis. To this end, a discriminate model was first calibrated and then 
validated using LRRS analysis on the calibration and validation sets, respectively. 
The ROC curves resulted from this analysis are shown in Figure 3. Error rates of 0.136 
and 0.104, sensitivities of 88% and 91% and specificities of 96% and 94% with AUC of 
0.987 and 0.980 were obtained for the LM and HM validation sets, respectively. 
The LRRS analysis performed on the combination of the logit of the classification 
probabilities obtained for the LM and HM validation sets resulted in an error of 0.0784, a 








Figure 2. For each isotopically resolved peptide or protein signal a specific m/z-window was 
defined to allow accurate quantification. The m/z-window was based on the resolving power at 
a specific m/z-value (A) and in the case of overlapping species further optimized (B). Note that 
the resolving power at m/z 3500 is higher in the High-mass measurements (i.e. ~ 150000) than 
in the Low-mass measurements (i.e. ~ 46000) as a result of the specific broadband frequency-
sweep waveform that was used to excite the ions into the ICR cell. 
 
The logit transformation involves a recalibration of the discriminant models obtained 
using the validation sets. The discriminant analysis performed on the recalibrated 
validation sets resulted in errors of 0.098 and 0.088, sensitivities of 88% and 90% and 
specificities of 96% and 93% with AUC of 0.987 and 0.977 for the LM and HM 






Figure 3. Receiver Operating Characteristic (ROC) curves generated from the case-control 
classification of the serum samples from both the calibration sets and the validation sets using 
Low-mass (LM) and High-mass (HM) data (four upper panels). The larger the area under the 
ROC curve (AUC), the better two groups (diseased/healthy) can be distinguished. The lower 
panel on the left hand-side shows ROC curves generated from the combination of the 
classification results obtained from the validation set. This combination involved the 
recalibration of the validated diagnostic rules, resulting in recalibrated LM and HM data. 
The lower panel on the right hand-side shows box plots that are obtained after sub-typing the 
PC cases into cases without any metastasis (i.e. regional lymph node-negatives (LN-) and no 
distant metastasis (DM-)) versus lymph node-positives (LN+) and/or distant metastasis (DM+) 







A sequential analysis was performed by sub-typing the PC cases into cases without any 
metastasis (i.e. regional lymph node-negative (LN-) and no distant metastasis (DM-)) 
versus cases that were lymph node-positives (LN+) and/or showed distant metastasis 
(DM+), based on TNM-classification summarized in Table 1. This sub-typing resulted in 
a box plot (see Figure 3) with separation between controls and cases, and in addition good 
separation between cases with and without metastasis (Wilcoxon Mann-Whitney test with 
a p-value of 7.7293e-05 for controls versus “(LN-)and(DM-)”, and a p-value of 0.015844 
for “(LN+)and/or(DM+)” versus “(LN-)and(DM-)”). Patient characteristics, number of 
serum samples, and the results of the classification methods set are shown in Table 1.  
 
Table 1. Patient characteristics for the calibration and validation sets. 

















HM and LM 
       N. of samples 46 45  39 35  
Age median 









Male 23 [16] 22 [17] 16 17 [15] 15 [11] 12 
Female 23 [15] 23 [15] 17 22 [17] 20 [15] 15 
Localisation 
(pancreas)       
Head 38 [28] 36 [27] 33 35 [28] 31 [22] 23 
Body 3 [1] 3 [2] 1 1 [1] 1 [1] 1 
Tail 3 [1] 4 [2] 2 1 [1] 1 [1] 1 
Unknown/Other 2 [1] 2 [1] 1 2 [2] 2 [2] 2 
Stage       
IA 7 [7] 7 [6] 7 2 [1] 2 [0] 0 
IB 5 [3] 5 [3] 3 2 [2] 1 [1] 1 
IIA 3 [2] 3 [1] 2 3 [1] 3 [0] 1 
IIB 19 [13] 17 [14] 13 21 [18] 20 [17] 17 
III 5 [3] 5 [4] 3 2 [2] 2 [2] 2 
IV 7 [3] 8 [4] 5 9 [8] 7 [6] 6 
Tumor 




12 [7] 11 [6] 7 11 [10] 10 [9] 9 
Grade 1 10 [5] 11 [5] 6 6 [2] 6 [3] 3 
Grade 2 11 [9] 11 [9] 9 15 [14] 13 [10] 10 
Grade 3 13 [10] 12 [12] 11 7 [6] 6 [4] 5 
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A logistic regression coefficient weighted by the standard deviation of the peak intensity 
was assigned to each peak as determined from multivariate analysis on the calibration set 
(i.e. the calibration of the discriminating rule). These discriminant weights denote the 
conditional effect associated with each peak, after taking into account the variation in 
expression across the other selected peaks. Thus, the higher the value of the discriminant 
weight the higher the case probability. Note that the reverse applies to control samples. 
The plots with the weighted discriminant coefficients vs the m/z-values are shown in 
Figure 1 (middle panel). A t-test was performed on peaks with absolute discriminant 
coefficient higher than 0.1 in the calibration set. A P-value smaller than 0.001 was 
considered as significant. Peaks that satisfied these criteria are reported in Table 2 with 
corresponding protein names, t-test values, standard deviations (SD), P-values, 95%-
confidence interval and the weighted discriminant coefficients. Note that the P-values here 





Table 2. Peptides present in MALDI-FTICR precision profiles with low P-values after 




* This species was observed as a doubly-charged ion. 
Observed 





Low-Mass MALDI-FTICR profiles  
1206.5753 FPA chain (5-16) 3.7 3.4 2.7E-04 1.1 3.5 -0.51 
1211.6535 Complement C3f fragment (7–16)  -4.0 2.0 1.1E-04 -2.1 -0.7 0.42 
1263.5965 FPA chain (4–16) 5.0 3.0 1.3E-06 1.6 3.7 -0.64 
1348.7118 Complement C3f fragment (6–16) -3.6 1.5 4.1E-04 -1.5 -0.4 0.16 
1350.6282 FPA chain (3–16) 4.4 3.5 2.4E-05 1.5 3.9 -0.56 
1449.7597 Complement C3f fragment (5–16) -4.0 3.3 1.1E-04 -3.5 -1.2 0.84 
1561.7265 Protrombin (315-327)  4.5 1.9 1.4E-05 0.8 2.2 -0.25 
1616.6584 FPA chain 1P 5.0 3.4 1.8E-06 1.8 4.2 -0.36 
1626.8458 Complement C4-A (1337–1350)  -3.7 1.1 3.2E-04 -1.1 -0.3 0.15 
1698.7450 n.i. -3.5 0.9 6.0E-04 -0.9 -0.3 0.12 
1718.9430 Complement C3f fragment (4–16) -4.2 1.6 4.4E-05 -1.7 -0.6 0.39 
1786.8545 ITIH4 (671–687)  -4.7 1.7 6.5E-06 -2.0 -0.8 0.23 
1984.9879 n.i. 3.6 1.2 4.8E-04 0.3 1.2 -0.25 
2685.3746 Thrombin light chain (342-363)  -5.8 1.1 3.9E-08 -1.5 -0.7 0.18 
2768.2293 FGA chain (576–600)  3.9 3.5 1.5E-04 1.2 3.7 -0.79 
2898.5334 FGB chain (45-71) + 15.9952 Da -6.3 1.3 4.0E-09 -2.0 -1.0 0.32 
2931.2909 FGA chain precursor (576–601) 4.9 3.8 2.2E-06 2.0 4.7 -0.70 
3190.4279 FGA chain (576–603)  5.9 3.1 2.9E-08 2.1 4.3 -0.76 
3206.4243 FGA chain (576–603) [Met-ox]  5.2 2.1 7.1E-07 1.2 2.7 -0.23 
3261.4664 FGA chain (576–604)  5.1 3.5 1.3E-06 1.9 4.4 -0.59 
High-Mass MALDI-FTICR profiles  
3679.8665 n.i. -4.3 0.7 3.7E-05 -0.8 -0.3 0.14 
3806.8902 n.i. -4.2 0.7 5.4E-05 -0.7 -0.3 0.19 
4051.9297 Thrombin light chain (328-363) (Cysteinylated) -5.8 2.8 4.4E-08 -3.8 -1.9 1.72 
4108.9479 Thrombin light chain (328-363) (Cysteinylated+Gly)  -4.6 1.5 7.6E-06 -1.8 -0.7 0.24 
4394.0803 n.i. 3.8 1.6 2.1E-04 0.5 1.7 -0.62 
4854.2768 Apolipoprotein CIII2 (21-99) * -3.9 2.5 1.7E-04 -2.6 -0.8 0.28 
4961.4906 FGA chain (529–574) or (513–558) -4.5 2.9 1.3E-05 -3.3 -1.3 1.16 
4979.4945 FGA chain (529–574) or (513–558)  + 15.9952 Da -5.0 2.1 1.7E-06 -2.6 -1.1 0.36 
4985.4806 n.i. -3.7 1.7 2.9E-04 -1.7 -0.5 -0.30 
5802.6370 FGA chain (576-627) -3.7 3.2 2.7E-04 -3.2 -1.0 0.62 
6223.3096 n.i. -4.5 1.4 1.2E-05 -1.6 -0.6 0.19 
7151.4191 n.i. -3.5 1.6 5.9E-04 -1.5 -0.4 0.11 
8205.0930 Apolipoprotein CII (23-101) -3.8 1.8 2.4E-04 -1.9 -0.6 0.88 
8781.2819 Apolipoprotein-CIII (21-99) + 15.9952 Da 3.8 2.8 1.8E-04 0.9 2.9 -1.19 
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Serum peptide identification by accurate mass difference measurement. A list of 
serum peptides and proteins that are commonly observed in MALDI-TOF profiles 
obtained after RPC18-based sample cleanup has been compiled previously and this was 
used for statistical evaluations [9]. However, a number of peptides remained unidentified 
in this list, and moreover in the current MALDI-FTICR ultrahigh resolution profiles many 
RPC18-MB serum eluate peaks are unknown. Likely, a large number of these degradome 
peptides originate from the same high abundant proteins after proteolytic cleavage as was 
reported earlier [18;28;29]. New peptide assignments were performed based on matching 
accurate mass measurements of m/z-differences between peaks in 15T MALDI-FTICR 
spectra with possible decreased or increased sequences (“degradome”). Thus, a search for 
consecutive mass differences corresponding to one amino acid was performed, starting 
from a previously identified peptide in the spectrum with relatively highest signal 
intensity. In this way, new peptides with one or more additional amino acids at the 
N-terminus or/and the C-terminus or modified peptides (i.e. oxidized, cysteinylated) were 
identified. Following this strategy the amino acid sequence of 34 new peptides was 
derived and these are reported in Table 3. In general, the LM and HM profiles provided 
sub- and low-ppm mass measurement errors for these identifications, respectively. 
Two examples of this approach are shown in Figure 1 (lower panel). The first one is the 
identification of an oxidized form of the peptide Fibrinogen alpha chain (576–604) that 
was statistically evaluated with a discriminant weight factor of -0.59 (see Table 2). In the 
second example the accurate mass-based identification of the species observed at m/z-
value 4051.9255 is depicted, a peptide that was found to be the best predictor (i.e. highest 
absolute discriminant weight) of healthy and disease individuals in HM profiles (see Table 
2). The mass difference between this peptide and a peptide previously MS/MS-identified 
as cysteinylated-Prothrombin (328-363), observed at m/z-value 4208.0269, was 156.1014 
Da. This mass difference corresponds to an arginine residue with an error of only 0.3 
milliDa. In addition, the accurate measurement of mass differences allowed the 
identification of peptides containing a single amino acid mutation. For example, a peptide 
from coagulation factor XIII (Factor XIIIa) alpha chain with a previously reported 
Val35Leu mutation corresponding to a mass difference of 14.0156 Da between “normal” 
and mutant fragment peptides was indeed observed (see Table 3). Here, the species at m/z-




whereas the species at m/z-value 2531.2735 and m/z-value 2545.2883 both lack an alanine 
residue but differ at the site of mutation (i.e. Val35 Factor XIIIa (15-38) and Leu35 Factor 
XIIIa (15-38), respectively). It is emphasized that isobaric peptides containing 
modifications such as oxidation cannot be uniquely characterized by the accurate 
measurement of mass differences. For this purpose additional MS/MS-experiments are 
needed to confirm the identifications and localize for instance modified amino acids in the 
sequence. As a final remark, the accurate and precise MALDI-FTICR mass measurements 
will allow a reliable match between the MS/MS-data obtained using other MS techniques 




Table 3. Proposed sequences of (large) peptides present in MALDI-FTICR precision profiles 
based on accurate mass measurements. 














DHAAYHPF.R +(NRF + 0.0033) 3141.6017 3141.6047 0.96 LM 
N.FRPGVLSSRQLGLPGPPDVPD





+(R - 0.0004) 2880.4904 2880.4896 -0.26 LM 
R.PGVLSSRQLGLPGPPDVPDH
AAYHPF.R - 2724.3893 2724.3889 -0.13 LM 
P.GVLSSRQLGLPGPPDVPDHAA
YHPF.R -(P + 0.0002) 2627.3365 2627.3360 -0.19 LM 
       
Thrombin  
light chain  
UniProt P00734 
L.FEKKSLEDKTERELLESYIDGR +(FEKK - 0.0011) 2685.3730 2685.3720 -0.36 LM 
F.EKKSLEDKTERELLESYIDGR +(EKK - 0.0008) 2538.3046 2538.3039 -0.28 LM 
E.KKSLEDKTERELLESYIDGR +(KK - 0.0005) 2409.2620 2409.2615 -0.19 LM 
K.KSLEDKTERELLESYIDGR +(K + 0.0004) 2281.1670 2281.1676 0.23 LM 
K.SLEDKTERELLESYIDGR - 2153.0721 2153.0722 0.04 LM 
S.LEDKTERELLESYIDGR -(S + 0.0012) 2066.0400 2066.0390 -0.53 LM 
L.EDKTERELLESYIDGR -(SL + 0.0001) 1952.9560 1952.9560 0.02 LM 
E.DKTERELLESYIDGR -(SLE + 0.0010) 1823.9134 1823.9124 -0.52 LM 
D.KTERELLESYIDGR -(SLED + 0.0001) 1708.8864 1708.8865 0.01 LM 
Thrombin  
light chain  
UniProt P00734 
TFGSGEADC(CysGly)GLRPLFEK
KSLEDKTERELLESYIDG +(G + 0.0032) 4265.0489 4265.0520 0.73 HM 
TFGSGEADC(Cys)GLRPLFEKK




-(R-Gly-0.0001) 4108.9478 4108.9479 0.02 HM 
TFGSGEADCGLRPLFEKKSLEDK
TERELLESYIDGR 
- (Cysteinylation + 
0.0010) 4089.0234 4089.0222 -0.27 HM 
TFGSGEADC(Cys)GLRPLFEKKS
LEDKTERELLESYIDG -(R - 0.0034) 4051.9263 4051.9297 0.82 HM 
TFGSGEADC(CysGly)GLRPLFEK
KSLEDKTERELLESYIDG +(G + 0.0032) 4265.0489 4265.0520 0.73 HM 
       
Fibrinogen  









-(V + 0.0010) 5802.63456 5802.6370 0.42 HM 
       
Fibrinogen  



















The past decade, MS-based profiling studies have been carried out to determine disease-
specific serum peptidome signatures in a “case-control” setting. Due to the relatively high 
biological variability of the serum peptidome (and proteome) a large number of samples 
are required for statistical evaluation. Thus, high-throughput analytical methodologies 
have been adopted in combination with MS, pioneered by SELDI-TOF platforms. 
In the same period, high-throughput robotic platforms with more flexible and user-defined 
sample preparation protocols were combined with MALDI-TOF read-out. Both low-
resolution TOF-profiles with a wide m/z-range and high-resolution profiles with smaller 
m/z-windows were reported for proteins and peptides, respectively [7;30;31]. However, 
single- or even multi-step protein fractionations still yield highly complex samples and the 
low resolving powers in linear mode SELDI- or MALDI-TOF profiles do not allow 




-(KRGHA - 0.0005) 4785.0401 4785.0442 0.86 HM 
       




























-(EA + 0.068) 7565.1147 7565.0933 -2.83 HM 
       
HMW Kininogen 
UniProt P01042 
H.NLGHGHKHERDQGHGHQ - 1943.9080 1943.9071 -0.47 LM 
HNLGHGHKHERDQGHGHQ +(H + 0.0001) 2080.9669 2080.9661 -0.39 LM 




SSKITHRIHWESASLLR - 2021.1039 2021.1040 0.04 LM 
S.SKITHRIHWESASLLR -(S + 0.0005) 1934.0719 1934.0715 -0.20 LM 
S.KITHRIHWESASLLR -(SS + 0.0013) 1847.0399 1847.0387 -0.63 LM 
H.RIHWESASLLR -(SSKITH + 0.0003) 1367.7542 1367.7541 -0.14 LM 
I.HWESASLLR or RIHWESASL.L -(SSKITHRI/L - 0.0005) 1098.5691 1098.5697 0.56 LM 




GVVPR.G - 2602.3107 2602.3113 0.22 LM 
A.VPPNNSNAAEDDLPTVELQGL
VPR.G  -(A - 14.0141) 2545.2893 2545.2883 -0.38 LM 
A.VPPNNSNAAEDDLPTVELQGV
VPR.G -(A - 0.0006) 2531.2736 2531.2735 -0.04 LM 
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routinely analysed with isotopic resolution using TOF-analysers in reflectron mode, but at 
the cost of restricting the analyzed m/z-range and thus excluding proteins from the 
evaluation. Moreover, reflectron mode profiles still contain a significant number of 
overlapping peptides, as we previously demonstrated in ultrahigh resolution MALDI-
FTICR profiles [20]. 
In this study the ultrahigh resolving power provided by a 15 tesla MALDI-FTICR system 
was exploited in terms of discriminative power of case-control peptidome profiles and 
identification of observed species. This is the first profiling study that reports on the 
application of such ultrahigh resolution profiles exemplified by a clinical cohort of serum 
samples from healthy individuals and PC patients. Aiming for cancer-specific peptide and 
protein signatures, these serum samples were first fractionated on a fully automated SPE-
platform based on functionalized MBs and then profiled using a 15T MALDI-FTICR 
mass spectrometer. In total, 487 peptides or small proteins (i.e. 196 and 291 in LM and 
HM spectra, respectively) were measured with isotopic resolution in the m/z-range 
1-9 kDa and quantified with high accuracy and precision. The ultrahigh resolving power 
allowed the correct quantification of peptides or proteins that previously were observed to 
suffer from overlapping isotopic distributions in lower resolution profiles (see Figure2). 
Note that the total number of detectable peptides was higher than 487, i.e. several peptides 
were detected only in few particular samples, probably due to a higher expression of a 
particular protein or an elevated protease activity.  
Two different MALDI-FTICR acquisition methods, namely a low mass and a high mass 
method, were used to generate peptide and protein profiles from two independent groups 
of serum samples. A calibrated and validated discriminating rule built on the combination 
of the data obtained from the two MALDI-FTICR methods resulted in a sensitivity of 
89% and a specificity of 100% with an AUC of 0.989. These results corroborate 
classification numbers from our previous MALDI-TOF studies [19;32]. The t-test analysis 
performed on the peptides with absolute discriminant weights higher than 0.1 resulted in 
the identification of 34 peptides that (i.e. p-value lower than 0.001) differentiate between 
case and control groups (see Table 2). The high precision and accuracy of the mass 
measurements allowed the identification of 26 of these peptides either by comparison with 
previously reported peptides or by accurate mass measurement of mass differences in the 




in the identification of peptides generated through proteolysis of the same protein. 
In fact, starting from a previously identified peak (i.e. peptide) it was found that accurate 
measurement of the difference between that specific m/z-value and the m/z-value of a new 
peak matched to a similar peptide with either one amino acid more or less at the C- or the 
N-terminus, corresponding to the “overall” protein sequence. Thus, up to 8 new peptides 
could be identified starting from the fragment peptide K.SLEDKTERELLESYIDGR of 
thrombin light chain (UniProt P00734) (see Table 3). Nevertheless, the presence of 
isobaric peptides cannot be excluded and MS/MS experiments are required to further 
validate the identifications. In conclusion, using the two identification approaches 
described above, we are now able to further expand the total number of identified 
peptides, especially at higher m/z-values. Other MALDI-profiling methods that so far 
have been used for the characterization of human serum peptides were not suitable for the 
identification of high molecular weight peptides or proteins, because these lacked 
sensitivity and resolving power [28;29].  
As a final remark, it should be noted that at this stage the peptidome profiles were not 
evaluated for the m/z-range from 9,000 to 10,000. Here, both the high density of peaks 
and the relatively lower resolving power do not permit binning of the data points. 
The most abundant peaks present in this range were identified as apolipoprotein-CIII 
isoforms [26] and these data will be evaluated in a separate study using a different 
quantification method. In this study, we have shown that high quality human serum 
peptide and protein profiles can be generated using a standardized and robust protocol for 
the sample preparation and ultrahigh resolution 15T MALDI-FTICR MS for the mass 
measurements. The use of this mass analyzer allowed the isotopic resolution and the 
accurate and precise mass measurement of a high number of peptides and small proteins 
in a wide m/z-range. Notably, recent innovation in ICR-cell technology potentially 
provides similar performance at a lower magnetic field strength [33]. The statistical 
analysis of profiles generated from a clinical cohort of samples allowed the discrimination 
between healthy individuals and PC patients with sensitivity and specificity comparable 
with those reported by other authors using MALDI-TOF MS. A total of 273 serum 
samples was processed and mass analyzed within a time frame of 24 hours and the high 
quality of the data both facilitated the interpretation and evaluation of the generated 
profiles. These ultrahigh resolution mass spectra represent a “next-generation” of 
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MS-based peptidome profiles and provide a new tool for a more detailed description of 

























Supplementary Table 1. Peptides present in MALDI-FTICR precision profiles that were 


















Protein (Uniprot Entry) Peptide sequence m/z-value Method 
Fibrinopeptide alpha chain 5-16 (P02671) G.EGDFLAEGGGVR 1206.5749 LM 
Fibrinopeptide alpha chain 3-16 (P02671) D.SGEGDFLAEGGGVR 1350.6284 LM 
Phosphorylated Fibrinopeptide alpha chain 
(P02671) ADSpGEGDFLAEGGGVR 1616.6594 LM 
Complement C3f fragment (P01024) SSKITHRIHWESASLLR 2022.1067 LM 
Factor XIIIa 14–38 (P00488) R.AVPPNNSNAAEDDLPTVELQGVVPR.G 2603.3136 LM 
Fibrinogen alpha chain precursor 576–601 
(P02671) K.SSSYSKQFTSSTSYNRGDSTFESKSY.K 2932.2944 LM 
Fibrinogen alpha chain 76–604 (P02671) K.SSSYSKQFTSSTSYNRGDSTFESKSYKMA.D 3262.4670 LM 
Prothrombin 328-363 (P00734) TFGSGEADC(Cys)GLRPLFEKKSLEDKTERELLESYIDGR 4208.0275 HM 
Fibrinogen alpha chain 577–624 ( P02671) K.SSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHA.K 5337.3618 HM 
Fibrinogen alpha chain 577–629 ( P02671) K.SSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV.R 5904.7111 HM 
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It is estimated that the human proteome contains more than a million different 
species, whereas the (current) number of human genes is approximately 20,300 [1]. 
The much higher complexity of the proteome than that of the genome is a result of not 
only gene expression itself but also of genetic variations, alternatively spliced RNA 
transcripts and a wide variety of post-translational modifications (PTMs). Proteins are 
generally considered as the work horses of the human cell and as such are a valuable 
source of information about physiological conditions. For this reason, disease-specific 
variations in proteins levels can be promising markers for (early) diagnosis or prognosis 
of the disease. In this context, although enormous progress has been made in the analysis 
(i.e. identification) of proteins, further scientific advancements are needed to link protein 
expression with disease (state). The need for new technologies and methodologies for the 
comprehensive analysis of the human proteome has driven the progress in the field of 
MS-based proteomics. Nowadays, a wide variety of separation techniques in combination 
with different mass spectrometers is available and used to obtain a detailed analysis of 
biological samples in terms of protein identity and quantity. However, proteome analysis 
is still limited by many factors, most importantly the ten orders of magnitude dynamic 
range in protein concentrations and the lack of information about different proteoforms. 
Consequently, worldwide, scientists have been and are still working on the development 
of new methodologies and technologies to further improve and innovate MS-based 
proteomics.  
MS-based protein profiling was one of the first approaches used to demonstrate 
specific changes in the expression of peptides and proteins in samples from diseased 
individuals and has been widely applied ever since. Within a given human population 
protein expression is highly variable and consequently disease-specific changes can only 
be identified with high specificity when a significant number of human samples is 
analysed. This can most easily be achieved using automated sample processing methods 
that allow high-throughput screening. Apart from the aspect of high-throughput, robotic 
platforms follow a robust and standardized workflow and provide precise, reproducible 
and accurate data that are required for clinical discovery studies. For routine analysis in 
the clinical laboratories similar characteristics on robustness and standardization are 
required. Thus, further development of robust sample processing procedures is pivotal for 




Cancer biomarker discovery studies based on serum peptide and protein profiling 
have been criticized because most of these discoveries could not be translated into a 
diagnostic clinical assay [2,3]. One common explanation for this setback is the inherent 
lack of “depth” in profiling studies, i.e. only the first three or four orders of magnitude of 
the protein concentration range are mapped [4]. Nevertheless, it may very well be that a 
layer of highly abundant proteins can still provide diagnostic or prognostic clues on a 
certain disease, as has been shown by others and is shown in Chapter 7 of this thesis [5]. 
The failed translation of initial MS-based biomarker studies more likely relates to a lack 
of standardized sample collection or issues with validation, as robustness and 
reproducibility of the analytical platform are essential [5-8]. With this in mind, we 
performed our MALDI profiling research as follows. First, a stringent protocol was 
followed for both the collection and storage of the human serum samples needed for our 
studies. Second, we developed and implemented two different automated liquid handling 
platforms in our workflow either based on functionalized magnetic beads or on cartridges 
packed with SPE material similar to that of the beads (Chapter 1). These platforms 
allowed the fractionation of serum peptides and proteins in a very reproducible way, 
thereby reducing the analytical variation generated in following processing steps. 
Both platforms provided similar MS results. It was concluded that the use of cartridges 
increased flexibility in sample preparation, since the cartridges can be packed with 
virtually any desired SPE material. In both cases, hundreds of samples can be processed in 
a few hours allowing the analysis of a large cohort of clinical samples in a few days. 
The performance of the mass analysers that were used for the acquisition of the 
peptide and protein profiles had a clear effect on the results of the profiling studies. 
While MALDI-TOF-MS has been the most commonly used platform for peptide and 
protein profiling, MALDI-FTICR-MS has been rarely used for this purpose. Since this 
latter technology clearly offers better MS performance, we evaluated the applicability of 
this platform for profiling studies. To this end, a small cohort of human serum samples 
was analysed using both TOF and FTICR mass spectrometers and the results were 
compared. As shown in Chapter 2, part-per-million (ppm) mass measurement accuracy 
and precision were obtained by MALDI-TOF-MS after a baseline correction and internal 
calibration of the spectra generated from replicate measurements of 96 different serum 




spectrometer resulted in even lower ppm mass accuracy and precision. The sub-ppm mass 
measurement errors and the improved precision of the MALDI-FTICR-MS measurements 
were shown to lead to a more reliable identification of the peptides and simplified the 
analysis making the spectral alignment more accurate and robust. This improvement 
would appear to be a valuable characteristic for valid comparisons of profiles in clinical 
studies. 
Despite the high standardization of used the sample preparation procedures and 
MS measurements, profiles with poor spectral quality can occasionally still be obtained 
because of several factors. For example, a “failure” of either the extraction procedure or 
the MALDI spotting can lead to profiles with an inadequate number of peaks, while the 
presence of contaminants will reduce the sensitivity of the platform with regard to 
measuring (lower abundant) peptides. The measurements with isotopic resolution in both 
MALDI-TOF and –FTICR MS experiments allowed the development of a quality control 
method for the selection of the best spectrum within the replicate measurements of one 
sample and for the removal of low quality spectra from further statistical analysis 
(Chapter 3). This method was based on the comparison of the observed isotopic 
distributions with the estimated polyaveragine distributions and allowed the 
semi-automated evaluation of a large cohort of samples, typical for clinical studies. 
In Chapter 4, we describe the application of ESI-FTICR-MS/MS CID- and ETD-
experiments for the identification of human serum peptides that are detected in MALDI-
FTICR profiles. The ultrahigh resolving power of the FTICR measurements allowed the 
confident assignment of many fragment ions resulting in high sequence coverage while 
the sub-ppm mass measurements errors and precision made the identifications more 
reliable. CID and ETD results were shown to be complementary in terms of sequence 
coverage. The high mass measurement precision allowed a window of overlap between 
species observed in MALDI profiles and those determined in ESI spectra lower than 1 
ppm.  
Each single MALDI-MS profile obtained from a human serum sample is 
characterized by hundreds of features (i.e. peaks). The number of detected features 
depends on the sensitivity and the mass resolving power of the mass spectrometer. In 
reflectron TOF and FTICR mass analyzers, these characteristics significantly decrease 




peptides could be isotopically resolved up to m/z-value 4,500, while using a 15T MALDI-
FTICR mass spectrometer it was possible to extend this range up to m/z-value 15,300 thus 
allowing the detection of a higher number of peaks. Moreover, MALDI-FTICR 
experiments clearly demonstrated MALDI-TOF overlapping peptides (Chapters 1-6). The 
development of an ultrahigh resolution MALDI-FTICR profiling method in the m/z-range 
from 6,000 to 15,300 allowed a more detailed investigation of endogenous peptides and 
small proteins detected in this m/z- range. The MALDI-FTICR-MS analysis of human 
serum samples in this mass range resulted in the detection of several apolipoproteins from 
the “C” family including glycosylated apolipoprotein-CIII isoforms (apoCIII’s), as is 
presented in Chapter 5. These isoforms contain different glycosylation on the Threonine 
74 and have different ionization efficiency in MALDI, resulting in a lower signal intensity 
of the forms with one or two sialic acids. The evaluation of the apoCIII’s distribution in 
96 different human serum samples showed a high biological variability and proved to be a 
powerful analytical tool. In view of the important role of apoCIII’s in various disease 
pathways, future studies will be performed using the developed MALDI-FTICR profiling 
platform to investigate a possible correlation of apoCIII’s with diseases in clinical cohorts. 
The identification of apolipoproteins and the other profiled peptides was performed by 
comparison with previously identified peaks in MALDI-TOF profiles and by MS/MS 
experiments. MALDI-TOF MS allows the identification of the profiled peptides using in 
source and post source decay (ISD and PSD) processes, collision-induced dissociation 
(CID) and their combination (e.g. LIFT, Bruker Daltonics). However, the identification of 
large polypeptides is limited by the lack of resolving power while the fragmentation of 
low intensity precursor ions usually leads to poor MS/MS spectra. Moreover, in MALDI-
TOF experiments peptides are inherently singly charged, which by itself is a limiting 
factor for fragmentation studies. For these reasons, complementary ESI-MS/MS 
experiments of the same kind of fractionated human serum peptides were performed. 
In general, multiply charged species are less stable than singly charged ions and their 
fragmentation leads to a higher sequence coverage. Ion trap MS has been successfully 
employed to identify peptides that were previously separated by liquid chromatography 
(LC) [9]. Direct infusion ESI-MS/MS experiments can be performed, provided the 




identification of thousands of peptides per run, direct infusion experiments can be used to 
optimize the fragmentation parameters for those peptides that were not identified.  
As reported in Chapter 6, the improved mass accuracy and precision of the 
ultrahigh resolution MALDI-FTICR-MS measurements allowed the identification of six 
new intact fucosylated apoCIII’s in the m/z-range from 6,000 to 15,300. These new 
glycoforms were less abundant than the normal apoCIII’s and showed a large variation in 
their relative abundance and frequency in the 96 studied serum samples. To corroborate 
these identifications, direct infusion ESI-FTICR-CID MS/MS experiments were used to 
elucidate the glycan moiety of one of the fucosylated forms while ion trap CID MS/MS 
experiments were performed to partially localize the modification site. It should be 
stressed that these apoCIII’s were previously observed in MALDI-TOF spectra, however 
not identified. In our study, the less abundant fucosylated forms could be detected as a 
result of the improved sensitivity and higher resolving power of the 15T MALDI-FTICR-
MS.  
The FTICR-MS system used to perform the experiments needed for our studies 
offered a large versatility of the mass measurements. Several parameters were optimized 
to improve the transmission of the ions from the ion source to the ICR cell and their 
detection. This resulted in different MS methods with enhanced sensitivity for specific 
m/z-ranges. Two of these methods were used to profile serum peptides and proteins in the 
m/z-ranges from 1,013 to 3,700 and from 3,500 to 10,000, respectively. These ultrahigh 
resolution MALDI-FTICR profiling methods were integrated with a fully automated, 
magnetic bead-based serum peptides and proteins fractionation protocol in a high-
throughput and standardized profiling platform for clinical applications. In order to test 
the performance of this platform a cohort of serum samples from healthy volunteers and 
pancreatic cancer (PC) patients was analysed. In Chapter 7, we reported the result of this 
study. Serum peptides or small proteins could be measured with isotopic resolution and 
quantified with a higher accuracy and precision than any previously reported MALDI-
TOF profiling study. PC discriminant proteomic signatures were identified after the 
statistical analysis of the profiles obtained from 273 serum samples. The specificities and 
sensitivities of these methods were in agreement with those previously reported by other 
authors. Many of the peptides observed in the MALDI-FTICR profiles have not yet been 




human serum and the possible linkage with disease processes. The high mass accuracy of 
the 15T MALDI-FTICR measurements allowed the identification of 34 new peptides in 
the spectra.  
In the field of MS-based proteomics, large efforts are made to identify proteins at 
very low concentration levels (secreted in serum), since these can be disease-specific early 
biomarkers. The profiling methods developed and described in this thesis primarily 
provide detection of high-abundance proteins and their proteolytic fragments, despite the 
improved dynamic range obtained using a 15T MALDI-FTICR-MS. Therefore, the 
development of fractionation techniques remains crucial for a more in-depth investigation 
of the serum proteome and the identification of a more specific peptide and protein 
signature which could be used as a valid disease marker. Different technologies and 
strategies are nowadays available to dig deep into the serum proteome. Unfortunately, 
these all lack the analytical robustness that is needed for clinical application. For example, 
the first 15-20 most abundant proteins can be removed by immunocapture using 
immobilized antibodies on chromatographic supports [10]. However, these techniques are 
not 100% efficient and their reproducibility has been criticized. Another example is the 
use of multidimensional separation-based bottom-up proteomics that on the one hand 
allows the identification and quantification of thousands of serum proteins but on the 
other hand has a very low-throughput thus limiting its application to only a small cohort 
of samples [9,11]. Another way of tackling the problem of the large dynamic 
concentration range of human serum proteins is by focusing the analysis only to specific 
protein(s) of interest [12]. To this end, targeted proteomics allows detection of a 
preselected group of proteins with high sensitivity, quantitative accuracy and 
reproducibility. Multiple-reaction monitoring (MRM) MS is highly sensitive and allows 
the accurate quantification of specific (often tryptic) peptides in a sample by using 
isotopically labelled internal peptide standards [13,14]. To further enhance sensitivity in 
an MRM-approach anti-peptide antibodies can be used to enrich specific peptides. 
This is commercialized by SISCAPA (Stable Isotope Standards and Capture by Anti-
Peptide Antibodies), a method that is based on one or more specific anti-peptide 
antibodies to quantify a singly protein in a complex (biological) sample [15]. 
Recent attempts to improve the throughput and robustness of this technique were based on 




MALDI-TOF MS for the measurements of the tryptic peptides. In this context, the 
ultrahigh resolution MALDI-FTICR MS methods developed for the studies and presented 
in this thesis can be used to pitch a SISCAPA platform for the accurate and precise 
analysis of small proteins and peptides. In addition, suitable antibodies can be used to 
enrich the isoforms of a specific protein allowing the evaluation of their distribution 
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The human serum proteome, i.e. the complex mixture of all proteins that are expressed in 
the body and subsequently captured in the blood circulation, is considered as a valuable 
source of information that can be used to describe the health status of an individual. 
This complexity, however, poses a challenge to the development of analytical techniques 
that aim for determination of protein identities and quantities, and which later on could be 
used routinely in clinical laboratories. In the last years much effort has been made to 
tackle the sample complexity and several analytical methods have been developed to 
identify and quantify serum proteins at different concentration levels. Mass spectrometry 
(MS) has evolved as the method of choice for the analysis of proteins resulting into a new 
scientific field called MS-based proteomics. In a mass spectrometer molecules are 
separated and detected in the gas phase after using different technologies for ionization. 
Over the years, the evolution of mass spectrometers has led to the improvement of both 
the ionization efficiency, the resolution in the separation of ions, the sensitivity, the 
precision, the accuracy, and the speed of detection expressed as a mass-to-charge ratio 
(m/z) of positively or negatively charged molecules (i.e. ions). Despite these 
improvements analysis of the human serum proteome is only informative (or possible) 
when MS is used in combination with sample preparation techniques that decrease serum 
complexity. The analysis of low abundant proteins is seriously hampered by two facts: (a) 
the twenty most abundant proteins constitute approximately 95% of the total serum 
protein content and (b) serum protein concentrations range over ten orders of magnitude. 
Thus, several analytical approaches have been used to separate and/or concentrate proteins 
prior to MS analysis. As an alternative of MS-based proteome analysis, serum peptide 
profiling has been used to find “features” in the enormous mixture of peptides that is 
generated as a result of proteolysis of the most abundant proteins. It has been found that 
the extent of the proteolysis can be correlated with certain diseases. Matrix-assisted laser 
desorption/ionization (MALDI) coupled with time-of-flight (TOF) MS has been the 
preferred MS platform for the acquisition of such peptide (and protein) profiles because of 
its high-throughput character. In the early days, unfortunately, these profiles were 
generated at a low mass resolution resulting in the detection of peptide and proteins as 
broad peaks over a wide mass range. With the advent of reflectron TOF mass analysers 




isotopic distribution, however at the cost of a narrower mass range. Based on serum 
peptide and protein profiles, early successes were reported on classification of groups of 
individuals with a specific disease versus groups of healthy (control) individuals with high 
specificities and sensitivities,. However, lack of standardization in sample preparation, 
mass measurement and statistical data processing has so far prevented translation of the 
discriminant methods into valid clinical assays.  
 
Fourier transform ion cyclotron resonance (FTICR) MS provides (a) ultrahigh mass 
resolving power that allows the analysis of large proteins and complex mixtures; (b) 
ultrahigh mass measurement accuracy and precision that allow a more reliable 
identification of the detected species; (c) a wide dynamic range that is favourable for the 
detection of low abundant components. Despite these excellent characteristics, MALDI-
FTICR MS has been rarely used for peptide and protein profiling of large cohorts of 
samples. In this thesis, the development and application of novel MALDI-FTICR-MS 
methods for high-throughput analysis of human serum peptides and proteins is described. 
Due to the large biological variability of human serum, the analysis of a large cohort is 
needed to obtain reliable statistical results. 
 
In Chapter 1 the implementation of various solid-phase extraction (SPE) sample 
preparation protocols on two different, dedicated platforms is described, namely: 1) 
Magnetic bead-based SPE of peptides and proteins from body fluids on a Hamilton liquid 
handling workstation; 2) Cartridge-based SPE on a SPARK Symbiosis system. These two 
platforms, specifically set-up for high-throughput analysis using optimized protocols, 
provide fast analytical sample preparation procedures needed for MS-based clinical 
proteomics. As discussed above, MALDI-TOF has been the most used MS platform for 
peptide profiling and therefore was used as a reference in our development strategies. To 
test the performance of a new Bruker solariXTM MALDI-FTICR system equipped with a 
15 tesla magnet, 96 different serum samples were processed using the magnetic bead-
based SPE protocol and measured with ultrahigh resolution up to  
m/z–value 6500 by MALDI-FTICR MS and up to m/z–value 3500 using a Bruker 
Ultraflex II system. In Chapter 2, the results obtained with the two mass spectrometers 




repeatability of the signal. The results show that the two systems perform rather similar 
with respect to the repeatability of the signal intensities, while mass measurement errors 
(MMEs) are a few ppm’s or at a sub-ppm level for TOF and FTICR measurement, 
respectively. Moreover, the mass measurement precision improves at least 10-fold in 
ultrahigh resolution data thus simplifying spectral alignment necessary for robust and 
quantitatively precise comparisons of profiles in large-scale clinical studies. In chapter 2, 
we furthermore report on additional identifications of reversed-phase (RP) C18-
fractionated serum peptides by collision-induced dissociation (CID) experiments 
performed on the FTICR system.  
 
It is common practice to measure each serum sample on multiple MALDI-spots in order 
to prevent loss of data in case of unsuccessful MALDI spotting, In Chapter 3, we 
describe the implementation of a new quality control (QC) parameter for both MALDI-
TOF and MALDI-FTICR peptide profiling based on isotopic distributions that allows the 
selection of the best MALDI spectrum from replicate spectra. To test the performance of 
this QC parameter, RPC18-fractionated human serum peptides were measured by high 
resolution MALDI-TOF and ultrahigh resolution MALDI-FTICR. For each single mass 
spectrum, the isotopic distributions of multiple peptides were compared with estimated 
polyaveragine distributions to calculate a QC value. This value, calculated for replicate 
spots, allows the selection of the optimal MALDI spectrum and exclusion of low quality 
spectra for further statistical analysis. Using this approach, spectra containing high 
intensities of polymers or other contaminants and lacking peptides of interest can be 
efficiently removed from a clinical dataset.  
 
The benefits of the ultrahigh resolving power and the high mass accuracy and precision 
provided by an FTICR mass spectrometer equipped with a 15-tesla magnet for the 
identification of human serum peptides is further shown in Chapter 4. 
Ultrahigh resolution data not only allow the assignment of fragment ions with high charge 
states (4+, 5+) but also enhance confidence of human serum peptide identifications from 
tandem MS experiments. This is exemplified with collision-induced dissociation (CID) 
and electron transfer dissociation (ETD) data of middle-down-sized endogenous or 





The new MALDI-FTICR methods described in this thesis allow the ultrahigh resolution 
MS analysis of peptides and small proteins up to m/z-value 15,300. Apolipoprotein C-III 
(apoCIII) is a small human serum protein that is expressed as four major isoforms. 
A detailed evaluation of these isoforms is reported in Chapter 5. MALDI-FTICR profiles 
generated from RPC18-fractionated human serum peptides and proteins are discussed 
with regard to reproducibility of the signal intensities as well as the accurate mass 
measurements. Moreover, ESI-FTICR-MS/MS spectra were evaluated to confirm the 
identity of the apoCIII glycoforms. The reported analytical procedure is well-suited for 
high-throughput screening of serum samples and provides detailed information of apoCIII 
isoforms, thus allowing detailed investigation on the role of this protein in various disease 
pathways.  
 
In Chapter 6, we describe the identification of six new apoCIII isoforms characterized by 
more complex glycan moieties which are fucosylated instead of sialylated. 
Top-down ESI-FTICR-MS/MS and bottom-up LC-ion trap MS/MS spectra were 
evaluated to confirm the glycan moiety and localize the glycosylation site. Analysis of 
these fucosylated isoforms in 96 different serum samples showed a large variation in their 
presence and abundance. This warrants further research to elucidate the possible 
implication of these glycoforms in studies where alterations in apoCIII have been linked 
to the development of different pathologies.  
 
In Chapter 7 a powerful, fast and robust approach for obtaining serum biomarker 
signatures based on a fully automated one-step solid-phase extraction serum sample clean-
up in combination with fast MALDI acquisition and ultrahigh precision FTICR-readout, is 
described. The ultrahigh resolution FTICR methods implemented in this analytical 
procedure allow the measurement with isotopic resolution and low-ppm accuracy of all 
peptide and proteins between 1 and 9 kDa. Moreover, as exemplified for a cohort of 
pancreatic cancer patient and controls, the generated ultrahigh resolution MALDI-FTICR 
spectra can be used to classify serum samples with sensitivity and selectivity values well 





The last part of this thesis, the General Discussion, contains a discussion about MS-based 
cancer biomarker discovery strategies and the new developments in human serum peptide 
and protein profiling by ultrahigh resolution MS reported in Chapters 1-7. 
Targeted proteomics approaches using multiple-reaction monitoring (MRM) MS are 
briefly discussed in the context of further validation of biomarker candidates. Finally, a 
growing interest is seen in SISCAPA (Stable Isotope Standards and Capture by Anti-








Het humane proteoom is het complexe mengsel van alle eiwitten die in het lichaam tot 
expressie worden gebracht. Een groot deel van deze eiwitten komt vervolgens terecht in 
de bloedsomloop. Dit zogenaamde serumproteoom wordt algemeen beschouwd als een 
rijke bron van informatie betreffende de gezondheidstoestand van een persoon. 
De complexiteit van het eiwitmengsel heeft echter tot gevolg dat de ontwikkeling van 
analytische technieken voor de nauwkeurige identificering en kwantificering van eiwitten 
voor grote uitdagingen staat, met name wanneer deze methoden later voor 
routinebepalingen in een klinisch laboratorium ingezet dienen te worden. 
Massaspectrometrie (MS) heeft zich inmiddels ruimschoots bewezen als meest geschikte 
technologie voor zulke bepalingen, en “MS-based proteomics” is een zelfstandig 
onderzoeksgebied geworden. In een massaspectrometer worden moleculen in de gasfase 
gescheiden en gedetecteerd, nadat deze zijn geïoniseerd met behulp van een 
ionisatiemethode. Moleculen worden gedetecteerd als positief dan wel negatief geladen 
ionen en het signaal wordt weergegeven in een massaspectrum met een massa-lading ratio 
(m/z) op de x-as en een intensiteit op de y-as. Instrumentparameters die gedurende 
tientallen jaren van ontwikkeling en vernieuwing een belangrijke rol hebben gespeeld zijn 
de ionisatie-efficiëntie, het scheidend vermogen (“resolutie”), de gevoeligheid, de 
nauwkeurigheid (“precisie”), de juistheid (“accuratesse”), en de snelheid van de meting. 
Voor succesvolle MS-metingen blijft een geschikte monstervoorbewerking cruciaal, dit 
ondanks de grote stappen die zijn gemaakt op het gebied van instrumentontwikkeling. 
In deze context is er veel werk verricht om de complexiteit van serummonsters te 
verkleinen en daarmee eiwitten van uiteenlopende concentraties te kunnen identificeren en 
kwantificeren. Veel van de duizenden verschillende typen eiwitten in het (serum) 
proteoom zijn namelijk aanwezig in lage concentraties (milligram, microgram of zelfs 
nanogram per liter). Bovendien zijn deze eiwitten “verstopt” onder een twintigtal hoog-
abundante eiwitten, die samen ongeveer 95% van de totale hoeveelheid eiwitmassa 
vertegenwoordigen. In plaats van het meten van alle eiwitten in het serumproteoom, een 
potentieel krachtige maar tijdrovende en kostbare strategie, is het ook mogelijk een enkel 
peptideprofiel te generen van een serummonster. Veel van deze peptiden zijn het resultaat 
van een proteolyse van de hoog-abundante eiwitten. In verschillende studies heeft men 




peptideprofielen, correleert met specifieke ziekten. Het meest gebruikte MS-platform voor 
het genereren van peptide- en eiwitprofielen bestaat uit een “time-of-flight (TOF)” massa-
analysator met een “matrix-assisted laser desorption/ionization (MALDI)” ionisatiebron. 
Aanvankelijk (10-15 jaar geleden) werden peptiden en eiwitten als brede pieken 
gedetecteerd, omdat de gebruikte apparatuur in deze vroege studies een laag-scheidend 
vermogen had. De komst van reflectron TOF (10 jaar geleden) betekende een enorme 
verbetering: hogere resolutie maakte isotoopdistributie van de peptiden zichtbaar, echter 
ten koste van de gevoeligheid voor eiwitten. Sindsdien hebben verschillende 
onderzoeksgroepen laten zien dat op basis van serumpeptide- en/of eiwitprofielen 
patiëntsera met hoge sensitiviteit en specificiteit kunnen worden geclassificeerd in 
zogenaamde “case-control” studies. Echter, door gebrek aan standaardisering van 
monstervoorbewerking, MS-experimenten en statistische analyses heeft (nog) geen 
translatie plaatsgevonden van deze discriminerende profielen naar een valide klinische 
test. 
 
Ultrahoge resolutie “Fourier transform ion cyclotron resonance (FTICR)” 
massaspectrometrie maakt metingen van grote eiwitten in complexe monsters mogelijk 
door het ultrahoog scheidend vermogen. Daarnaast zorgen de verbeterde precisie en 
accuratesse ervoor dat gedetecteerde peptiden en eiwitten met grotere zekerheid kunnen 
worden geïdentificeerd. Tenslotte maakt het grote dynamisch bereik van een FTICR-
analyse deze techniek zeer geschikt voor het detecteren van componenten met een lage 
concentratie. Desalniettemin is de combinatie van MALDI en FTICR nog slechts zelden 
ingezet voor de analyse van een cohort. In dit proefschrift beschrijven wij de ontwikkeling 
en de toepassing van nieuwe MALDI-FTICR-MS methoden voor de “high-throughput” 
(hoge-doorvoer) analyse van humane serumpeptiden en –eiwitten. Het is belangrijk te 
vermelden dat serummonsters veel verschillen tussen verschillende individuen vertonenn 
(biologische variatie), zodat analyse van grote cohorten essentieel is voor het verkrijgen 
van betrouwbare statische data. De implementatie van verschillende protocollen voor 
monstervoorbewerking gebaseerd op “solid-phase” (vaste-fase) extractie (SPE) is 
beschreven in Hoofdstuk 1. Twee platforms zijn ingezet: 1) SPE met behulp van 
gefunctionaliseerde paramagnetische bolletjes op een Hamilton pipetteerrobot en 2) SPE 





opgezet voor “high-throughput” analyses met geoptimaliseerde protocollen zorgen voor 
een snelle monstervoorbewerking, noodzakelijk voor “MS-based clinical proteomics”. 
Voor het verkrijgen van peptideprofielen werd een Bruker Ultraflex II MALDI-TOF 
gebruikt als referentie (tot m/z 3500) en daarnaast een Bruker solariXTM MALDI-FTICR 
systeem, uitgerust met een 15 tesla magneet (tot m/z 6500). In Hoofdstuk 2 zijn de 
verkregen profielen met elkaar vergelijken voor wat betreft accuratesse, precisie van de 
massabepaling en herhaalbaarheid van de meting met betrekking tot intensiteiten. 
MALDI-TOF en MALDI-FTICR waren op dit laatste punt gelijkwaardig. Echter, de 
andere twee parameters waren meer dan 10x beter op het ultrahoge resolutie systeem, 
waarmee het op één-lijn-brengen van alle profielen in een cohort eenvoudiger en 
robuuster wordt. Daarnaast zijn in Hoofdstuk 2 nieuwe identificaties van serum peptiden 
gerapporteerd. 
 
In de meeste studies worden van ieder serummonster meerdere MALDI-spots 
(“replica’s”) gemaakt ten einde kwaliteitscontrole mogelijk te maken. In Hoofdstuk 3 is 
een nieuw type kwaliteitscontrole beschreven voor peptideprofielen. Deze parameter is 
gebaseerd op isotoopdistributies, waarmee voor elke meting bepaald kan worden wat het 
beste profiel van een monster is binnen een set replica’s. Profielen, of spectra, van slechte 
kwaliteit kunnen op deze manier worden uitgesloten van verdere statistische analyses. 
Daarna is in Hoofdstuk 4 opnieuw aangetoond dat het gebruik van ultrahoge resolutie 
FTICR-MS zeer geschikt is voor identificatie van (nieuwe) serumpeptiden. Hiervoor zijn 
twee fragmentatietechnieken gebruikt, namelijk "collision-induced dissociation (CID)” en 
“electron transfer dissociation (ETD)”. Vervolgens zijn de MALDI-FTICR methoden 
ingezet voor het verkrijgen van peptide- en eiwitprofielen van humane serummonsters tot 
een m/z-waarde van 15300. In de profielen zijn verschillende isovormen van het eiwit 
apolipoprotein C-III aanwezig, zoals beschreven in Hoofdstuk 5 van dit proefschrift. Het 
“profilen” van dit eiwit, met daarbij de isovormen met hun verschillende 
glycaanstructuren, is veelbelovend voor het monitoren van een bepaalde ziekte waarbij 
apolipoproteinen een belangrijke rol spelen. In Hoofdstuk 6 is verder onderzoek 
beschreven aan apolipoprotein C-III. In dit hoofdstuk zijn zes nieuwe isovormen 
gerapporteerd, waarbij de glycanen fucose-eenheden bevatten in plaats van siaalzuren. 




MS/MS-experiments”. De analyse van deze nieuwe structuren in 96 verschillende 
serummonsters gaf een gedetailleerd inzicht in de biologische variatie die gepaard gaat 
met glycosylering van eiwitten in het algemeen en fucosylering op apolipoprotein C-III in 
het bijzonder. Tenslotte is in Hoofdstuk 7 een studie beschreven, waarbij de ontwikkelde, 
krachtige “high-throughput” MALDI-FTICR-MS strategie in combinatie met één-staps-
monstervoorbewerking (gefunctionaliseerde paramagnetische bolletjes) ingezet is voor de 
analyse van een cohort van serummonsters van patiënten met alvleesklierkanker. 
Aan de hand van peptideprofielen met isotoopresolutie tot 9 kDa konden patiënten van 
controles worden onderscheiden met sensitiviteits- en specificiteitswaarden hoger dan 
85%, voor zowel een calibratie- als een validatieset. In het laatste deel van dit proefschrift, 
de Algemene Discussie, wordt kort vooruitgeblikt op “multiple-reaction monitoring 
(MRM) MS” methoden, die kunnen dienen voor het verder valideren van de biomarker 
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